(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 December 2000 (14.12.2000)

PCT

(10) International Publication Number
WO 00/75338 A2

(51) International Patent Classification[7]: C12N 15/51, C07K 14/18, 16/18, A61K 38/00, 39/00

(21) International Application Number: PCT/US00/15446

(22) International Filing Date: 2 June 2000 (02.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/137,693 4 June 1999 (04.06.1999) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 60/137,693 (CON)
Filed on 4 June 1999 (04.06.1999)

(71) Applicant *(for all designated States except US)*: THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; Office of Technology Transfer, National Institutes of Health, Suite 325, 6011 Executive Boulevard, Rockville, MD 20852 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: YANAGI, Masayuki [JP/US]; 257 Congressional Lane, #402, Rockville, MD 20852 (US). BUKH, Jens [DK/US]; 2018 Baltimore Road #J42, Rockville, MD 20851 (US). EMERSON, Suzanne, U. [US/US]; 4517 Everett Street, Kensington, MD 20895 (US). PURCELL, Robert, H. [US/US]; 17517 White Ground Road, Boyds, MD 20841 (US).

(74) Agents: FEILER, William, S. et al.; Morgan & Finnegan, L.L.P., 345 Park Avenue, New York, NY 10154 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *Without international search report and to be republished upon receipt of that report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CLONED GENONE OF INFECTIOUS HEPATITIS C VIRUS OF GENOTYPE 2a AND USES THEREOF



(57) Abstract: The present invention discloses nucleic acid sequence which encodes infectious hepatitis C virus of strain HC-J6$_{CH}$, genotype 2a, and the use of the sequence, and polypeptides encoded by all or part of the sequence, in the development of vaccines and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV.

WO 00/75338 A2

Title Of Invention

Cloned Genome Of Infectious Hepatitis C Virus of Genotype 2a And Uses Thereof

Field Of Invention

The present invention relates to molecular approaches to the production of nucleic acid sequence which comprises the genome of infectious hepatitis C virus. In particular, the invention provides a nucleic acid sequence which comprises the genome of an infectious hepatitis C virus of genotype 2a. The invention therefore relates to the use of the nucleic acid sequence and polypeptides encoded by all or part of the sequence in the development of vaccines and diagnostic assays for HCV and in the development of screening assays for the identification of antiviral agents for HCV.

Background Of Invention

Hepatitis C virus (HCV) has a positive-sense single-strand RNA genome and is a member of the genus *Hepacivirus* within the *Flaviviridae* family of viruses (Rice, 1996). As for all positive-stranded RNA viruses, the genome of HCV functions as mRNA from which all viral proteins necessary for propagation are translated.

The viral genome of HCV is approximately 9600 nucleotides (nts) in length and consists of a highly conserved 5′ untranslated region (UTR), a single long open reading frame (ORF) of approximately 9,000 nts and a complex 3′ UTR. The 5′ UTR contains an internal ribosomal entry site (Tsukiyama-Kohara et al., 1992;

Honda et al., 1996). The 3' UTR consists of a short variable region, a polypyrimidine tract of variable length and, at the 3' end, a highly conserved region of approximately 100 nucleotides (Kolykhalov et al., 1996; Tanaka et al., 1995; Tanaka et al., 1996; Yamada et al., 1996). The last 46 nucleotides of this conserved region were predicted to form a stable stem-loop structure thought to be critical for viral replication (Blight and Rice, 1997; Ito and Lai, 1997; Tsuchihara et al., 1997). The ORF encodes a large polypeptide precursor that is cleaved into at least 10 proteins by host and viral proteinases (Rice, 1996). The predicted envelope proteins contain several conserved N-linked glycosylation sites and cysteine residues (Okamoto et al., 1992a). The NS3 gene encodes a serine protease and an RNA helicase and the NS5B gene encodes an RNA-dependent RNA polymerase.

A remarkable characteristic of HCV is its genetic heterogeneity, which is manifested throughout the genome (Bukh *et al.*, 1995). The most heterogeneous regions of the genome are found in the envelope genes, in particular the hypervariable region 1 (HVR1) at the N-terminus of E2 (Hijikata *et al.*, 1991; Weiner *et al.*, 1991). HCV circulates as a quasispecies of closely related genomes in an infected individual. Globally, six major HCV genotypes (genotypes 1-6) and multiple subtypes (a, b, c, etc.) have been identified (Bukh et al., 1993; Simmonds et al., 1993).

The nucleotide and deduced amino acid sequences among isolates within a quasispecies generally differ by < 2%, whereas those between isolates of different genotypes vary by as much as 35%. Genotypes

1, 2 and 3 are found worldwide and constitute more than 90% of the HCV infections in North and South America, Europe, Russia, China, Japan and Australia (Forns and Bukh, 1998). Throughout these regions genotype 1 accounts for the majority of HCV infections but genotypes 2 and 3 each account for 5-15%.

At present, more than 80% of individuals infected with HCV become chronically infected and these chronically infected individuals have a relatively high risk of developing chronic hepatitis, liver cirrhosis and hepatocellular carcinoma (Hoofnagle, 1997). The only effective therapy for chronic hepatitis C, interferon (IFN), alone or in combination with ribavirin, induces a sustained response in less than 50% of treated patients (Davis et al., 1998; McHutchinson et al., 1998). Consequently, HCV is currently the most common cause of end stage liver failure and the reason for about 30% of liver transplants performed in the U.S. (Hoofnagle, 1997). In addition, a number of recent studies suggested that the severity of liver disease and the outcome of therapy may be genotype-dependent (reviewed in Bukh et al., 1997). In particular, these studies suggested that infection with HCV genotype 1b was associated with more severe liver disease (Brechot, 1997) and a poorer response to IFN therapy (Fried and Hoofnagle, 1995). As a result of the inability to develop a universally effective therapy against HCV infection, it is estimated that there are still more than 25,000 new infections yearly in the U.S. (Alter 1997) Moreover, since there is no vaccine for HCV, HCV remains a serious public health problem.

Despite the intense interest in the development of vaccines and therapies for HCV, progress has been hindered by the absence of a useful cell culture system and the lack of any small animal model for laboratory study. For example, while replication of HCV in several cell lines has been reported, such observations have turned out not to be highly reproducible. In addition, the chimpanzee is the only animal model, other than man, for this disease. Consequently, HCV has been studied only by using clinical materials obtained from patients or experimentally infected chimpanzees, an animal model whose availability is very limited.

However, several researchers have recently reported the construction of infectious cDNA clones of HCV, the identification of which would permit a more effective search for susceptible cell lines and facilitate molecular analysis of the viral genes and their function. For example, Yoo et al., and Dash et al., (1997) (1995) reported that RNA transcripts from cDNA clones of HCV-1 (genotype 1a) and HCV-N (genotype 1b), respectively, resulted in viral replication after transfection into human hepatoma cell lines. Unfortunately, the viability of these clones was not tested in vivo and concerns were raised about the infectivity of these cDNA clones in vitro (Fausto, 1997). In addition, both clones did not contain the terminal 98 conserved nucleotides at the very 3' end of the UTR.

Kolykhalov et al., (1997) and Yanagi et al. (1997, 1998) reported the derivation from HCV strains H77 (genotype 1a) and HC-J4 (genotype 1b) of cDNA clones

of HCV that are infectious for chimpanzees. However, while these infectious clones will aid in studying HCV replication and pathogenesis and will provide an important tool for development of in vitro replication and propagation systems, it is important to have infectious clones of more than one genotype, given the extensive genetic heterogeneity of HCV and the potential impact of such heterogeneity on the development of effective therapies and vaccines for HCV.

In addition, synthetic chimeric viruses can be used to map the functional regions of viruses with different phenotypes. In flaviviruses and pestiviruses, infectious chimeric viruses have been successfully engineered to express different functional units of related viruses (Bray and Lai, 1991; Pletnev *et al.*, 1992, 1998; Vassilev *et al.*, 1997) and in some cases it has been possible to make chimeras between non-related or distantly related viruses. For instance, the IRES element of poliovirus or bovine viral diarrhea virus has been replaced with IRES sequences from HCV (Frolov *et al.*, 1998; Lu and Wimmer, 1996; Zhao *et al.*, 1999). Recently, the construction of an infectious chimera of two closely related HCV subtypes has been reported. The chimera contained the complete ORF of a genotype 1b strain but had the 5' and 3' termini of a genotype 1a strain (Yanagi *et al.*, 1998).

It is important to determine whether chimeras constructed from more divergent HCV strains are infectious because such chimeras could be used to define the functions of viral units and to dissect the immune response.

Summary Of The Invention

The present invention relates to nucleic acid sequence which comprises the genome of infectious hepatitis C virus and in particular, nucleic acid sequence which comprises the genome of infectious hepatitis C virus of genotype 2a. It is therefore an object of the invention to provide nucleic acid sequence which encodes infectious hepatitis C virus. Such nucleic acid sequence is referred to throughout the application as "infectious nucleic acid sequence".

For the purposes of this application, nucleic acid sequence refers to RNA, DNA, cDNA or any variant thereof capable of directing host organism synthesis of a hepatitis C virus polypeptide. It is understood that nucleic acid sequence encompasses nucleic acid sequences, which due to degeneracy, encode the same polypeptide sequence as the nucleic acid sequences described herein.

The invention also relates to the use of the infectious nucleic acid sequences to produce chimeric genomes consisting of portions of the open reading frames of nucleic acid sequences of other genotypes (including, but not limited to, genotypes 1, 2, 3, 4, 5 and 6) and subtypes (including, but not limited to, subtypes 1a, 1b, 2a, 2b, 2c, 3a, 4a-4f, 5a and 6a) of HCV. For example, infectious nucleic acid sequence of the 2a strain HC-J6, described herein can be used to produce chimeras with sequences from the genomes of other strains of HCV from different genotypes or subtypes. Nucleic acid sequences which comprise sequences from two or more HCV genotypes or subtypes are designated "chimeric nucleic acid sequences".

The invention further relates to mutations of the infectious nucleic acid sequence of the invention where mutation includes, but is not limited to, point mutations, deletions and insertions. In one embodiment, a gene or fragment thereof can be deleted to determine the effect of the deleted gene or genes on the properties of the encoded virus such as its virulence and its ability to replicate. In an alternative embodiment, a mutation may be introduced into the infectious nucleic acid sequences to examine the effect of the mutation on the properties of the virus.

The invention also relates to the introduction of mutations or deletions into the infectious nucleic acid sequence in order to produce an attenuated hepatitis C virus suitable for vaccine development.

The invention further relates to the use of the infectious nucleic acid sequence to produce attenuated viruses via passage in vitro or in vivo of the viruses produced by transfection of a host cell with the infectious nucleic acid sequence.

The present invention also relates to the use of the nucleic acid sequence of the invention or fragments thereof in the production of polypeptides where "nucleic acid sequence of the invention" refers to infectious nucleic acid sequence, mutations of infectious nucleic acid sequence, chimeric nucleic acid sequence and sequences which comprise the genome of attenuated viruses produced from the infectious nucleic acid sequence of the invention. In one embodiment, said polypeptide or polypeptides are fully or partially purified from hepatitis C virus produced by cells transfected with nucleic acid sequence of the invention.

In another embodiment, the polypeptide or polypeptides are produced recombinantly from a fragment of the nucleic acid sequences of the invention. In yet another embodiment, the polypeptides are chemically synthesized.

The polypeptides of the invention, especially structural polypeptides, can serve as immunogens in the development of vaccines or as antigens in the development of diagnostic assays for detecting the presence of HCV in biological samples.

The invention therefore also relates to vaccines for use in immunizing mammals especially humans against hepatitis C. In one embodiment, the vaccine comprises one or more polypeptides made from the nucleic acid sequence of the invention or fragment thereof. In a second embodiment, the vaccine comprises a hepatitis C virus produced by transfection of host cells with the nucleic acid sequences of the invention.

The present invention therefore relates to methods for preventing hepatitis C in a mammal. In one embodiment the method comprises administering to a mammal a polypeptide or polypeptides encoded by the nucleic acid sequence of the invention in an amount effective to induce protective immunity to hepatitis C. In another embodiment, the method of prevention comprises administering to a mammal a hepatitis C virus of the invention in an amount effective to induce protective immunity against hepatitis C.

In yet another embodiment, the method of protection comprises administering to a mammal the nucleic acid sequence of the invention or a fragment thereof in an amount effective to induce protective immunity against hepatitis C.

The invention also relates to hepatitis C viruses produced by host cells transfected with the nucleic acid sequence of the present invention.

The invention therefore also provides pharmaceutical compositions comprising the nucleic acid sequence of the invention and/or the encoded hepatitis C viruses. The invention further provides pharmaceutical compositions comprising polypeptides encoded by the nucleic acid sequence of the invention or fragments thereof. The pharmaceutical compositions of the invention may be used prophylactically or therapeutically.

The invention also relates to antibodies to the hepatitis C virus of the invention or their encoded polypeptides and to pharmaceutical compositions comprising these antibodies.

The invention also relates to the use of the nucleic acid sequences of the invention to identify cell lines capable of supporting the replication of HCV in vitro.

The invention further relates to the use of the nucleic acid sequences of the invention or their encoded viral enzymes (e.g. NS3 serine protease, NS3 helicase, NS5B RNA polymerase) to develop screening assays to identify antiviral agents for HCV.

Brief Description Of Figures

Figure 1 shows the amplification and cloning of hepatitis C virus genotype 2a (strain HC-J6$_{Ch}$). The nucleotide positions correspond to the sequence of PJ6CF, a full length cDNA clone of hepatitis C virus, genotype 2a, strain HC-J6$_{CH}$. Products from polymerase

chain reaction are also shown. The names of the clones obtained from these products are indicated (number of clones sequenced are shown in parenthesis). The composition of the full-length cDNA clone is shown at the bottom. The restriction enzymes used for cloning are indicated. An *Xba*I site in HC-J6$_{CH}$ was eliminated by a silent substitution at position 5494.

Figure 2 shows tree analysis of clones amplified from an infectious acute phase plasma pool generated in a chimpanzee inoculated with human plasma containing strain HC-J6 (Okamoto *et al.*, 1991) as well as a tree of the predicted polyprotein sequence of HC-J6$_{CH}$ and the infectious HC-J6$_{CH}$ cDNA clone (pJ6CF). The nucleotide positions with deletions or insertions were stripped in the analysis of the clones. Multiple sequence alignments and tree analyses were performed with GeneWorks (Oxford Molecular Group) (Bukh *et al.*, 1995). Genotype designations are indicated. Other sequences included in the analysis are HC-J8 (Okamoto *et al.*, 1992), genotype 1a infectious clone BEBE1 (Nakao *et al.*, 1996), H77C (Yanagi *et al.*, 1997); genotype 1b infectious clone J4L6S (Yanagi *et al.*, 1998). The scale in each tree indicates the calculated genetic distance.

Figure 3 shows the alignment of the hypervariable region 1 sequences from 8 J6S clones of strain HC-J6$_{CH}$. HC-J6$_{CH}$ represents the consensus amino acid sequence of the infectious plasma pool from an experimentally infected chimpanzee. HC-J6 is the published amino acid sequence of the original inoculum (Okamoto *et al.*, 1991).

Figure 4 shows the construction of four intertypic chimeric cDNA clones. White boxes are

sequences derived from genotype 2a clone pJ6CF, and black boxes are sequences derived from genotype 1a clone pCV-H77C (Yanagi *et al.*, 1997). An *Nde*I site (mutation at position 9158 of pCV-H77C) was eliminated and an artificial *Nde*I site (mutation at position 2765 of pCV-H77C) was created by site-directed mutagenesis; silent mutations are underlined.

Figures 5A and 5B show the alignment of the nucleotide sequences of the 5' (Fig. 5A) and 3' UTRs (Fig. 5B) and the amino acid sequences of E2/p7/NS2 junctions (Fig. 5B) in the intertypic 1a, 2a chimeric cDNA clones. In the 5' UTR alignment, the first 39 nts of core believed to be important for the IRES function were included (Lemon and Honda, 1997). Top line: the sequence of the infectious genotype 1a clone pCV-H77C (Yanagi *et al.*, 1997). Bottom line: the sequence of the infectious genotype 2a clone pJ6CF. Dot: identity with the sequence of H77C. Capital letter: different from the sequence of H77C. Dash: deletion. Bold face: initiation or stop codon of the ORF. Underlined: *Age*I cleavage site. Arrow: putative sites in the HCV polyprotein cleaved by host signal peptidases. Numbering corresponds to the sequence of pCV-H77C.

Figures 6A-6F show the nucleotide sequence of the infectious hepatitis C virus clone of genotype 1a strain H77C and Figures 6G-6H show the amino acid sequence encoded by the clone.

Figures 7A-7F show the nucleotide sequence of the infectious hepatitis C virus clone of genotype 1b strain HC-J4 and Figures 7G-H show the amino acid sequence encoded by the clone.

DESCRIPTION OF THE INVENTION

The present invention relates to nucleic acid sequence which comprises the genome of an infectious hepatitis C virus. More specifically, the invention relates to nucleic acid sequence which encodes infectious hepatitis C virus of strain HC-J6$_{CH}$, genotype 2a. The infectious nucleic acid sequence of the invention is shown in SEQ ID NO:1 and is contained in a plasmid construct deposited with the American Type Culture Collection (ATCC) on May 28, 1999 and having ATCC accession number PTA-153.

The invention also relates to "chimeric nucleic acid sequences" where the chimeric nucleic acid sequences consist of open-reading frame sequences and/or 5′ and/or 3′ untranslated sequences taken from nucleic acid sequences of hepatitis C viruses of different genotypes or subtypes.

In one embodiment, the chimeric nucleic acid sequence consists of sequence from the genome of infectious HCV of genotype 2a which encodes structural polypeptides and sequence from the genome of a HCV of a different genotype or subtype which encodes nonstructural polypeptides.

Alternatively, the nonstructural region of infectious HCV of genotype 2a and structural region of a HCV of a different genotype or subtype may be combined. This will result in a chimeric nucleic acid sequence consisting of sequence from the genome of infectious HCV of genotype 2a which encodes nonstructural polypeptides and sequence from the genome of a HCV of a another genotype or subtype which encodes structural polypeptides.

Preferably, the nucleic acid sequence from the genome of the infectious HCV clone of genotype 1a (deposited with the ATCC on June 2, 1999 ; Figures 6A-6F), or the nucleic acid sequence from the genome of the infectious HCV clone of genotype 1b (ATCC accession number 209596; Figures 7A-7F) is used to construct the chimeric nucleic acid sequence with the HCV of genotype 2a of the invention.

It is believed that the construction of such chimeric nucleic acid sequences will be of importance in studying the growth and virulence properties of hepatitis C virus and in the production of candidate hepatitis C virus vaccines suitable to confer protection against multiple genotypes of HCV. For example, one might produce a "multivalent" vaccine by putting epitopes from several genotypes or subtypes into one clone. Alternatively one might replace just a single gene from an infectious sequence with the corresponding gene from the genomic sequence of a strain from another genotype or subtype or create a chimeric gene which contains portions of a gene from two genotypes or subtypes. Examples of genes which could be replaced or which could be made chimeric, include, but are not limited to, the E1, E2 and NS4 genes.

The invention further relates to mutations of the infectious nucleic acid sequences where "mutations" include, but are not limited to, point mutations, deletions and insertions. Of course, one of ordinary skill in the art would recognize that the size of the insertions would be limited by the ability of the resultant nucleic acid sequence to be properly packaged within the virion. Such mutations could be produced by

techniques known to those of skill in the art such as site-directed mutagenesis, fusion PCR, and restriction digestion followed by religation.

In one embodiment, mutagenesis might be undertaken to determine sequences that are important for viral properties such as replication or virulence. For example, one may introduce a mutation into the infectious nucleic acid sequence which eliminates the cleavage site between the NS4A and NS4B polypeptides to examine the effects on viral replication and processing of the polypeptide.

Alternatively, one may delete all or part of a gene or of the 5' or 3' nontranslated region contained in an infectious nucleic acid sequence and then transfect a host cell (animal or cell culture) with the mutated sequence and measure viral replication in the host by methods known in the art such as RT-PCR. Preferred genes include, but are not limited to, the P7, NS4B and NS5A genes. Of course, those of ordinary skill in the art will understand that deletion of part of a gene, preferably the central portion of the gene, may be preferable to deletion of the entire gene in order to conserve the cleavage site boundaries which exist between proteins in the HCV polyprotein and which are necessary for proper processing of the polyprotein.

In the alternative, if the transfection is into a host animal such as a chimpanzee, one can monitor the virulence phenotype of the virus produced by transfection of the mutated infectious nucleic acid sequence by methods known in the art such as measurement of liver enzyme levels (alanine aminotransferase (ALT) or isocitrate dehydrogenase (ICD)) or by histopathology

of liver biopsies. Thus, mutations of the infectious nucleic acid sequences may be useful in the production of attenuated HCV strains suitable for vaccine use.

The invention also relates to the use of the infectious nucleic acid sequence of the present invention to produce attenuated viral strains via passage in vitro or in vivo of the virus produced by transfection with the infectious nucleic acid sequence.

The present invention therefore relates to the use of the nucleic acid sequence of the invention to identify cell lines capable of supporting the replication of HCV.

In particular, it is contemplated that the mutations of the infectious nucleic acid sequence of the invention and the production of chimeric sequences as discussed above may be useful in identifying sequences critical for cell culture adaptation of HCV and hence, may be useful in identifying cell lines capable of supporting HCV replication.

Transfection of tissue culture cells with the nucleic acid sequences of the invention may be done by methods of transfection known in the art such as electroporation, precipitation with DEAE-Dextran or calcium phosphate or liposomes.

In one such embodiment, the method comprises the growing of animal cells, especially human cells, in vitro and transfecting the cells with the nucleic acid of the invention, then determining if the cells show indicia of HCV infection. Such indicia include the detection of viral antigens in the cell, for example, by immunofluorescence procedures well known in the art; the detection of viral polypeptides by Western blotting

using antibodies specific therefor; and the detection of newly transcribed viral RNA within the cells via methods such as RT-PCR. The presence of live, infectious virus particles following such tests may also be shown by injection of cell culture medium or cell lysates into healthy, susceptible animals, with subsequent exhibition of the signs and symptoms of HCV infection.

Suitable cells or cell lines for culturing HCV include, but are not limited to, lymphocyte and hepatocyte cell lines known in the art.

Alternatively, primary hepatocytes can be cultured, and then infected with HCV; or, the hepatocyte cultures could be derived from the livers of infected chimpanzees. In addition, various immortalization methods known to those of ordinary skill in the art can be used to obtain cell lines derived from hepatocyte cultures. For example, primary hepatocyte cultures may be fused to a variety of cells to maintain stability.

The present invention further relates to the in vitro and in vivo production of hepatitis C viruses from the nucleic acid sequences of the invention.

In one embodiment, the sequences of the invention can be inserted into an expression vector that functions in eukaryotic cells. Eukaryotic expression vectors suitable for producing high efficiency gene transfer in vivo are well known to those of ordinary skill in the art and include, but are not limited to, plasmids, vaccinia viruses, retroviruses, adenoviruses and adeno-associated viruses.

In another embodiment, the sequences contained in the recombinant expression vector can be transcribed in vitro by methods known to those of ordinary skill in

the art in order to produce RNA transcripts which encode the hepatitis C viruses of the invention. The hepatitis C viruses of the invention may then be produced by transfecting cells by methods known to those of ordinary skill in the art with either the in vitro transcription mixture containing the RNA transcripts or with the recombinant expression vectors containing the nucleic acid sequences described herein.

The hepatitis C viruses produced from the sequences of the invention may be purified or partially purified from the transfected cells by methods known to those of ordinary skill in the art. In a preferred embodiment, the viruses are partially purified prior to their use as immunogens in the pharmaceutical compositions and vaccines of the present invention.

The present invention therefore relates to the use of the hepatitis C viruses produced from the nucleic acid sequences of the invention as immunogens in live or killed (e.g., formalin inactivated) vaccines to prevent hepatitis C in a mammal.

In an alternative embodiment, the immunogen of the present invention may be an infectious nucleic acid sequence, a chimeric nucleic acid sequence, or a mutated infectious nucleic acid sequence which encodes a hepatitis C virus. Where the sequence is a cDNA sequence, the cDNAs and their RNA transcripts may be used to transfect a mammal by direct injection into the liver tissue of the mammal as described in the Examples.

Alternatively, direct gene transfer may be accomplished via administration of a eukaryotic expression vector containing a nucleic acid sequence of the invention.

In yet another embodiment, the immunogen may be a polypeptide encoded by the nucleic acid sequences of the invention. The present invention therefore also relates to polypeptides produced from the nucleic acid sequences of the invention or fragments thereof. In one embodiment, polypeptides of the present invention can be recombinantly produced by synthesis from the nucleic acid sequences of the invention or isolated fragments thereof, and purified, or partially purified, from transfected cells using methods already known in the art. In an alternative embodiment, the polypeptides may be purified or partially purified from viral particles produced via transfection of a host cell with the nucleic acid sequences of the invention. Such polypeptides might, for example, include either capsid or envelope polypeptides prepared from the sequences of the present invention.

When used as immunogens, the nucleic acid sequences of the invention, or the polypeptides or viruses produced therefrom, are preferably partially purified prior to use as immunogens in pharmaceutical compositions and vaccines of the present invention. When used as a vaccine, the sequences and the polypeptide and virus products thereof, can be administered alone or in a suitable diluent, including, but not limited to, water, saline, or some type of buffered medium. The vaccine according to the present invention may be administered to an animal, especially a mammal, and most especially a human, by a variety of routes, including, but not limited to, intradermally, intramuscularly, subcutaneously, or in any combination thereof.

Suitable amounts of material to administer for prophylactic and therapeutic purposes will vary depending on the route selected and the immunogen (nucleic acid, virus, polypeptide) administered. One skilled in the art will appreciate that the amounts to be administered for any particular treatment protocol can be readily determined without undue experimentation. The vaccines of the present invention may be administered once or periodically until a suitable titer of anti-HCV antibodies appear in the blood. For an immunogen consisting of a nucleic acid sequence, a suitable amount of nucleic acid sequence to be used for prophylactic purposes might be expected to fall in the range of from about 100 µg to about 5 mg and most preferably in the range of from about 500 µg to about 2mg. For a polypeptide, a suitable amount to use for prophylactic purposes is preferably 100 ng to 100 µg and for a virus 10^2 to 10^6 infectious doses. Such administration will, of course, occur prior to any sign of HCV infection.

A vaccine of the present invention may be employed in such forms as capsules, liquid solutions, suspensions or elixirs for oral administration, or sterile liquid forms such as solutions or suspensions. An inert carrier is preferably used, such as saline or phosphate-buffered saline, or any such carrier in which the HCV of the present invention can be suitably suspended. The vaccines may be in the form of single dose preparations or in multi-dose flasks which can be utilized for mass-vaccination programs of both animals and humans. For purposes of using the vaccines of the present invention reference is made to Remington's

Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., Osol (Ed.) (1980); and New Trends and Developments in Vaccines, Voller et al. (Eds.), University Park Press, Baltimore, Md. (1978), both of which provide much useful information for preparing and using vaccines. Of course, the polypeptides of the present invention, when used as vaccines, can include, as part of the composition or emulsion, a suitable adjuvant, such as alum (or aluminum hydroxide) when humans are to be vaccinated, to further stimulate production of antibodies by immune cells. When nucleic acids, viruses or polypeptides are used for vaccination purposes, other specific adjuvants such as CpG motifs (Krieg, A.K. et al.(1995) and (1996)), may prove useful.

When the nucleic acids, viruses and polypeptides of the present invention are used as vaccines or inocula, they will normally exist as physically discrete units suitable as a unitary dosage for animals, especially mammals, and most especially humans, wherein each unit will contain a predetermined quantity of active material calculated to produce the desired immunogenic effect in association with the required diluent. The dose of said vaccine or inoculum according to the present invention is administered at least once. In order to increase the antibody level, a second or booster dose may be administered at some time after the initial dose. The need for, and timing of, such booster dose will, of course, be determined within the sound judgment of the administrator of such vaccine or inoculum and according to sound principles well known in the art. For example, such booster dose could reasonably be expected to be advantageous at some time

between about 2 weeks to about 6 months following the initial vaccination. Subsequent doses may be administered as indicated.

The nucleic acid sequences, viruses and polypeptides of the present invention can also be administered for purposes of therapy, where a mammal, especially a primate, and most especially a human, is already infected, as shown by well known diagnostic measures. When the nucleic acid sequences, viruses or polypeptides of the present invention are used for such therapeutic purposes, much of the same criteria will apply as when it is used as a vaccine, except that inoculation will occur post-infection. Thus, when the nucleic acid sequences, viruses or polypeptides of the present invention are used as therapeutic agents in the treatment of infection, the therapeutic agent comprises a pharmaceutical composition containing a sufficient amount of said nucleic acid sequences, viruses or polypeptides so as to elicit a therapeutically effective response in the organism to be treated. Of course, the amount of pharmaceutical composition to be administered will, as for vaccines, vary depending on the immunogen contained therein (nucleic acid, polypeptide, virus) and on the route of administration.

The therapeutic agent according to the present invention can thus be administered by subcutaneous, intramuscular or intradermal routes. One skilled in the art will certainly appreciate that the amounts to be administered for any particular treatment protocol can be readily determined without undue experimentation. Of course, the actual amounts will vary depending on the route of administration as well as the sex, age, and

clinical status of the subject which, in the case of human patients, is to be determined with the sound judgment of the clinician.

The therapeutic agent of the present invention can be employed in such forms as capsules, liquid solutions, suspensions or elixirs, or sterile liquid forms such as solutions or suspensions. An inert carrier is preferably used, such as saline, phosphate-buffered saline, or any such carrier in which the HCV of the present invention can be suitably suspended. The therapeutic agents may be in the form of single dose preparations or in the multi-dose flasks which can be utilized for mass-treatment programs of both animals and humans. Of course, when the nucleic acid sequences, viruses or polypeptides of the present invention are used as therapeutic agents they may be administered as a single dose or as a series of doses, depending on the situation as determined by the person conducting the treatment.

The nucleic acids, polypeptides and viruses of the present invention can also be utilized in the production of antibodies against HCV. The term "antibody" is herein used to refer to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules. Examples of antibody molecules are intact immunoglobulin molecules, substantially intact immunoglobulin molecules and portions of an immunoglobulin molecule, including those portions known in the art as Fab, $F(ab')_2$ and F(v) as well as chimeric antibody molecules.

Thus, the polypeptides, viruses and nucleic acid sequences of the present invention can be used in

the generation of antibodies that immunoreact (i.e., specific binding between an antigenic determinant-containing molecule and a molecule containing an antibody combining site such as a whole antibody molecule or an active portion thereof) with antigenic determinants on the surface of hepatitis C virus particles.

The present invention therefore also relates to antibodies produced following immunization with the nucleic acid sequences, viruses or polypeptides of the present invention. These antibodies are typically produced by immunizing a mammal with an immunogen or vaccine to induce antibody molecules having immunospecificity for polypeptides or viruses produced in response to infection with the nucleic acid sequences of the present invention. When used in generating such antibodies, the nucleic acid sequences, viruses, or polypeptides of the present invention may be linked to some type of carrier molecule. The resulting antibody molecules are then collected from said mammal. Antibodies produced according to the present invention have the unique advantage of being generated in response to authentic, functional polypeptides produced according to the actual cloned HCV genome.

The antibody molecules of the present invention may be polyclonal or monoclonal. Monoclonal antibodies are readily produced by methods well known in the art. Portions of immunoglobin molecules, such as Fabs, as well as chimeric antibodies, may also be produced by methods well known to those of ordinary skill in the art of generating such antibodies.

The antibodies according to the present invention may also be contained in blood, plasma, serum, hybridoma supernatants, and the like. Alternatively, the antibody of the present invention is isolated to the extent desired by well known techniques such as, for example, using DEAE Sephadex. The antibodies produced according to the present invention may be further purified so as to obtain specific classes or subclasses of antibody such as IgM, IgG, IgA, and the like. Antibodies of the IgG class are preferred for purposes of passive protection.

The antibodies of the present invention are useful in the prevention and treatment of diseases caused by hepatitis C virus in animals, especially mammals, and most especially humans.

In providing the antibodies of the present invention to a recipient mammal, preferably a human, the dosage of administered antibodies will vary depending on such factors as the mammal's age, weight, height, sex, general medical condition, previous medical history, and the like.

In general, it will be advantageous to provide the recipient mammal with a dosage of antibodies in the range of from about 1 mg/kg body weight to about 10 mg/kg body weight of the mammal, although a lower or higher dose may be administered if found desirable. Such antibodies will normally be administered by intravenous or intramuscular route as an inoculum. The antibodies of the present invention are intended to be provided to the recipient subject in an amount sufficient to prevent, lessen or attenuate the severity, extent or duration of any existing infection.

The antibodies prepared by use of the nucleic acid sequences, viruses or polypeptides of the present invention are also highly useful for diagnostic purposes. For example, the antibodies can be used as in vitro diagnostic agents to test for the presence of HCV in biological samples taken from animals, especially humans. Such assays include, but are not limited to, radioimmunoassays, EIA, fluorescence, Western blot analysis and ELISAs. In one such embodiment, the biological sample is contacted with antibodies of the present invention and a labeled second antibody is used to detect the presence of HCV to which the antibodies are bound.

Such assays may be, for example, direct where the labeled first antibody is immunoreactive with the antigen, such as, for example, a polypeptide on the surface of the virus; indirect where a labeled second antibody is reactive with the first antibody; a competitive protocol such as would involve the addition of a labeled antigen; or sandwich where both labeled and unlabeled antibody are used, as well as other protocols well known and described in the art.

In one embodiment, an immunoassay method would utilize an antibody specific for HCV envelope determinants and would further comprise the steps of contacting a biological sample with the HCV-specific antibody and then detecting the presence of HCV material in the test sample using one of the types of assay protocols as described above. Polypeptides and antibodies produced according to the present invention may also be supplied in the form of a kit, either present in vials as purified material, or present in

compositions and suspended in suitable diluents as previously described.

In a preferred embodiment, such a diagnostic test kit for detection of HCV antigens in a test sample comprises in combination a series of containers, each container a reagent needed for such assay. Thus, one such container would contain a specific amount of HCV-specific antibody as already described, a second container would contain a diluent for suspension of the sample to be tested, a third container would contain a positive control and an additional container would contain a negative control. An additional container could contain a blank.

For all prophylactic, therapeutic and diagnostic uses, the antibodies of the invention and other reagents, plus appropriate devices and accessories, may be provided in the form of a kit so as to facilitate ready availability and ease of use.

The present invention also relates to the use of nucleic acid sequences and polypeptides of the present invention to screen potential antiviral agents for antiviral activity against HCV. Such screening methods are known by those of skill in the art. Generally, the antiviral agents are tested at a variety of concentrations, for their effect on preventing viral replication in cell culture systems which support viral replication, and then for an inhibition of infectivity or of viral pathogenicity (and a low level of toxicity) in an animal model system.

In one embodiment, animal cells (especially human cells) transfected with the nucleic acid sequences of the invention are cultured in vitro and the cells are

treated with a candidate antiviral agent (a chemical, peptide etc.) by adding the candidate agent to the medium. The treated cells are then exposed, possibly under transfecting or fusing conditions known in the art, to the nucleic acid sequences of the present invention. A sufficient period of time would then be allowed to pass for infection to occur, following which the presence or absence of viral replication would be determined versus untreated control cells by methods known to those of ordinary skill in the art. Such methods include, but are not limited to, the detection of viral antigens in the cell, for example, by immunofluorescence procedures well known in the art; the detection of viral polypeptides by Western blotting using antibodies specific therefor; the detection of newly transcribed viral RNA within the cells by RT-PCR; and the detection of the presence of live, infectious virus particles by injection of cell culture medium or cell lysates into healthy, susceptible animals, with subsequent exhibition of the signs and symptoms of HCV infection. A comparison of results obtained for control cells (treated only with nucleic acid sequence) with those obtained for treated cells (nucleic acid sequence and antiviral agent) would indicate, the degree, if any, of antiviral activity of the candidate antiviral agent. Of course, one of ordinary skill in the art would readily understand that such cells can be treated with the candidate antiviral agent either before or after exposure to the nucleic acid sequence of the present invention so as to determine what stage, or stages, of viral infection and replication said agent is effective against.

In an alternative embodiment, viral enzyme such as NS3 protease, NS2-NS3 protease, NS3 helicase or NS5B RNA polymerase may be produced from a nucleic acid sequence of the invention and used to screen for inhibitors which may act as antiviral agents. The structural and nonstructural regions of the HCV genome, including nucleotide and amino acid locations, have been determined, for example, as depicted in Houghton, M. (1996), Fig. 1; and Major, M.E. et al. (1997), Table 2.

Such above-mentioned protease inhibitors may take the form of chemical compounds or peptides which mimic the known cleavage sites of the protease and may be screened using methods known to those of skill in the art (Houghton, M. (1996) and Major, M.E. et al. (1997)). For example, a substrate may be employed which mimics the protease's natural substrate, but which provides a detectable signal (e.g. by fluorimetric or colorimetric methods) when cleaved. This substrate is then incubated with the protease and the candidate protease inhibitor under conditions of suitable pH, temperature etc. to detect protease activity. The proteolytic activities of the protease in the presence or absence of the candidate inhibitor are then determined.

In yet another embodiment, a candidate antiviral agent (such as a protease inhibitor) may be directly assayed in vivo for antiviral activity by administering the candidate antiviral agent to a chimpanzee transfected with a nucleic acid sequence of the invention or infected with a virus of the invention and then measuring viral replication in vivo via methods such as RT-PCR. Of course, the chimpanzee may be treated with the candidate agent either before or after

transfection with the infectious nucleic acid sequence or infected with a virus of the invention so as to determine what stage, or stages, of viral infection and replication the agent is effective against.

The invention also provides that the nucleic acid sequences, viruses and polypeptides of the invention may be supplied in the form of a kit, alone or in the form of a pharmaceutical composition.

All scientific publication and/or patents cited herein are specifically incorporated by reference. The following examples illustrate various aspects of the invention but are in no way intended to limit the scope thereof.

EXAMPLES

Materials and Methods

Source of HCV

An infectious plasma pool of HCV genotype 2a ($HC\text{-}J6_{CH}$) prepared from acute phase plasma of a chimpanzee experimentally inoculated with plasma from a Japanese patient infected with strain HC-J6 (Okamoto *et al.*, 1991) was used for cloning. An infectious cDNA clone of HCV strain H77, genotype 1a was also used (pCV-H77C; Yanagi *et al.*, 1997).

Amplification, cloning and sequence analysis

Viral RNA was extracted from 100 µl aliquots of the $HC\text{-}J6_{CH}$ plasma pool with the TRIzol system (GIBCO/BRL) (Yanagi *et al.*, 1997). Primers used in cDNA synthesis and PCR amplification were based on the genomic sequence of strain HC-J6 (Okamoto *et al.*, 1991) and from the conserved region (3'X) of the 3' UTR of HCV genotype 2a (Tanaka *et al.*, 1996) (Table 1). The RNA

was denatured at 65°C for 2 min, and cDNA was synthesized at 42°C for 1 hour with Superscript II reverse transcriptase (GIBCO/BRL) and specific reverse primers in 20 µl reaction volumes. The cDNA mixtures were treated with RNase H and RNase T1 (GIBCO/BRL) at 37°C for 20 min.

TABLE 1

Oligonucleotides used for amplification and cloning of strain HC-J6$_{CH}$, genotype 2a

Designation	Sequence (5′ → 3′)a
2427S-H77	ACTGGACACGGAGGTGGCCGCGTC
2426S-H77	TTGTTCTTGTCGGGTTAATGGCGC
2645R-H77	GGGTGTACTACACACATGAGTAAG
2832R-H77	AAGCGCCCCTAACTGATGATG
H2751SII	**CGTCATCGATA**CCTCAGCGGGCATATGCACTGGACACGGA
H2786R	GTCCAGTGCATATGCCCGCTGAGG
H2870R	CATGCACCAGCTGATATAGCGCTTGTAATATG
H7851S	TCCGTAGAGGAAGCTTGCAGCCTGACGCCC
H9140S (M)	CAGAGGAGGCAGGGTGCTATATGTGGCAAGTAC
H9173R (M)	GTACTTGCCACATATAGCAGCCCTGCCTCCTCTG
H9471R	**CGTCTCTAGA**CAGGAAATGGCTTAAGAGGCCGGAGTGTTTACC
J6-H2556S	TTATGGATGCTCATCTTGTTGGGCCAGGCCGAAGCAGCTTTGGAGAACCTCGTAATACT CAATGC
356RF-J6H	AGGATTTGTGCTCATGGTGCACGGTCTACGAG
1S-J6F[b]	**TTTTTTTTGCGGCCGC*TAATACGACTCACTATAG***ACCCGCCCCTAATAGG
333S-J6	CCGTGCACCATGAGCACAAATCCTAAACCTC
753R-J6	GGATGTACCCCATGAGGTCGGCAAAG
2543S-J6F	GTTTGCGCCTGCTTATGGATGCTCATCTTG
2787R-J6(26)	GCGTCATAAGCATATGCCTGTTGGGG
3329R-J6	CCCTCAGCACTGGAGTACATCTG
5487-J6F	**CGTCATGCATA**CCCCTAGGGCGGCTCTCATTGAAGAGGG
5518R-J6F	CGTCCCCTCTTCAATGAGAGCCGCTCTAGA
9251S-J6F	GCGGTGAAGACCAAGCTCAAACTCACTC
9305R-J6F	**AATCTAGA**AGGCGCGCTTCCGGCAATGGAGTGAGTTTGAGC
9310R-J6F	**CGTCTCTAGA**GGATAAATCCAGGAGGCGCGCTTCCGGC
9399S-J6F	TACTTTTTGTAGGGGTAGGCCTTTTCC
9464-J6F	**CGTCTCTAGA**GTGTAGCTAATGTGTGCCGCTCTA
9470(24)-J6	CTATGGAGTGTAGCTAATGTGTGC
J6-3′ XR	**CGTCTCTAGA**CATGATCTGCAGAGAGACCAGTTACGGCACTCTCTGFCAGTCATGCGGC TCACGGACCTTTCACAGCTAGCCGTGACTAGGGCTAAGATGGAGCCACC

a HCV-specific sequences are shown in plain text, non HCV-specific sequences are shown in bold face, and cleavage sites used for cDNA cloning are underlined.

b The core sequence of the T7 promotor is shown in italics.

The strategy used to amplify and clone the full-length HC-J6$_{CH}$ sequence is shown in Fig. 1. Nucleotide positions correspond to those of the 2a

infectious clone (pJ6CF) that is described herein. The 5' end of HC-J6$_{CH}$ (nts. 17-297, excluding primer sequences) was amplified from 2 µl of cDNA synthesized with primer a-2 (Yanagi *et al.*, 1996). PCR was performed with *AmpliTaq Gold* DNA polymerase (Perkin-Elmer) as described previously (Yanagi *et al.*, 1996) using primers 1S-J6F and a-2. After purification, the amplified products were cloned into pGEM-T Easy vector (Promega) using standard procedures and 5 clones (pJ6-5'UTR) were sequenced.

The 3' end of HC-J6$_{CH}$ was amplified in 3 overlapping pieces. RT-PCR of a short fragment of NS5B (nts. 9279-9439) was performed with primers 9251S-J6F and 9464R-J6F as described above. The PCR products were cloned into pGEM-T Easy vector and sequence analysis was performed from 5 pJ6-3'F clones. A second region spanning from NS5B to the conserved region of the 3' UTR (nts. 9376-9629) was amplified in RT-nested PCR (external primers H9261F and H3'X58R, internal primers H9282F and H3'X45R) (Yanagi *et al.*, 1997). The amplified products were cloned into pGEM-9zf(-) by using *Hind*III and *Xba*I sites and 14 pJ6-3'VR clones were sequenced. The third fragment, which included the 3' terminal sequence was amplified with primers 9399S-J6F and J6-3'XR from one of the pJ6-3'VR clones, and cloned into one of the pJ6-3'F clones by using *Stu*I and *Xba*I sites (pJ6-3'X).

The ORF of HCV HC-J6$_{CH}$ was amplified by long RT-PCR in 3 overlapping pieces. The amplification was performed on 2 µl of the cDNA mixtures with the Advantage cDNA polymerase mix (Clontech) (Yanagi *et al.*, 1997). The J6S fragment (nts. 86-2761) was amplified

with primers a-1 (Yanagi et al., 1996) and J6-2787R from cDNA synthesized with primer J6-3329R. A single PCR round was performed in a Robocycler thermal cycler (Stratagene), and consisted of denaturation at 99°C for 35 sec, annealing at 67°C for 30 sec and elongation at 68°C for 4 min 30 sec during the first 5 cycles, 5 min during the next 10 cycles, 5 min 30 sec during the following 10 cycles and 6 min during the last 10 cycles. The J6B fragment (nts. 2573-5488) was amplified with primers 2543S-J6F and 5518R-J6F from cDNA synthesized with primer 5518R-J6F. Finally, the J6A fragment (nts. 5515-9282) was amplified with primers 5487S-J6F and 9310R-J6F from cDNA synthesized with primer 9470R(24)-J6F. PCR amplifications of fragments J6B and J6A consisted of denaturation at 99°C for 35 sec, annealing at 67°C for 30 sec and elongation at 68°C for 6 min during the first 5 cycles, 7 min during the next 10 cycles, 8 min during the following 10 cycles and 9 min during the last 10 cycles.

After purification of the long PCR products with QIAquick PCR purification kit (QIAGEN), A-tailing reactions were performed with *AmpliTaq* DNA polymerase (Perkin Elmer) at 72 °C for 1 hour. The gel-purified A-tailed PCR products were cloned into pCR2.1 vector (Invitrogen) or pGEM-T Easy vector (Promega). DH5-alpha competent cells (GIBCO BRL) were transformed and selected on LB agar plates containing 100 µg/ml ampicillin (SIGMA) and amplified in LB liquid cultures at 30°C for 18 - 20 hrs (Yanagi *et al.*, 1997). Midiprep was performed using Wizard *Plus* Midipreps DNA

Purification System (Promega). Multiple clones of the J6S, J6A and the J6B fragments were sequenced.

The consensus sequence of strain HC-$J6_{CH}$ (nts. 17-9629) was determined by direct sequencing of PCR products (nts. 297-3004 and nts. 4893-5762) and by sequence analysis of the TA clones (nts. 17-5488 and nts. 5515-9629)(Fig. 1). Both strands of DNA were sequenced in all cases. Analyses of genomic sequences, including multiple sequence alignments and tree analyses, were performed with GeneWorks (Oxford Molecular Group) (Bukh *et al.*, 1995).

Construction of chimeric cDNA clones of genotypes 1a & 2a

Four full-length intertypic chimeric cDNA clones were constructed (Figs. 4, 5A, 5B). In each clone the C, E1 and E2 genes encoded the consensus amino acid sequence of HC-$J6_{CH}$. The p7 protein was encoded either by the HC-$J6_{CH}$ or pCV-H77C consensus sequence, and the NS proteins were all encoded by pCV-H77C genes. To engineer these cDNA clones, an *Nde*I site from pCV-H77C was first eliminated by a silent substitution (C to T) at position 9158. In brief, two fragments were amplified from pCV-H77C with primers H7851S and H9173R(M) and with primers H9140S(M) and H9417R (Table 3), gel-purified and used for fusion PCR with primers H7851S and H9417R. The fusion PCR products were cloned into pCV-H77C by using *Hind*III and *Afl*II sites. A new artificial *Nde*I site was introduced by a silent substitution (C to T) at position 2765. PCR products, which were amplified from pCV-H77C with primer H2751SII containing artificial *Cla*I and NdeI sites and primer H2870R, were cloned into the modified pCV-H77C by using

*Cla*I and *Eco*47III sites. The final construct (pH77CV) was used as a cassette vector to construct the intertypic chimeric HCV cDNA clones.

The four chimeric cDNA clones were constructed as follows. pH77CV-J6S (nucleotide sequence shown in SEQ ID No:3 and amino acid sequence shown in SEQ ID No:4): The *Age*I/*Bsm*I fragment of clone J6S2 and the *Bsm*I/*Nde*I fragment of clone J6S1, were cloned into pH77CV by using *Age*I and *Nde*I sites; pH77 (p7)CV-J6S (nucleotide sequence shown in SEQ ID No:5 and amino acid sequence shown in SEQ ID No:6): A fragment of pH77CV-J6S was replaced with a fragment amplified from pCV-H77C with primers J6-H2556S and H2786R by using *Bsa*BI and *Nde*I sites; J6S (nucleotide sequence shown in SEQ ID No:7 and amino acid sequence shown in SEQ ID No:8): A fragment amplified from pH77pCV-H77C with primers a-1 and 356RF-J6H77 and another fragment amplified from pH77CV-J6S with primers 333S-J6 and 753R-J6 were gel-purified and a fusion-PCR was performed with primers a-1 and 753R-J6. The *Age*I/*Cla*I fragment of the subcloned fusion PCR products and the *Cla*I/*Nde*I fragment of pH77CV-J6S were cloned into pH77CV-J6S by using *Age*I and *Nde*I sites; pH77(p7)-J6S (nucleotide sequence shown in SEQ ID No:9 and amino acid sequence shown in SEQ ID No:10): The AgeI/ClaI fragment of J6S and the *Cla*I/*Nde*I fragment of (p7)CV-J6S were cloned into pH77(p7)CV-J6S by using *Age*I and *Nde*I sites.

Each intertypic chimeric cDNA clone was retransformed to select a single clone, and large-scale preparation of plasmid DNA was performed with a QIAGEN plasmid Maxi kit as described previously (Yanagi *et al.*, 1997). Each of the four cDNA clones was completely

sequenced before inoculation. Each clone was genetically stable since the digestion pattern was as expected following retransformation and the complete sequence was the expected one.

Construction of full-length cDNA clone HC-$J6_{CH}$

An overview of the full-length HC-$J6_{CH}$ clone is presented in Fig. 1. In the final construct pJ6CF, which encodes the consensus polyprotein of HC-$J6_{CH}$, an *Xba*I site was eliminated by a silent substitution (A to G) at position 5494. Digested fragments containing the consensus sequence were purified from the appropriate subclones and ligated using the sites indicated. The full-length cDNA clone (pJ6CF) was retransformed to select a single clone, and large-scale preparation of plasmid DNA followed by the complete sequence analysis was performed. Clone pJ6CF was genetically stable.

Intrahepatic transfection of chimpanzee with transcribed RNA

In duplicate 100 µl reactions, RNA was transcribed *in vitro* with T7 RNA polymerase (Promega) from 10 µg of template plasmid linearized with *Xba*I (Promega) as described previously (Yanagi *et al.*, 1997). The integrity of the RNA was checked by electrophoresis through agarose gel stained with ethidium bromide (Yanagi *et al.*, 1997). Each transcription mixture was diluted with 400 µl of ice-cold phosphate-buffered saline without calcium or magnesium and then immediately frozen on dry ice and stored at -80°C. Within 24 hours, both transcription mixtures were injected into the same chimpanzee by percutaneous intrahepatic injection guided by ultrasound (Yanagi *et al.*, 1998, 1999). If the

chimpanzee did not become infected, the same transfection was repeated once. After two negative results, the next clone was inoculated into the same chimpanzee following the same protocol. Injections were performed at weeks 0 and 2 with pH77CV-J6S, at weeks 5 and 8 with pH77(p7)CV-J6S, at weeks 14 and 16 with pH77-J6S, at weeks 19 and 23 with pH77(p7)-J6S, at week 28 with pJ6CF, and finally at week 34 with pCV-H77C. The chimpanzee was maintained under conditions that met or exceeded all requirements for its use in an approved facility.

Serum samples were collected weekly from the chimpanzee and monitored for liver enzyme levels by standard procedures, anti-HCV antibodies by the second-generation ELISA (Abbott) and HCV RNA by a sensitive RT-nested PCR assay with *AmpliTaq Gold* DNA polymerase using primers from the 5' UTR (Yanagi *et al.*, 1996). Samples were scored as negative for HCV RNA if two independent tests on 100 µl of serum were negative. The genome equivalent (GE) titer of HCV in positive samples was determined by RT-nested PCR on 10-fold serial dilutions of the extracted RNA (Bukh *et al.*, 1998). The consensus sequence of the complete ORF from the chimpanzee infected with RNA transcripts of pJ6CF was determined by direct sequencing of overlapping PCR products obtained by long RT-nested PCR as previously described (Yanagi *et al.*, 1997) with HC-J6 specific primers. After the intrahepatic transfection with RNA transcripts of pCV-H77C, we performed H77(genotype 1a)-specific RT-nested PCR with primers 2427S-H77 and 2832R-H77 for the 1st round and with primers 2462S-H77 and 2645R-H77 for the 2nd round (Table 3). The

sensitivity of this assay was equivalent to that of the assay using 5' UTR primers when testing serum containing only H77, genotype 1a. The genome titer of genotype 1a was determined by using this specific RT- nested PCR on 10-fold serial dilutions of the extracted RNA.

EXAMPLE 1

Sequence analysis of HCV strain HC-J6$_{CH}$

As minor deviations from the consensus amino acid sequence were found previously to render full-length HCV cDNA clones noninfectious (Yanagi *et al.*, 1997, 1998), the consensus sequence of the cloning source of genotype 2a (strain HC-J6$_{CH}$) was determined prior to constructing any full-length clones. In brief, a plasma pool containing strain HC-J6$_{CH}$ was prepared from acute phase plasmapheresis units collected from a chimpanzee experimentally infected with HC-J6 (Okamoto *et al.*, 1991). The HCV genome titer of this pool was $10^{5.4}$ genome equivalents (GE)/ml (Quantiplex HCV RNA bDNA 2.0, Chiron) and the infectivity titer was 10^4 chimpanzee infectious doses/ml.

The consensus sequence of the 5' UTR of HC-J6$_{CH}$ (nts. 17-340) was deduced from 5 clones containing nts. 17-297 and 8 clones containing nts. 86-340. The 5' UTR of the various clones was highly conserved, but the consensus sequence of HC-J6$_{CH}$ differed by 2 nucleotides from that published previously for HC-J6 (Okamoto *et al.*, 1991: C to T at position 36 and T to C at position 222).

The consensus sequence of 14 clones of the 3' UTR of HC-J6$_{CH}$ indicated that the 39 nucleotide long variable region was highly conserved in this strain and

was identical to that previously published for HC-J6 (Okamoto *et al.*, 1991). The polypyrimidine tract varied greatly in length (84-164 nucleotides), and contained some conserved A residues. In the conserved region, the proximal 16 nucleotides were identical to those previously published for isolates of different HCV genotypes (Kolykhalov *et al.*, 1996; Tanaka *et al.*, 1996; Yamada *et al.*, 1996). The remaining 82 nucleotides of the conserved region were determined for other genotype 2a strains (Tanaka *et al.*, 1996) but not for HC-J6 or $HC\text{-}J6_{CH}$.

The ORF of $HC\text{-}J6_{CH}$ was amplified in 3 fragments by RT-PCR (Fig. 1). Eight clones of the J6S fragment (nts. 86-2761), 6 clones of the J6B fragment (nts. 2573-5488) and 6 clones of the J6A fragment (nts. 5515-9298) were sequenced. PCR fragments containing nts. 5489-5514 were sequenced directly. A quasispecies was found at 243 nucleotide (2.7%) and 69 amino acid (2.3%) positions, scattered throughout the 9099 nts (3033 aa) of the ORF. However, the majority, 231 nucleotide substitutions, were detected only once and 71.6 % of these represented silent mutations. The 12 remaining nucleotide substitutions were each restricted to 2 clones and only 4 of these resulted in amino acid changes. The nucleotide difference among the J6S clones ranged from 0.1 - 1.3%, among the J6B clones it ranged from 0.1 - 0.3%, and it ranged from 0.2 - 4.0% among the J6A clones (Fig. 2). Three of 8 J6S clones, 4 of 6 J6B clones, and all 6 J6A clones had defective polyproteins due to nucleotide deletions, insertions or substitutions.

The sequences of clones of strain HC-J6$_{CH}$ were relatively homogeneous. This was highlighted by the high degree of conservation among clones of the HVR1 (Fig. 3), a region frequently used to study the quasispecies of HCV (Bukh *et al.*, 1995). An exception was the sequence of clone J6A1, which differed by about 4% from the other clones of this region (Fig. 2). Importantly, the consensus sequence of strain HC-J6$_{CH}$ (nts. 17-9629) could be determined with no ambiguity at the nucleotide or deduced amino acid level. The difference between the consensus ORF sequence of HC-J6$_{CH}$ from the experimentally infected chimpanzee and that of HC-J6 of the inoculum (Okamoto *et al.*, 1991) was 4.1 % and 2.2 % at the nucleotide and deduced amino acid levels, respectively (Fig. 2, Table 2). Moreover, we found that 12 (44.4%) of the 27 amino acids constituting HVR1 differed between HC-J6$_{CH}$ and HC-J6 (Fig. 3). Such diversities are greater than the < 2 % generally considered to comprise a quasispecies. In fact, these differences are equivalent to those found between the two prototype strains of HCV genotype 1a [strains HCV-1 (Choo *et al.*, 1991) and H77 (Yanagi *et al.*, 1997)]. These results indicated that HC-J6$_{CH}$, which represented the major species in the experimentally infected chimpanzee, was a minor species in the original inoculum.

TABLE 2

Percent difference of nucleotide and predicted amino acid sequences between strain HC-J6 (Okamoto *et al.*, 1991) and strain HC-J6$_{CH}$ from acute phase plasma pool of a chimpanzee inoculated with HC-J6

Genome Region	nt.position[a]	% nt. difference	% a.a. difference
ORF	341-9439	4.1 (373/9099)[b]	2.2 (66/3033)[b]
5' UTR	17-340	0.6 (2/324)	
Core	341-913	0.5 (3/573)	0 (0/191)
E1	914-1489	4.3 (25/576)	2.1 (4/192)
HVR1	1490-1570	24.7 (20/81)	44.4 (12/27)
E2-$_{HVR1}$	1571-2590	3.9 (40/1020)	3.2 (11/340)
p7	2591-2779	3.7 (7/189)	3.2 (2/63)
NS2	2780-3430	4.0 (26/651)	2.8 (6/217)
NS3	3431-5323	4.0 (76/1893)	0.8 (5/631)
NS4A	5324-5485	4.3 (7/162)	1.9 (1/54)
NS4B	5486-6268	3.7 (29/783)	0.4 (1/261)
NS5A	6269-7666	5.4 (75/1398)	3.4 (16/466)
NS5B	7667-9439	3.7 (65/1773)	1.4 (8/591)
3' UTR	9440-9481	0 (0/42)	

a The nucleotide positions correspond to those of the infectious full-length genotype 2a clone (pJ6CF).

b The numbers in parenthesis indicate the nucleotide or amino acid differences for each region.

Example 2

Chimeric molecular clones

As chimeric flaviviruses with substituted structural genes have been useful in defining the biological function of viral sequences or proteins, in analyzing immune responses and in generating attenuated vaccine candidates (Bray and Lai, 1991; Chambers *et al.*, 1999; Pletnev *et al.*, 1992, 1993, 1998). The consensus sequence of the 2a structural genes and surrounding region was substituted for that of the infectious 1a cDNA clone. In the genotype 1a backbone, two silent mutations were introduced for cloning purposes [at positions 2765 (p7) and 9158 (NS5B) of pCV-H77C] (Fig. 4). The complete sequence of each chimera was verified. Infectivity of RNA transcripts from four different

intertypic chimeric clones (Figs. 4, 5A, 5B) was evaluated by consecutive intrahepatic transfections of a chimpanzee. Clones were considered not to be viable if viral RNA was not detected in the serum within two weeks of the repeat transfection. All chimeric clones contained the C, E1 and E2 genes of genotype 2a. The two chimeric clones tested initially differed from each other in that one had the p7 gene of 2a (pH77CV-J6S) and the other [pH77(p7)CV-J6S] the p7 gene of 1a. They differed from the two other clones in that the 186 nucleotides of the 5' UTR just upstream of the initiation codon were from the 2a genotype. Since neither clone containing the chimeric 5' UTR was infectious, the chimeric 5' UTR was replaced with the consensus genotype 1a 5' UTR to generate the two p7 varieties [pH77-J6S and pH77(p7)-J6S]. After consecutive transfection of the four clones, no HCV RNA, anti-HCV or ALT elevation was detected in the chimpanzee during 28 weeks of follow-up, suggesting that RNA transcripts from these intertypic chimeric clones were not viable *in vivo*.

This finding that the intertypic clones between genotypes 1a and 2a were not viable was surprising since flavivirus chimeras containing the structural region of dengue virus type 1 or 2 or of tick-borne encephalitis virus and the nonstructural region of an infectious dengue type 4 virus were viable (Bray and Lai, 1991; Pletnev *et al.*, 1992, 1993). While considerable sequence variation exists between the infectious genotype 1a and 2a clones of HCV (Table 3), these viruses exhibit a higher degree of genetic heterogeneity than do the major genotypes of HCV. For other flaviviruses, however, it was possible to obtain

infectious chimeric clones only if the capsid region was derived from the backbone cDNA clone (Chambers *et al.*, 1999; Pletnev and Men, 1998).

TABLE 3

Percent difference of the amino acid sequences between the infectious clone of genotype 1a (pCV-H77C; Yanagi *et al.*, 1997) and the infectious clone of genotype 2a (pJ6CF) of hepatitis C virus

Genome Region[a]	% difference
Polyprotein	27.9 (839/3007)[b]
Core	8.9 (17/191)
E1	37.0 (71/192)
HVR1	59.3 (16/27)
$E2-_{HVR1}$	27.1 (91/336)
p7	38.1 (24/63)
NS2	41.9 (91/217)
NS3	19.2 (121/631)
NS4A	33.3 (18/54)
NS4B	26.8 (70/261)
NS5A	38.5 (171/444)
NS5B	25.2 (149/591)

a Genome regions defined as in Table 1.
b The numbers in parenthesis indicate the amino acid differences for each region. Positions with deletions or insertions in E2 (4 aa positions) and NS5A (26 aa positions) were not considered.

Trivial explanations may account for the lack of viability of these intertypic chimeras. First, the two silent mutations introduced in the genotype 1a backbone (one in p7 and one in NS5B) for cloning purposes could potentially eliminate infectivity. This is, however, very unlikely since mutations at these positions exist among field isolates of HCV including strain $HC-J6_{CH}$ (Bukh *et al.*, 1998). Also, it is noteworthy that the three previously published infectious clones of strain H77 had numerous silent nucleotide differences (Hong *et al.*, 1999; Kolykhalov *et al.*, 1997; Yanagi *et al.*, 1997). Second, signal peptidases might not cleave the chimeric E2/p7 or p7/NS2

junction. This seems unlikely, however, since eukaryotic signal peptidases typically recognize the amino acid sequences upstream of the cleavage site [the (-3, -1) rule] (Nielsen *et al.*, 1997) and the amino acids at these two sites are conserved between genotypes 1a and 2a (Fig. 5B). Finally, the E2/p7 and/or p7/NS2 gene junctions could differ between genotypes 1a and 2a. The junctions determined for genotypes 1a and 1b were used (Lin *et al.*, 1994; Mizushima *et al.*, 1994; Selby *et al.*, 1994) because those for genotype 2a have not been identified. In the latter two cases, further analyses of genotype 2a should eventually provide sufficient data to overcome such potential problems and it would most likely be possible to construct a viable chimera.

More complicated explanations for the lack of viability of the chimeras might be required if critical genotype-specific interactions occur as regards the structural proteins, the nonstructural proteins and the genomic RNA. For instance, one cannot rule out that the chimeras were not viable because the IRES function was compromised. In *in vitro* studies the IRES activity depended on RNA sequences not only in the 5' UTR but also extending 3' of the translation initiation site (Hahm *et al.*, 1998; Lemon and Honda, 1997; Reynolds *et al.*, 1995). Although the 3' border of the HCV IRES is still controversial it is believed to involve at most the first 39 nts of the core gene (Lemon and Honda, 1997). The 5' UTR of the intertypic chimeras was either a chimera of genotype 1a and 2a sequences or the entire 5' UTR was derived from the 1a clone (Figs. 4, 5A). Importantly, the 5' end of core is conserved among genotypes 1a and 2a (Fig. 5A). Thus, the predicted

IRES-like secondary structure is maintained in these chimeras, suggesting that the IRES activity most likely was maintained.

Possible interactions between the structural proteins and the nonstructural proteins and/or the genomic RNA, which involve RNA packaging, replication or translation are conceivable. In poliovirus, which is another positive-sense RNA virus, functional coupling of RNA packaging to RNA replication and of RNA replication to translation have been suggested (Novak and Kirkegaard, 1994 ; Nugent *et al.*, 1999). Similar to other viruses of the *Flaviviridae* family, a membrane-associated replicase complex is thought to initiate replication at the 3' end of HCV and to synthesize a complementary negative-strand RNA (Rice, 1996). The putative cis-acting elements at the 5' and 3' termini which are believed to be important for viral genome replication (Rice 1996; Frolov et al., 1998) should be maintained in the intertypic HCV chimeras at least in the two constructs with the authentic 1a 5'UTR. However, it is conceivable that the viral packaging system was interrupted (Frolov *et al.*, 1998). Studies using a Kunjin flavivirus replicon system and providing the structural proteins *in trans* suggested that the essential encapsidation signals did not reside in the structural region of the genome (Khromykh *et al.*, 1997, 1998). The location of the packaging signals of HCV is not known. However, if the structural proteins encapsidate viral RNA via genotype-specific sequences outside of the structural region, the chimeras would be unable to package the RNA and it might be extremely

difficult to construct viable chimeras between highly divergent strains.

Example 3

A consensus molecular clone of genotype 2a is infectious *in vivo*

In order to prove that the genotype 2a portion used in the 4 intertypic chimeric cDNA clones indeed represented the infectious sequence, a consensus full-length cDNA clone of HC-J6$_{CH}$ (pJ6CF) was constructed. The core sequence of the T7 promoter, a 5' guanosine residue and the full-length sequence of HC-J6$_{CH}$ (9711 nts) were cloned into pGEM-9Zf vector using NotI/XbaI sites. Within the HCV sequence there were no deduced amino acid differences and only 4 nucleotide differences (at nucleotide positions 1822, 5494, 9247 and 9289) from the consensus sequence of HC-J6$_{CH}$ as determined in the present study. The silent mutation at position 1822 was within the structural region and so was also present in the four intertypic chimeras. The 5' terminal 16 nts and the 3' terminal 82 nts were deduced from previously published HCV genotype 2a sequences (Okamoto *et al.*, 1991, Tanaka *et al.*, 1996). The full-length cDNA clone of genotype 2a contained a 5' UTR of 340 nts, an ORF of 9099 nts encoding 3033 amino acids and a 3' UTR consisting of a variable region of 39 nts followed by a 132 nucleotide-long polypyrimidine tract interrupted with 3 A residues and the 3' terminal conserved region of 98 nts.

RNA transcripts from pJ6CF were injected into the same chimpanzee used for injection of the 4 intertypic chimeras. The chimpanzee became infected at

the first attempt with an HCV titer of 10^2 GE/ml at week 1 post inoculation (p.i.), and 10^3-10^4 GE/ml during weeks 2 to 6 p.i. The consensus sequence of PCR products of the complete ORF, amplified from serum obtained during week 5 p.i., was identical to the sequence of pJ6CF and there was no evidence of a quasispecies. Since RNA transcripts of this infectious genotype 2a clone were infectious *in vivo*, and it shared an exact sequence with the non-infectious intertypic chimeric clones, their failure to replicate must have been the result of incompatibilities between the genotype 1a and 2a sequences.

To confirm that the chimpanzee used was susceptible also to infection by genotype 1a, which comprised most of the intertypic chimeras, the chimpanzee was subsequently inoculated with RNA transcripts from the infectious genotype 1a clone (pCV-H77C). Serum samples were tested in an H77-specific RT-PCR assay to identify super-infection with genotype 1a. At week 1 p.i. the total HCV genome titer was 10^4 GE/ml and the H77-specific (1a) genome titer was 10^2 GE/ml. The H77-specific genome titer increased to 10^3 GE/ml at week 2 p.i., and reached 10^4 GE/ml during weeks 3-6 p.i. The consensus sequence of PCR products amplified with H77-specific primers at weeks 1-6 p.i. were found to be identical to that of pCV-H77C. However, the direct sequences of PCR products amplified with the 5' UTR primers at weeks 1-2 after inoculation of pCV-H77C were identical to that of pJ6CF indicating that the 2a genotype was still present and represented the majority species. These experiments confirmed that the inability of the intertypic 1a, 2a

cDNA clones to infect the chimpanzee was not the result of protective immune responses in the chimpanzee but represented deficiencies intrinsic to the chimeras.

Discussion

The published infectious cDNA clones of HCV represent the two most important subtypes of genotype 1 (Hong *et al.*, 1999; Kolykhalov *et al.*, 1997; Yanagi *et al.*, 1997, 1998). However, 5 more major genotypes of HCV are recognized. In the above Examples, the infectivity of a cDNA clone of a second major HCV genotype was demonstrated. As in previous studies, the infectivity of RNA transcripts was demonstrated *in vivo* by intrahepatic transfection of a chimpanzee. This new infectious clone (pJ6CF) encodes the consensus polyprotein of HCV strain HC-J6$_{CH}$, genotype 2a. Its encoded polyprotein differs from those of the infectious clones of genotypes 1a and 1b by approximately 30% (Table 2). Genotype 2 strains, in particular subtypes 2a and 2b, have a worldwide distribution and important differences between genotypes 1 and 2 with respect to pathogenesis and treatment were indicated in previous studies. The availability of an infectious clone representing a second major genotype of HCV should permit new ways of studying the molecular biology and immunopathology of this important and genetically quite different human pathogen.

The 5' and 3' UTRs of HCV are believed to be critical for viral replication, translation and viral packaging (Rice, 1996). The 5' 203 terminal nucleotides and the 3' 101 terminal nucleotides of the published infectious clones of genotypes 1a and 1b were identical.

However, the sequences of UTRs of the genotype 2a clone differ from those of the genotype 1 clones. Overall, the 5' UTR of the genotype 2a clone has 17 nt differences and a single nucleotide deletion compared with the infectious clones of genotype 1a (Fig. 5A). Five of these differences and the deletion are within the first 30 nucleotides, whereas the remainder are found within the predicted IRES structure. Differences also exist between the 3' UTR of the genotype 2a clone and the clones of genotype 1a (Fig. 5B). The sequences of the variable region are very different. Recent study has shown this region is not critical for infectivity *in vivo* (Yanagi *et al.*, 1999). Within the regions which are critical for infectivity *in vivo* (Yanagi *et al.*, 1999), the 132 nucleotide-long polypyrimidine tract of the genotype 2a clone has 3 unique A residues interspersed and the 3' terminal conserved region of 98 nts has 4 nt differences within the 3' terminal stable stem-loop structure (Fig. 5B) (Kolykhalov *et al.*, 1996; Tanaka *et al.*, 1996). Since the 2a clone was infectious these sequence differences are apparently real and are compatible with infectivity. Further studies are required to determine whether these represent critical genotype-specific sequences.

References

1. Alter, M. J. (1997). Hepatology 26, 62S-65S.

2. Blight, K. J. and Rice, C. M. (1997). J. Virol. 71, 7345-7352.

3. Brechot, C. (1997). Hepatology 25, 772-774.

4. Bray, M. and Lai, C.-J. (1991). Construction of intertypic chimeric dengue viruses by substitution of structural protein genes. *Proc. Natl. Acad. Sci. USA* 88, 10342-10346.

5. Bukh, J., Apgar, C. L., Engle, R., Govindarajan, S., Hegerich, P. A., Tellier, R., Wong, D. C., Elkins, R. & Kew, M. C. (1998). Experimental infection of chimpanzees with hepatitis C virus of genotype 5a: genetic analysis of the virus and generation of a standardized challenge pool. *J. Infect. Dis.* 178, 1193-1197.

6. Bukh, J., Emerson, S. U. and Purcell, R. H. (1997). Genetic heterogeneity of hepatitis C virus and related viruses. In "Viral Hepatitis and Liver Disease, Proceedings of IX Triennial International Symposium on Viral Hepatitis and Liver Disease, Rome, Italy, 1996" (M. Rizzetto, R. H. Purcell, J. L. Gerin and G. Verme, Eds.), pp. 167-175. Edizioni Minerva Medica, Turin.

7. Bukh, J., Miller, R. H. and Purcell, R. H. (1995). Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. *Semin. Liver Dis.* 15, 41-63.

8. Bukh, J., Purcell, R. H. and Miller, R. H. (1993). At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide. *Proc. Natl. Acad. Sci. USA* 90, 8234-8238.

9. Choo, Q.-L., Richman, K. H., Han, J. H., Berger, K., Lee, C., Dong, C., Gallegos, C., Coit, D., Medina-Selby, A., Barr, P. J., Weiner, A. J., Bradley, D. W., Kuo, G. and Houghton M. (1991). Genetic organization and diversity of the hepatitis C virus. *Proc. Natl. Acad. Sci. USA* 88, 2451-2455.

10. Chambers T. J., Nestorowicz A., Mason P. W. and Rice C. M. (1999). Yellow Fever/Japanese Encephalitis Chimeric Viruses: Construction and Biological Properties. *J. Virol.* 73: 3095-3101.

11. Dash, S., et al. (1997). Am. J. Pathol. 151, 363-373.

12. Davis, G. L., Esteban-Mur, R., Rustgi, V., Hoefs, J.,Gordon, S. C., Trepo, C., Shiffman, M. L., Zeuzem, S., Craxi, A., Ling, M.-H. and Albrecht, J., for the international hepatits interventional therapy group. (1998). Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. *N. Engl. J. Med.* 339, 1493-1499.

13. Fausto, N. (1997). Am. J. Pathol. 151, 361.

14. Forns, X., Bukh, J., Purcell, R. H., Emerson, S. U. (1997). How *Escherichia coli* can bias the results of molecular cloning: preferential selection of defective genomes of hepatitis C virus during the cloning procedure. *Proc. Natl. Acad. Sci. USA* 94, 13909-13914.

15. Forns, X. and Bukh, J. (1998). Methods for determining the hepatitis C virus genotype. *Viral Hepatitis Reviews* 4, 1-19.

16. Fried, M. W. and Hoofnagle, J. H. (1995). Semin. Liver Dis. 15, 82-91.

17. Frolov, I., McBride, M. S. and Rice, C. M. (1998). Cis-acting RNA elements required for replication of bovine viral diarrhea virus-hepatits C virus 5' nontranslated region chimeras. *RNA* 4, 1418-1435.

18. Hahm, B., Kim, Y. K., Kim, J. H., Kim, T. Y. and Jang, S. K. (1998). Heterogeneous nuclear ribonucleoprotein L interacts with the 3' border of the internal ribosomal entry site of hepatits C virus. *J. Virol.* 72, 8782-8788.

19. Hijikata, M., Kato, N., Ootsuyama, Y., Nakagawa, M., Ohkoshi, S. and Shimotohno, K. (1991). Hypervariable regions in the putative glycoprotein of hepatitis C virus. *Biochem. Biophys. Res. Commun.* 175, 220-228.

20. Honda, M., et al. (1996). RNA 2, 955-968.

21. Hong, Z., Beaudet-Miller, M., Lanford, R. E., Guerra, B., Wright-Minogue, J., Skelton, A., Baroudy, B. M., Reyes, G. R. and Lau, J. Y. N. (1999). Generation of transmissible hepatitis C virions from a molecular clone in chimpanzees. *Virology* 256, 36-44.

22. Hoofnagle, J. H. (1997). Hepatitis C: the clinical spectrum of disease. *Hepatology* 26, 15S-20S.

23. Houghton, M. (1996). Hepatitis C viruses. In "Fields Virology" (B. N. Fields, D. M. Knipe, P. M. Howley, *et al.*, Eds.), Third ed., pp. 1035-1058. Lippincott-Raven Publishers, Philadelphia.

24. Khromykh, A. A. and Westaway, E. G. (1997). Subgenomic replicons of the flavivirus Kunjin: construction and applications. *J. Virol.* 71, 1497-1505.

25. Ito, T. and Lai, M. M. C. (1997). J. Virol. 71, 8698-8706.

26. Khromykh, A. A., Varnavski, A. N. and Westaway, E. G. (1998). Encapsidation of the flavivirus Kunjin replicon RNA by using a complementation system providing Kunjin virus structural proteins in *trans*. *J. Virol.* 72, 5967-5977.

27. Kolykhalov, A. A., Feinstone, S. M. and Rice, C. M. (1996). Identification of a highly conserved sequence element at the 3' terminus of hepatitis C virus genome RNA. *J. Virol.* 70, 3363-3371.

28. Kolykhalov, A. A., Agapov, E. V., Blight, K. J., Mihalik, K., Feinstone, S. M. and Rice, C. M. (1997). Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. *Science* 277, 570-574.

29. Lemon, S. M. and Honda, M. (1997). Internal ribosome entry sites within the RNA genomes of hepatits C virus and other flaviviruses. *Semin. Virol.* 8, 274-288.

30. Lin, C., Lindenbach, B. D., Pragai, B. M., McCourt, D. W. and Rice, C. M. (1994). Processing in the hepatitis C virus E2-NS2 region: identification of p7 and two distinct E2-specific products with different C termini. *J. Virol.* 68, 5063-5073.

31. Lu, H.-H. and Wimmer, E. (1996). Poliovirus chimeras replicating under the translational control of genetic elements of hepatitis C virus reveal unusual properties of the internal ribosomal entry site of hepatitis C virus. *Proc. Natl. Acad. Sci. USA* 93, 1412-1417.

32. McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M.-H., Cort, S. and Albrecht, J. K., for the hepatits interventional therapy group. (1998). Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. *N. Engl. J. Med.* 339, 1485-1492.

33. Mizushima, H., Hijikata, M., Asabe, S.-I., Hirota, M., Kimura, K. and Shimotohno, K. (1994). Two hepatitis C virus glycoprotein E2 products with different C termini. *J. Virol.* 68, 6215-6222.

34. Nakao, H., Okamoto, H., Tokita, H., Inoue, T., Iizuka, H., Pozzato, G. and Mishiro, S. (1996). Full-length genomic sequence of a hepatitis C virus genotype 2c isolate (BEBE1) and the 2c-specific PCR primers. *Arch. Virol.* 141, 701-704.

35. Nielsen, H., Engelbrecht, J., Brunak, S. and von Heijne, G. (1997). Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. *Protein Eng.* 10, 1-6.

36. Novak, J. E. and Kirkegaard, K. (1994). Coupling between genome translation and replication in an RNA virus. *Genes Dev.* 8, 1726-1737.

37. Nugent, C. I., Johnson, K. L., Sarnow, P. and Kirkegaard, K. (1999). Functional coupling between replication and packaging of poliovirus replicon RNA. *J. Virol.* 73, 427-435.

38. Okamoto, H., Kurai, K., Okada, S. I., Yamamoto, K., Iizuka, H., Tanaka, T., Fukuda, S., Tsuda, F. and Mishiro, S. (1992). Full-length sequence of hepatitis C virus genome having poor homology to reported isolates: comparative study of four distinct genotypes. *Virology* 188, 331-341.

39. Okamoto, H., Okada, S., Sugiyama, Y., Kurai, K., Iizuka, H., Machida, A., Miyakawa, Y. and

40. Mayumi, M. (1991). Nucleotide sequence of the genomic RNA of hepatitis C virus isolated from a human carrier: comparison with reported isolates for conserved and divergent regions. *J. Gen. Virol.* 72, 2697-2704.

41. Pletnev, A. G., Bray, M., Huggins, J. and Lai, C.-J. (1992). Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses. *Proc. Natl. Acad. Sci. USA* 89, 10532-10536.

42. Pletnev, A. G., Bray, M. and Lai, C.-J. (1993). Chimeric tick-borne encephalitis and dengue type 4 viruses: Effects of mutations on neurovirulence in mice. *J. Virol.* 67, 4956-4963.

43. Pletnev, A. G. and Men, R. (1998). Attenuation of the Langat tick-borne flavivirus by chimerization with mosquito-borne flavivirus dengue type 4. *Proc. Natl. Acad. Sci. USA* 95, 1746-1751.

44. Reynolds, J. E., Kaminski, A., Kettinen, H. J., Grace, K., Clarke, B. E., Carroll, A. R., Rowlands, D. J. and Jackson, R. J. (1995). Unique features of internal initiation of hepatitis C virus RNA translation. *EMBO J.* 14, 6010-6020.

45. Rice, C. M. (1996). Flaviviridae: The viruses and their replication, In "Fields Virology". (B. N. Fields, D. M. Knipe, P. M. Howley, et al., Eds.), Third ed., pp. 931-959. Lippincott-Raven Publishers, Philadelphia.

46. Robertson, B., Myers, G., Howard, C., Brettin, T., Bukh, J., Gaschen, B., Gojobori, T., Maertens, G., Mizokami, M., Nainan, O., Netesov, S., Nishioka, K., Shin-i, T., Simmonds, P., Smith, D., Stuyver, L. and Weiner, A. (1998). Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. *Arch. Virol.* 143, 2493-2503.

47. Selby, M. J., Glazer, E., Masiarz, F. and Houghton, M. (1994). Complex processing and protein:protein interactions in the E2:NS2 region of HCV. *Virology* 204, 114-122.

48. Simmonds, P., Holmes, E. C., Cha, T.-A., Chan, S.-W., McOmish, F., Irvine, B., Beall, E., Yap, P. L., Kolberg, J. and Urdea, M. S. (1993). Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. *J. Gen. Virol.* 74, 2391-2399.

49. Tanaka, T., Kato, N., Cho, M.-J. and Shimotohno, K. (1995). A novel sequence found at the 3' terminus of hepatitis C virus genome. *Biochem. Biophys. Res. Commun.* 215, 744-749.

50. Tanaka, T., Kato, N., Cho, M.-J., Sugiyama, K. and Shimotohno, K. (1996). Structure of the 3' terminus of the hepatitis C virus genome. *J. Virol.* 70, 3307-3312.

51. Tsuchihara, K., et al. (1997) J. Virol. 71, 6720-6726.

52. Tsukiyama-Kohara, K., et al. (1992) J. Virol. 66, 1476-1483.

53. Vassilev, V. B., Collett, M. S. and Donis, R. O. (1997). Authentic and chimeric full-length genomic cDNA clones of bovine viral diarrhea virus that yield infectious transcripts. *J. Virol.* 71, 471-478.

54. Weiner, A. J., Brauer, M. J., Rosenblatt, J., Richman, K. H., Tung, J., Crawford, K., Bonino, F., Saracco, G., Choo, Q.-L., Houghton, M. and Han, J. H. (1991). Variable and hypervariable domains are found in the regions of HCV corresponding to the Flavivirus envelope and NS1 proteins and the Pestivirus envelope glycoproteins. *Virology* 180, 842-848.

55. World Health Organization (1997). Hepatitis C. *Weekly Epidemiol. Rec.* 72, 65-72.

56. Yamada, N., Tanihara, K., Takada, A., Yorihuzi, T., Tsutsumi, M., Shimomura, H., Tsuji, T. and Date, T. (1996). Genetic organization and diversity of the 3' noncoding region of the hepatitis C virus genome. *Virology* 223, 255-261.

57. Yanagi, M., Bukh, J., Emerson, S. U. and Purcell, R. H. (1996). Contamination of commercially available fetal bovine sera vith bovine viral diarrhea virus genomes: implications for the study of hepatitis C virus in cell cultures. *J. Infect. Dis.* 174, 1324-1327.

58. Yanagi, M., Purcell, R. H., Emerson, S. U. and Bukh, J. (1997). Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. *Proc. Natl. Acad. Sci. USA* 94, 8738-8743.

59. Yanagi, M., St. Claire, M., Shapiro, M., Emerson, S. U., Purcell, R. H. and Bukh, J. (1998). Transcripts of a chimeric cDNA clone of hepatitis C virus genotype 1b are infectious *in vivo*. *Virology* 244, 161-172.

60. Yanagi, M., St. Claire, M., Emerson, S. U., Purcell, R. H. and Bukh, J. (1999). *In vivo* analysis of the 3' untranslated region of hepatitis C virus after in vitro mutagenesis of an infectious cDNA clone. *Proc. Natl. Acad. Sci. USA* 96, 2291-2295.

61. Yoo, B. J., et al. (1995). J. Virol. 69, 32-38.

62. Zhao, W. D., Wimmer, E. and Lahser, F. C. (1999). Poliovirus/hepatitis C virus (internal ribosomal entry site-core) chimeric viruses: improved growth properties through modification of a proteolytic cleavage site and requirement for core RNA sequences but not for core-related polypeptides. *J. Virol.* 73, 1546-1554.

WHAT IS CLAIMED IS:

1. A purified and isolated nucleic acid molecule which encodes human hepatitis C virus of genotype 2a, said molecule capable of expressing said virus when transfected into cells.

2. The nucleic acid molecule of claim 1, wherein said molecule encodes the amino acid sequence of SEQ ID NO:2.

3. The nucleic acid molecule of claim 2, wherein said molecule comprises the nucleic acid sequence of SEQ ID NO:1.

4. A DNA construct comprising a nucleic acid molecule according to claim 1.

5. A DNA construct comprising a nucleic acid molecule according to claim 3.

6. An RNA transcript of the DNA construct of claim 4.

7. An RNA transcript of the DNA construct of claim 5.

8. A cell transfected with the DNA construct of claim 4.

9. A cell transfected with the DNA construct of claim 5.

10. A cell transfected with RNA transcript of claim 6.

11. A cell transfected with RNA transcript of claim 7.

12. A hepatitis C virus polypeptide produced by the cell of claims 8 or 9.

13. A hepatitis C virus polypeptide produced by the cell of claims 10 or 11.

14. A hepatitis C virus produced by the cell of claims 8 or 9.

15. A hepatitis C virus produced by the cell of claims 10 or 11.

16. A hepatitis C virus whose genome comprises a nucleic acid molecule according to claim 1.

17. A hepatitis C virus whose genome comprises a nucleic acid molecule according to claim 3.

18. A method for producing a hepatitis C virus comprising transfecting a host cell with the RNA transcript of claims 6 or 7.

19. A polypeptide encoded by a nucleic acid sequence according to claim 1.

20. A polypeptide encoded by a nucleic acid sequence according to claim 3.

21. The polypeptide of claim 19, wherein said polypeptide is selected from the group consisting of NS3 protease, E1 protein, E2 protein or NS4 protein.

22. The polypeptide of claim 20, wherein said polypeptide is selected from the group consisting of NS3 protease, E1 protein, E2 protein or NS4 protein.

23. A method for assaying candidate antiviral agents for activity against HCV, comprising:

a) exposing a cell containing the hepatitis C virus of claims 16 or 17 to the candidate antiviral agent; and

b) measuring the presence or absence of hepatitis C virus replication in the cell of step (a).

24. The method of claim 23, wherein said replication in step (b) is measured by at least one of the following: negative strand RT-PCR, quantitative RT-PCR, Western blot, immunofluoresence, or infectivity in a susceptible animal.

25. A method for assaying candidate antiviral agents for activity against HCV, comprising:

a) exposing an HCV protease encoded by a nucleic acid sequence according to claims 1 or 3 or a fragment thereof to the candidate antiviral agent in the presence of a protease substrate; and

b) measuring the protease activity of said protease.

26. The method of claim 25, wherein said HCV protease is selected from the group consisting of an NS3 domain protease, an NS3-NS4A fusion polypeptide, or an NS2-NS3 protease.

27. An antiviral agent identified as having antiviral activity for HCV by the method of claim 23.

28. An antiviral agent identified as having antiviral activity for HCV by the method of claim 25.

29. Antibody to the polypeptide of claim 19.

30. Antibody to the polypeptide of claim 20.

31. Antibody to the hepatitis C virus of claim 16.

32. Antibody to the hepatitis C virus of claim 17.

33. A method for determining the susceptibility of cells *in vitro* to support HCV infection, comprising the steps of:

a) growing animal cells in vitro;

b) transfecting into said cells the nucleic acid of claim 1; and

c) determining if said cells show indicia of HCV replication.

34. The method according to claim 33, wherein said cells are human cells.

35. A composition comprising a polypeptide of claim 19 suspended in a suitable amount of a pharmaceutically acceptable diluent or excipient.

36. A composition comprising a polypeptide of claim 20 suspended in a suitable amount of a pharmaceutically acceptable diluent or excipient.

37. A composition comprising a nucleic acid molecule of claim 1 suspended in a suitable amount of a pharmaceutically acceptable diluent or excipient.



FIG. 1



FIG. 2



FIG. 3



FIG. 4

5' Untranslated Region

FIG. 5A

```
                1                                                                                                   90
H77C            GCCAGCCCCC TGATGGGGGC GACACTCCAC CATGAATCAC TCCCCTGTGA GGAACTACTG TCTTCACGCA GAAAGCGTCT AGCCATGGCG
H77CV-J6S       .......... .......... .......... .......... .......... .......... .......... .......... ..........
H77(p7)CV-J6S   .......... .......... .......... .......... .......... .......... .......... .......... ..........
H77-J6S         .......... .......... .......... .......... .......... .......... .......... .......... ..........
H77(p7)-J6S     .......... .......... .......... .......... .......... .......... .......... .......... ..........
J6CF            A..C.....- .A..A..... ........G. .......... .......... .......... .......... .......... ..........

               91                                                                                                  180
H77C            TTAGTATGAG TGTCGTGCAG CCTCCAGGAC CCCCCCTCCC GGGAGAGCCA TAGTGGTCTG CGGAACCGGT GAGTACACCG GAATTGCCAG
H77CV-J6S       .......... .......... .......... .......... .......... .......... ....______ .......... ........G.
H77(p7)CV-J6S   .......... .......... .......... .......... .......... .......... ....______ .......... ........G.
H77-J6S         .......... .......... .......... .......... .......... .......... ....______ .......... ..........
H77(p7)-J6S     .......... .......... .......... .......... .......... .......... ....______ .......... ..........
J6CF            .......... ......A... ........C. .......... .......... .......... ....______ .......... ........G.
                                                                                      AgeI
               181                                                                                                  270
H77C            GACGACCGGG TCCTTTCTTG GATAAACCCG CTCAATGCCT GGAGATTTGG GCGTGCCCCC GCAAGACTGC TAGCCGAGTA GTGTTGGGTC
H77CV-J6S       ..A...T... .......... .........G ...T.....C ..CC...... .......... .......... .......... .C.......T
H77(p7)CV-J6S   ..A...T... .......... .........G ...T.....C ..CC...... .......... .......... .......... .C.......T
H77-J6S         .......... .......... .......... .......... .......... .......... .......... .......... ..........
H77(p7)-J6S     .......... .......... .......... .......... .......... .......... .......... .......... ..........
J6CF            ..A...T... .......... .........G ...T.....C ..CC...... .......... .......... .......... .C.......T

               271                                                                                                  360
H77C            GCGAAAGGCC TTGTGGTACT GCCTGATAGG GTGCTTGCGA GTGCCCCGGG AGGTCTCGTA GACCGTGCAC CATGAGCACG AATCCTAAAC
H77CV-J6S       .......... .......... .......... .......... .......... .......... .......... .........A ..........
H77(p7)CV-J6S   .......... .......... .......... .......... .......... .......... .......... .........A ..........
H77-J6S         .......... .......... .......... .......... .......... .......... .......... .........A ..........
H77(p7)-J6S     .......... .......... .......... .......... .......... .......... .......... .........A ..........
J6CF            .......... .......... .......... .......... .......... .......... .......... .........A ..........
```

FIG. 5B

3' Untranslated Region

```
              9375                                                                                                           9518
H77C          TGAAGGTTGG GGTAAACACT CCGGCCTCTT AAGCCATTTC CTG (Polypyrimidine tract)81  AATGGTGGCT CCATCTTAGC
H77CV-J6S     .......... .......... .......... .......... ... (Polypyrimidine tract)81  .......... ..........
H77(p7)CV-J6S .......... .......... .......... .......... ... (Polypyrimidine tract)81  .......... ..........
H77-J6S       .......... .......... .......... .......... ... (Polypyrimidine tract)81  .......... ..........
H77(p7)-J6S   .......... .......... .......... .......... ... (Polypyrimidine tract)81  .......... ..........
J6CF          .AG..CGGCA CAC.TTAG.. A.ACT.CA.A GCTAAC.G.. .C- (Polypyrimidine tract)132 ---....... ..........

              9519                                                                             9599
H77C          CCTAGTCACG GCTAGCTGTG AAAGGTCCGT GAGCCGCATG ACTGCAGAGA GTGCTGATAC TGGCCTCTCT GCAGATCATG T
H77CV-J6S     .......... .......... .......... .......... .......... .......... .......... .......... .
H77(p7)CV-J6S .......... .......... .......... .......... .......... .......... .......... .......... .
H77-J6S       .......... .......... .......... .......... .......... .......... .......... .......... .
H77(p7)-J6S   .......... .......... .......... .......... .......... .......... .......... .......... .
J6CF          .......... .......... .......... .......... .......... ....C.TA.. ...T...... .......... .
```

E2/p7/NS2 Region

```
                                  E2/p7                          p7                              p7/NS2
                                    ↓                                                               ↓
              730                                                                                                     825
H77C          RVCSCLWMMLLISQAEA ALENLVILNAASLAGTHGLVSFLVFFCFAWYLKGRWVPGAVYALYGMWPLLLLLLALPQRAYA LDTEVAASCGGVVLVG
H77CV-J6S     ...A....LI.LG.... ...K....H...A.SCN.FLY.VI..VA...I...V..L.T.S.T.L.SFS........Q... ................
H77(p7)CV-J6S ...A....LI.LG.... .............................................................. ................
H77-J6S       ...A....LI.LG.... ...K....H...A.SCN.FLY.VI..VA...I...V..L.T.S.T.L.SFS........Q... ................
H77(p7)-J6S   ...A....LI.LG.... .............................................................. ................
J6CF          ...A....LI.LG.... ...K....H...A.SCN.FLY.VI..VA...I...V..L.T.S.T.L.SFS........Q... Y.AS.HGQI.AAL..M
```

H77C

10	20	30	40	50	
1234567890	1234567890	1234567890	1234567890	1234567890	
GCCAGCCCCC	TGATGGGGGC	GACACTCCAC	CATGAATCAC	TCCCCTGTGA	50
GGAACTACTG	TCTTCACGCA	GAAAGCGTCT	AGCCATGGCG	TTAGTATGAG	100
TGTCGTGCAG	CCTCCAGGAC	CCCCCCTCCC	GGGAGAGCCA	TAGTGGTCTG	150
CGGAACCGGT	GAGTACACCG	GAATTGCCAG	GACGACCGGG	TCCTTTCTTG	200
GATAAACCCG	CTCAATGCCT	GGAGATTTGG	GCGTGCCCCC	GCAAGACTGC	250
TAGCCGAGTA	GTGTTGGGTC	GCGAAAGGCC	TTGTGGTACT	GCCTGATAGG	300
GTGCTTGCGA	GTGCCCCCGG	AGGTCTCGTA	GACCGTGCAC	CATGAGCACG	350
AATCCTAAAC	CTCAAAGAAA	AACCAAACGT	AACACCAACC	GTCGCCCACA	400
GGACGTCAAG	TTCCCGGGTG	GCGGTCAGAT	CGTTCGTCGA	GTTTACTTGT	450
TGCCGCGCAG	GGGCCCTAGA	TTGGGTGTGC	GCGCGACGAG	GAAGACTTCC	500
GAGCGGTCGC	AACCTCGAGG	TAGACGTCAG	CCTATCCCCA	AGGCACGTCG	550
GCCCGAGGGC	AGGACCTCGG	CTCAGCCCGG	GTACCCTTGG	CCCCTCTATG	600
GCAATGAGGG	TTGCGGGTGG	GCGGGATGGC	TCCTGTCTCC	CCGTGGCTCT	650
CGGCCTAGCT	GGGGCCCCAC	AGACCCCCGG	CGTAGGTCGC	GCAATTTGGG	700
TAAGGTCATC	GATACCCTTA	CGTGCGGCTT	CGCCGACCTC	ATGGGGTACA	750
TACCGCTCGT	CGGCGCCCCT	CTTGGAGGCG	CTGCCAGGGC	CCTGGCGCAT	800
GGCGTCCGGG	TTCTGGAAGA	CGGCGTGAAC	TATGCAACAG	GGAACCTTCC	850
TGGTTGCTCT	TTCTCTATCT	TCCTTCTGGC	CCTGCTCTCT	TGCCTGACTG	900
TGCCCGCTTC	AGCCTACCAA	GTGCGCAATT	CCTCGGGGCT	TTACCATGTC	950
ACCAATGATT	GCCCTAACTC	GAGTATTGTG	TACGAGGCGG	CCGATGCCAT	1000
CCTGCACACT	CCGGGGTGTG	TCCCTTGCGT	TCGCGAGGGT	AACGCCTCGA	1050
GGTGTTGGGT	GGCGGTGACC	CCCACGGTGG	CCACCAGGGA	CGGCAAACTC	1100
CCCACAACGC	AGCTTCGACG	TCATATCGAT	CTGCTTGTCG	GGAGCGCCAC	1150
CCTCTGCTCG	GCCCTCTACG	TGGGGGACCT	GTGCGGGTCT	GTCTTTCTTG	1200
TTGGTCAACT	GTTTACCTTC	TCTCCCAGGC	GCCACTGGAC	GACGCAAGAC	1250
TGCAATTGTT	CTATCTATCC	CGGCCATATA	ACGGGTCATC	GCATGGCATG	1300
GGATATGATG	ATGAACTGGT	CCCCTACGGC	AGCGTTGGTG	GTAGCTCAGC	1350
TGCTCCGGAT	CCCACAAGCC	ATCATGGACA	TGATCGCTGG	TGCTCACTGG	1400
GGAGTCCTGG	CGGGCATAGC	GTATTTCTCC	ATGGTGGGGA	ACTGGGCGAA	1450
GGTCCTGGTA	GTGCTGCTGC	TATTTGCCGG	CGTCGACGCG	GAAACCCACG	1500
TCACCGGGGG	AAATGCCGGC	CGCACCACGG	CTGGCTTGT	TGGTCTCCTT	1550
ACACCAGGCG	CCAAGCAGAA	CATCCAACTG	ATCAACACCA	ACGGCAGTTG	1600
GCACATCAAT	AGCACGGCCT	TGAATTGCAA	TGAAAGCCTT	AACACCGGCT	1650
GGTTAGCAGG	GCTCTTCTAT	CAACACAAAT	TCAACTCTTC	AGGCTGTCCT	1700
GAGAGGTTGG	CCAGCTGCCG	ACGCCTTACC	GATTTTGCCC	AGGGCTGGGG	1750
TCCTATCAGT	TATGCCAACG	GAAGCGGCCT	CGACGAACGC	CCCTACTGCT	1800
GGCACTACCC	TCCAAGACCT	TGTGGCATTG	TGCCCGCAAA	GAGCGTGTGT	1850
GGCCCGGTAT	ATTGCTTCAC	TCCCAGCCCC	GTGGTGGTGG	GAACGACCGA	1900

FIG. 6A

SUBSTITUTE SHEET (RULE 26)

H77C

10	20	30	40	50	
1234567890	1234567890	1234567890	1234567890	1234567890	
CAGGTCGGGC	GCGCCTACCT	ACAGCTGGGG	TGCAAATGAT	ACGGATGTCT	1950
TCGTCCTTAA	CAACACCAGG	CCACCGCTGG	GCAATTGGTT	CGGTTGTACC	2000
TGGATGAACT	CAACTGGATT	CACCAAAGTG	TGCGGAGCGC	CCCCTTGTGT	2050
CATCGGAGGG	GTGGGCAACA	ACACCTTGCT	CTGCCCCACT	GATTGCTTCC	2100
GCAAACATCC	GGAAGCCACA	TACTCTCGGT	GCGGCTCCGG	TCCCTGGATT	2150
ACACCCAGGT	GCATGGTCGA	CTACCCGTAT	AGGCTTTGGC	ACTATCCTTG	2200
TACCATCAAT	TACACCATAT	TCAAAGTCAG	GATGTACGTG	GGAGGGGTCG	2250
AGCACAGGCT	GGAAGCGGCC	TGCAACTGGA	CGCGGGCGGA	ACGCTGTGAT	2300
CTGGAAGACA	GGGACAGGTC	CGAGCTCAGC	CCGTTGCTGC	TGTCCACCAC	2350
ACAGTGGCAG	GTCCTTCCGT	GTTCTTTCAC	GACCCTGCCA	GCCTTGTCCA	2400
CCGGCCTCAT	CCACCTCCAC	CAGAACATTG	TGGACGTGCA	GTACTTGTAC	2450
GGGGTAGGGT	CAAGCATCGC	GTCCTGGGCC	ATTAAGTGGG	AGTACGTCGT	2500
TCTCCTGTTC	CTTCTGCTTG	CAGACGCGCG	CGTCTGCTCC	TGCTTGTGGA	2550
TGATGTTACT	CATATCCCAA	GCGGAGGCGG	CTTTGGAGAA	CCTCGTAATA	2600
CTCAATGCAG	CATCCCTGGC	CGGGACGCAC	GGTCTTGTGT	CCTTCCTCGT	2650
GTTCTTCTGC	TTTGCGTGGT	ATCTGAAGGG	TAGGTGGGTG	CCCGGAGCGG	2700
TCTACGCCCT	CTACGGGATG	TGGCCTCTCC	TCCTGCTCCT	GCTGGCGTTG	2750
CCTCAGCGGG	CATACGCACT	GGACACGGAG	GTGGCCGCGT	CGTGTGGCGG	2800
CGTTGTTCTT	GTCGGGTTAA	TGGCGCTGAC	TCTGTCGCCA	TATTACAAGC	2850
GCTATATCAG	CTGGTGCATG	TGGTGGCTTC	AGTATTTTCT	GACCAGAGTA	2900
GAAGCGCAAC	TGCACGTGTG	GGTTCCCCCC	CTCAACGTCC	GGGGGGGGCG	2950
CGATGCCGTC	ATCTTACTCA	TGTGTGTAGT	ACACCCGACC	CTGGTATTTG	3000
ACATCACCAA	ACTACTCCTG	GCCATCTTCG	GACCCCTTTG	GATTCTTCAA	3050
GCCAGTTTGC	TTAAAGTCCC	CTACTTCGTG	CGCGTTCAAG	GCCTTCTCCG	3100
GATCTGCGCG	CTAGCGCGGA	AGATAGCCGG	AGGTCATTAC	GTGCAAATGG	3150
CCATCATCAA	GTTAGGGGCG	CTTACTGGCA	CCTATGTGTA	TAACCATCTC	3200
ACCCCTCTTC	GAGACTGGGC	GCACAACGGC	CTGCGAGATC	TGGCCGTGGC	3250
TGTGGAACCA	GTCGTCTTCT	CCCGAATGGA	GACCAAGCTC	ATCACGTGGG	3300
GGGCAGATAC	CGCCGCGTGC	GGTGACATCA	TCAACGGCTT	GCCCGTCTCT	3350
GCCCGTAGGG	GCCAGGAGAT	ACTGCTTGGG	CCAGCCGACG	GAATGGTCTC	3400
CAAGGGGTGG	AGGTTGCTGG	CGCCCATCAC	GGCGTACGCC	CAGCAGACGA	3450
GAGGCCTCCT	AGGGTGTATA	ATCACCAGCC	TGACTGGCCG	GGACAAAAAC	3500
CAAGTGGAGG	GTGAGGTCCA	GATCGTGTCA	ACTGCTACCC	AAACCTTCCT	3550
GGCAACGTGC	ATCAATGGGG	TATGCTGGAC	TGTCTACCAC	GGGGCCGGAA	3600
CGAGGACCAT	CGCATCACCC	AAGGGTCCTG	TCATCCAGAT	GTATACCAAT	3650
GTGGACCAAG	ACCTTGTGGG	CTGGCCCGCT	CCTCAAGGTT	CCCGCTCATT	3700
GACACCCTGT	ACCTGCGGCT	CCTCGGACCT	TTACCTGGTC	ACGAGGCACG	3750
CCGATGTCAT	TCCCGTGCGC	CGGCGAGGTG	ATAGCAGGGG	TAGCCTGCTT	3800

FIG. 6B

H77C

10	20	30	40	50	
1234567890	1234567890	1234567890	1234567890	1234567890	
TCGCCCCGGC	CCATTTCCTA	CTTGAAAGGC	TCCTCGGGGG	GTCCGCTGTT	3850
GTGCCCCGCG	GGACACGCCG	TGGGCCTATT	CAGGGCCGCG	GTGTGCACCC	3900
GTGGAGTGGC	TAAAGCGGTG	GACTTTATCC	CTGTGGAGAA	CCTAGGGACA	3950
ACCATGAGAT	CCCCGGTGTT	CACGGACAAC	TCCTCTCCAC	CAGCAGTGCC	4000
CCAGAGCTTC	CAGGTGGCCC	ACCTGCATGC	TCCCACCGGC	AGCGGTAAGA	4050
GCACCAAGGT	CCCGGCTGCG	TACGCAGCCC	AGGGCTACAA	GGTGTTGGTG	4100
CTCAACCCCT	CTGTTGCTGC	AACGCTGGGC	TTTGGTGCTT	ACATGTCCAA	4150
GGCCCATGGG	GTTGATCCTA	ATATCAGGAC	CGGGGTGAGA	ACAATTACCA	4200
CTGGCAGCCC	CATCACGTAC	TCCACCTACG	GCAAGTTCCT	TGCCGACGGC	4250
GGGTGCTCAG	GAGGTGCTTA	TGACATAATA	ATTTGTGACG	AGTGCCACTC	4300
CACGGATGCC	ACATCCATCT	TGGGCATCGG	CACTGTCCTT	GACCAAGCAG	4350
AGACTGCGGG	GGCGAGACTG	GTTGTGCTCG	CCACTGCTAC	CCCTCCGGGC	4400
TCCGTCACTG	TGTCCCATCC	TAACATCGAG	GAGGTTGCTC	TGTCCACCAC	4450
CGGAGAGATC	CCCTTTTACG	GCAAGGCTAT	CCCCCTCGAG	GTGATCAAGG	4500
GGGGAAGACA	TCTCATCTTC	TGCCACTCAA	AGAAGAAGTG	CGACGAGCTC	4550
GCCGCGAAGC	TGGTCGCATT	GGGCATCAAT	GCCGTGGCCT	ACTACCGCGG	4600
TCTTGACGTG	TCTGTCATCC	CGACCAGCGG	CGATGTTGTC	GTCGTGTCGA	4650
CCGATGCTCT	CATGACTGGC	TTTACCGGCG	ACTTCGACTC	TGTGATAGAC	4700
TGCAACACGT	GTGTCACTCA	GACAGTCGAT	TTCAGCCTTG	ACCCTACCTT	4750
TACCATTGAG	ACAACCACGC	TCCCCCAGGA	TGCTGTCTCC	AGGACTCAAC	4800
GCCGGGGCAG	GACTGGCAGG	GGGAAGCCAG	GCATCTATAG	ATTTGTGGCA	4850
CCGGGGGAGC	GCCCCTCCGG	CATGTTCGAC	TCGTCCGTCC	TCTGTGAGTG	4900
CTATGACGCG	GGCTGTGCTT	GGTATGAGCT	CACGCCCGCC	GAGACTACAG	4950
TTAGGCTACG	AGCGTACATG	AACACCCCGG	GGCTTCCCGT	GTGCCAGGAC	5000
CATCTTGAAT	TTTGGGAGGG	CGTCTTTACG	GGCCTCACTC	ATATAGATGC	5050
CCACTTTTTA	TCCCAGACAA	AGCAGAGTGG	GGAGAACTTT	CCTTACCTGG	5100
TAGCGTACCA	AGCCACCGTG	TGCGCTAGGG	CTCAAGCCCC	TCCCCCATCG	5150
TGGGACCAGA	TGTGGAAGTG	TTTGATCCGC	CTTAAACCCA	CCCTCCATGG	5200
GCCAACACCC	CTGCTATACA	GACTGGGCGC	TGTTCAGAAT	GAAGTCACCC	5250
TGACGCACCC	AATCACCAAA	TACATCATGA	CATGCATGTC	GGCCGACCTG	5300
GAGGTCGTCA	CGAGCACCTG	GGTGCTCGTT	GGCGGCGTCC	TGGCTGCTCT	5350
GGCCGCGTAT	TGCCTGTCAA	CAGGCTGCGT	GGTCATAGTG	GGCAGGATCG	5400
TCTTGTCCGG	GAAGCCGGCA	ATTATACCTG	ACAGGGAGGT	TCTCTACCAG	5450
GAGTTCGATG	AGATGGAAGA	GTGCTCTCAG	CACTTACCGT	ACATCGAGCA	5500
AGGGATGATG	CTCGCTGAGC	AGTTCAAGCA	GAAGGCCCTC	GGCCTCCTGC	5550
AGACCGCGTC	CCGCCATGCA	GAGGTTATCA	CCCCTGCTGT	CCAGACCAAC	5600
TGGCAGAAAC	TCGAGGTCTT	TTGGGCGAAG	CACATGTGGA	ATTTCATCAG	5650
TGGGATACAA	TACTTGGCGG	GCCTGTCAAC	GCTGCCTGGT	AACCCCGCCA	5700

FIG. 6C

H77C

10	20	30	40	50	
1234567890	1234567890	1234567890	1234567890	1234567890	
TTGCTTCATT	GATGGCTTTT	ACAGCTGCCG	TCACCAGCCC	ACTAACCACT	5750
GGCCAAACCC	TCCTCTTCAA	CATATTGGGG	GGGTGGGTGG	CTGCCCAGCT	5800
CGCCGCCCCC	GGTGCCGCTA	CTGCCTTTGT	GGGTGCTGGC	CTAGCTGGCG	5850
CCGCCATCGG	CAGCGTTGGA	CTGGGGAAGG	TCCTCGTGGA	CATTCTTGCA	5900
GGGTATGGCG	CGGGCGTGGC	GGGAGCTCTT	GTAGCATTCA	AGATCATGAG	5950
CGGTGAGGTC	CCCTCCACGG	AGGACCTGGT	CAATCTGCTG	CCCGCCATCC	6000
TCTCGCCTGG	AGCCCTTGTA	GTCGGTGTGG	TCTGCGCAGC	AATACTGCGC	6050
CGGCACGTTG	GCCCGGGCGA	GGGGGCAGTG	CAATGGATGA	ACCGGCTAAT	6100
AGCCTTCGCC	TCCCGGGGGA	ACCATGTTTC	CCCCACGCAC	TACGTGCCGG	6150
AGAGCGATGC	AGCCGCCCGC	GTCACTGCCA	TACTCAGCAG	CCTCACTGTA	6200
ACCCAGCTCC	TGAGGCGACT	GCATCAGTGG	ATAAGCTCGG	AGTGTACCAC	6250
TCCATGCTCC	GGTTCCTGGC	TAAGGGACAT	CTGGGACTGG	ATATGCGAGG	6300
TGCTGAGCGA	CTTTAAGACC	TGGCTGAAAG	CCAAGCTCAT	GCCACAACTG	6350
CCTGGGATTC	CCTTTGTGTC	CTGCCAGCGC	GGGTATAGGG	GGGTCTGGCG	6400
AGGAGACGGC	ATTATGCACA	CTCGCTGCCA	CTGTGGAGCT	GAGATCACTG	6900
GACATGTCAA	AAACGGGACG	ATGAGGATCG	TCGGTCCTAG	GACCTGCAGG	6950
AACATGTGGA	GTGGGACGTT	CCCCATTAAC	GCCTACACCA	CGGGCCCCTG	6550
TACTCCCCTT	CCTGCGCCGA	ACTATAAGTT	CGCGCTGTGG	AGGGTGTCTG	6600
CAGAGGAATA	CGTGGAGATA	AGGCGGGTGG	GGGACTTCCA	CTACGTATCG	6650
GGTATGACTA	CTGACAATCT	TAAATGCCCG	TGCCAGATCC	CATCGCCCGA	6700
ATTTTTCACA	GAATTGGACG	GGGTGCGCCT	ACACAGGTTT	GCGCCCCCTT	6750
GCAAGCCCTT	GCTGCGGGAG	GAGGTATCAT	TCAGAGTAGG	ACTCCACGAG	6800
TACCCGGTGG	GGTCGCAATT	ACCTTGCGAG	CCCGAACCGG	ACGTAGCCGT	6850
GTTGACGTCC	ATGCTCACTG	ATCCCTCCCA	TATAACAGCA	GAGGCGGCCG	6900
GGAGAAGGTT	GGCGAGAGGG	TCACCCCCTT	CTATGGCCAG	CTCCTCGGCT	6950
AGCCAGCTGT	CCGCTCCATC	TCTCAAGGCA	ACTTGCACCG	CCAACCATGA	7000
CTCCCCTGAC	GCCGAGCTCA	TAGAGGCTAA	CCTCCTGTGG	AGGCAGGAGA	7050
TGGGCGGCAA	CATCACCAGG	GTTGAGTCAG	AGAACAAAGT	GGTGATTCTG	7100
GACTCCTTCG	ATCCGCTTGT	GGCAGAGGAG	GATGAGCGGG	AGGTCTCCGT	7150
ACCTGCAGAA	ATTCTGCGGA	AGTCTCGGAG	ATTCGCCCGG	GCCCTGCCCG	7200
TCTGGCGCG	GCCGGACTAC	AACCCCCCGC	TAGTAGAGAC	GTGGAAAAAG	7250
CCTGACTACG	AACCACCTGT	GGTCCATGGC	TGCCCGCTAC	CACCTCCACG	7300
GTCCCCTCCT	GTGCCTCCGC	CTCGGAAAAA	GCGTACGGTG	GTCCTCACCG	7350
AATCAACCCT	ATCTACTGCC	TTGGCCGAGC	TTGCCACCAA	AAGTTTTGGC	7400
AGCTCCTCAA	CTTCCGGCAT	TACGGGCGAC	AATACGACAA	CATCCTCTGA	7450
GCCCGCCCCT	TCTGGCTGCC	CCCCCGACTC	CGACGTTGAG	TCCTATTCTT	7500
CCATGCCCCC	CCTGGAGGGG	GAGCCTGGGG	ATCCGGATCT	CAGCGACGGG	7550
TCATGGTCGA	CGGTCAGTAG	TGGGGCCGAC	ACGGAAGATG	TCGTGTGCTG	7600

FIG. 6D

H77C

10	20	30	40	50	
1234567890	1234567890	1234567890	1234567890	1234567890	
CTCAATGTCT	TATTCCTGGA	CAGGCGCACT	CGTCACCCCG	TGCGCTCGCG	7650
AAGAACAAAA	ACTGCCCATC	AACGCACTGA	GCAACTCGTT	GCTACGCCAT	7700
CACAATCTGG	TGTATTCCAC	CACTTCACGC	AGTGCTTGCC	AAAGGCAGAA	7750
GAAAGTCACA	TTTGACAGAC	TGCAAGTTCT	GGACAGCCAT	TACCAGGACG	7800
TGCTCAAGGA	GGTCAAAGCA	GCGGCGTCAA	AAGTGAAGGC	TAACTTGCTA	7850
TCCGTAGAGG	AAGCTTGCAG	CCTGACGCCC	CCACATTCAG	CCAAATCCAA	7900
GTTTGGCTAT	GGGGCAAAAG	ACGTCCGTTG	CCATCCCAGA	AAGCCCGTAG	7950
CCCACATCAA	CTCCGTGTGG	AAAGACCTTC	TGGAAGACAG	TGTAACACCA	8000
ATAGACACTA	CCATCATGGC	CAAGAACGAG	GTTTTCTGCG	TTCAGCCTGA	8050
GAAGGGGGGT	CGTAAGCCAG	CTCGTCTCAT	CGTGTTCCCC	GACCTGGGCG	8100
TGCGCGTGTG	CGAGAAGATG	GCCCTGTACG	ACGTGGTTAG	CAAGCTCCCC	8150
CTGGCCGTGA	TGGGAAGCTC	CTACGGATTC	CAATACTCAC	CAGGACAGCG	8200
GGTTGAATTC	CTCGTGCAAG	CGTGGAAGTC	CAAGAAGACC	CCGATGGGGT	8250
TCTCGTATGA	TACCCGCTGT	TTTGACTCCA	CAGTCACTGA	GAGCGACATC	8300
CGTACGGAGG	AGGCAATTTA	CCAATGTTGT	GACCTGGACC	CCCAAGCCCG	8350
CGTGGCCATC	AAGTCCCTCA	CTGAGAGGCT	TTATGTTGGG	GGCCCTCTTA	8400
CCAATTCAAG	GGGGGAAAAC	TGCGGCTACC	GCAGGTGCCG	CGCGAGCGGC	8450
GTACTGACAA	CTAGCTGTGG	TAACACCCTC	ACTTGCTACA	TCAAGGCCCG	8500
GGCAGCCTGT	CGAGCCGCAG	GGCTCCAGGA	CTGCACCATG	CTCGTGTGTG	8550
GCGACGACTT	AGTCGTTATC	TGTGAAAGTG	CGGGGGTCCA	GGAGGACGCG	8600
GCGAGCCTGA	GAGCCTTCAC	GGAGGCTATG	ACCAGGTACT	CCGCCCCCCC	8650
CGGGGACCCC	CCACAACCAG	AATACGACTT	GGAGCTTATA	ACATCATGCT	8700
CCTCCAACGT	GTCAGTCGCC	CACGACGGCG	CTGGAAAGAG	GGTCTACTAC	8750
CTTACCCGTG	ACCCTACAAC	CCCCCTCGCG	AGAGCCGCGT	GGGAGACAGC	8800
AAGACACACT	CCAGTCAATT	CCTGGCTAGG	CAACATAATC	ATGTTTGCCC	8850
CCACACTGTG	GGCGAGGATG	ATACTGATGA	CCCATTTCTT	TAGCGTCCTC	8900
ATAGCCAGGG	ATCAGCTTGA	ACAGGCTCTT	AACTGTGAGA	TCTACGGAGC	8950
CTGCTACTCC	ATAGAACCAC	TGGATCTACC	TCCAATCATT	CAAAGACTCC	9000
ATGGCCTCAG	CGCATTTTCA	CTCCACAGTT	ACTCTCCAGG	TGAAATCAAT	9050
AGGGTGGCCG	CATGCCTCAG	AAAACTTGGG	GTCCCGCCCT	TGCGAGCTTG	9100
GAGACACCGG	GCCCCGGAGCG	TCCGCGCTAG	GCTTCTGTCC	AGAGGAGGCA	9150
GGGCTGCCAT	ATGTGGCAAG	TACCTCTTCA	ACTGGGCAGT	AAGAACAAAG	9200
CTCAAACTCA	CTCCAATAGC	GGCCGCTGGC	CGGCTGGACT	TGTCCGGTTG	9250
GTTCACGGCT	GGCTACAGCG	GGGGAGACAT	TTATCACAGC	GTGTCTCATG	9300
CCCGGCCCCG	CTGGTTCTGG	TTTTGCCTAC	TCCTGCTCGC	TGCAGGGGTA	9350
GGCATCTACC	TCCTCCCCAA	CCGATGAAGG	TTGGGGTAAA	CACTCCGGCC	9400
TCTTAAGCCA	TTTCCTGTTT	TTTTTTTTT	TTTTTTTTTT	TTTTCTTTT	9450
TTTTTTTCTT	TCCTTTCCTT	CTTTTTTTCC	TTTCTTTTTC	CCTTCTTTAA	9500

FIG. 6E

H77C

10	20	30	40	50	
1234567890	1234567890	1234567890	1234567890	1234567890	
TGGTGGCTCC	ATCTTAGCCC	TAGTCACGGC	TAGCTGTGAA	AGGTCCGTGA	9550
GCCGCATGAC	TGCAGAGAGT	GCTGATACTG	GCCTCTCTGC	AGATCATGT	9599

FIG. 6F

H77C

10	20	30	40	50	
1234567890	1234567890	1234567890	1234567890	1234567890	
MSINPKPQRK	TKRNINRRPQ	DVKFPGGGQI	VGGVYLLPRR	GPRLGVRATR	50
KTSERSQPRG	RRQPIPKARR	PEGRTWAQPG	YPWPLYGNEG	CGWAGWLLSP	100
RGSRPSWGPT	DPRRRSRNLG	KVIDTLTCGF	ADLMGYIPLV	GAPLGGAARA	150
LAHGVRVLED	GVNYATGNLP	GCSFSIFLLA	LLSCLTVPAS	AYQVRNSSGL	200
YHVTNDCPNS	SIVYEAADAI	LHTPGCVPCV	REGNASRCWV	AVTPTVATRD	250
GKLPTTQLRR	HIDLLVGSAT	LCSALYVGDL	CGSVFLVGQL	FTFSPRRHWT	300
TQDCNCSIYP	GHITGHRMAW	DMMMNWSPTA	ALVVAQLLRI	PQAIMDMIAG	350
AHWGVLAGIA	YFSMVGNWAK	VLVVLLLFAG	VDAETHVTGG	NAGRTTAGLV	400
GLLTPGAKQN	IQLINTNGSW	HINSTALNCN	ESLNTGWLAG	LFYQHKFNSS	450
GCPERLASCR	RLTDFAQGWG	PISYANGSGL	DERPYCWHYP	PRPCGIVPAK	500
SVCGPVYCFT	PSPVVVGTTD	RSGAPTYSWG	ANDTDVFVLN	NTRPPLGNWF	550
GCTWMNSTGF	TKVCGAPPCV	IGGVGNNTLL	CPTDCFRKHP	EATYSRCGSG	600
PWITPRCMVD	YPYRLWHYPC	TINYTIFKVR	MYVGGVEHRL	EAACNWTRGE	650
RCDLEDRDRS	ELSPLLLSTT	QWQVLPCSFT	TLPALSTGLI	HLHQNIVDVQ	700
YLYGVGSSIA	SWAIKWEYVV	LLFLLLADAR	VCSCLWMMLL	ISQAEAALEN	750
LVILNAASLA	GTHGLVSFLV	FFCFAWYLKG	RWVPGAVYAL	YGMWPLLLLL	800
LALPQRAYAL	DTEVAASCGG	VVLVGLMALT	LSPYYKRYIS	WCMWWLQYFL	850
TRVEAQLHVW	VPPLNVRGGR	DAVILLMCVV	HPTLVFDITK	LLLAIFGPLW	900
ILQASLLKVP	YFVRVQGLLR	ICALARKIAG	GHYVQMAIIK	LGALTGTYVY	950
NHLTPLRDWA	HNGLRDLAVA	VEPVVFSRME	TKLITWGADT	AACGDIINGL	1000
PVSARRGQEI	LLGPADGMVS	KGWRLLAPIT	AYAQQTRGLL	GCIITSLTGR	1050
DKNQVEGEVQ	IVSTATQTFL	ATCINGVCWT	VYHGAGTRTI	ASPKGPVIQM	1100
YTNVDQDLVG	WPAPQGSRSL	TPCTCGSSDL	YLVTRHADVI	PVRRRGDSRG	1150
SLLSPRPISY	LKGSSGGPLL	CPAGHAVGLF	RAAVCTRGVA	KAVDFIPVEN	1200
LETTMRSPVF	TDNSSPPAVP	QSFQVAHLHA	PTGSGKSTKV	PAAYAAQGYK	1250
VLVLNPSVAA	TLGFGAYMSK	AHGVDPNIRT	GVRTITTGSP	ITYSTYGKFL	1300
ADGGCSGGAY	DIIICDECHS	TDATSILGIG	TVLDQAETAG	ARLVVLATAT	1350
PPGSVTVSHP	NIEEVALSTT	GEIPFYGKAI	PLEVIKGGRH	LIFCHSKKKC	1400
DELAAKLVAL	GINAVAYYRG	LDVSVIPTSG	DVVVVSTDAL	MTGFTGDFDS	1450
VIDCNTCVTQ	TVDFSLDPTF	TIETTTLPQD	AVSRTQRRGR	TGRGKPGIYR	1500
FVAPGERPSG	MFDSSVLCEC	YDAGCAWYEL	TPAETTVRLR	AYMNTPGLPV	1550
CQDHLEFWEG	VFTGLTHIDA	HFLSQTKQSG	ENFPYLVAYQ	ATVCARAQAP	1600
PPSWDQMWKC	LIRLKPTLHG	PTPLLYRLGA	VQNEVTLTHP	ITKYIMTCMS	1650
ADLEVVTSTW	VLVGGVLAAL	AAYCLSTGCV	VIVGRIVLSG	KPAIIPDREV	1700
LYQEFDEMEE	CSQHLPYIEQ	GMMLAEQFKQ	KALGLLQTAS	RHAEVITPAV	1750
QTNWQKLEVF	WAKHMWNFIS	GIQYLAGLST	LPGNPAIASL	MAFTAAVTSP	1800
LTTGQTLLFN	ILGGWVAAQL	AAPGAATAFV	GAGLAGAAIG	SVGLGKVLVD	1850
ILAGYGAGVA	GALVAFKIMS	GEVPSTEDLV	NLLPAILSPG	ALVVGVVCAA	1900

FIG. 6G

H77C

10	20	30	40	50	
1234567890	1234567890	1234567890	1234567890	1234567890	
ILRRHVGPGE	GAVQWMNRLI	AFASRGNHVS	PTHYVPESDA	AARVTAILSS	1950
LTVTQLLRRL	HQWISSECTT	PCSGSWLRDI	WDWICEVLSD	FKTWLKAKLM	2000
PQLPGIPFVS	CQRGYRGVWR	GDGIMHTRCH	CGAEITGHVK	NGTMRIVGPR	2050
TCRNMVSGTF	PINAYTTGPC	TPLPAPNYKF	ALWRVSAEEY	VEIRRVGDFH	2100
YVSGMTTDNL	KCPCQIPSPE	FFTELDGVRL	HRFAPPCKPL	LREEVSFRVG	2150
LHEYPVGSQL	PCEPEPDVAV	LTSMLTDPSH	ITAEAAGRRL	ARGSPPSMAS	2200
SSASQLSAPS	LKATCTANHD	SPDAELIEAN	LLWRQEMGGN	ITRVESENKV	2250
VILDSFDPLV	AEEDEREVSV	PAEILRKSRR	FARALPVWAR	PDYNPPLVET	2300
WKKPDYEPPV	VHGCPLPPPR	SPPVPPPRKK	RTVVLTESTL	STALAELATK	2350
SFGSSSTSGI	TGDNTTTSSE	PAPSGCPPDS	DVESYSSMPP	LEGEPGDPDL	2400
SDGSWSTVSS	GADTEDVVCC	SMSYSWTGAL	VTPCAAEEQK	LPINALSNSL	2450
LRHHNLVYST	TSRSACQRQK	KVTFDRLQVL	DSHYQDVLKE	VKAAASKVKA	2500
NLLSVEEACS	LTPPHSAKSK	FGYGAKDVRC	HARKAVAHIN	SVWKDLLEDS	2550
VTPIDTTIMA	KNEVFCVQPE	KGGRKPARLI	VFPDLGVRVC	EKMALYDVVS	2600
KLPLAVMGSS	YGFQYSPGQR	VEFLVQAWKS	KKTPMGFSYD	TRCFDSTVTE	2650
SDIRTEEAIY	QCCDLDPQAR	VAIKSLTERL	YVGGPLTNSR	GENCGYRRCR	2700
ASGVLTTSCG	NTLTCYIKAR	AACRAAGLQD	CTMLVCGDDL	VVICESAGVQ	2750
EDAASLRAFT	EAMTRYSAPP	GDPPQPEYDL	ELITSCSSNV	SVAHDGAGKR	2800
VYYLTRDPTT	PLARAAWETA	RHTPVNSWLG	NIIMFAPTLW	ARMILMTHFF	2850
SVLIARDQLE	QALNCEIYGA	CYSIEPLDLP	PIIQRLHGLS	AFSLHSYSPG	2900
EINRVAACLR	KLGVPPLRAW	RHRARSVRAR	LLSRGGRAAI	CGKYLFNWAV	2950
RTKLKLTPIA	AAGRLDLSGW	FTAGYSGGDI	YHSVSHARPR	WFWFCLLLLA	3000
AGVGIYLLPN R					3011

FIG. 6H

HC-J4

10	20	30	40	50	
1234567890	1234567890	1234567890	1234567890	1234567890	
GCCAGCCCCC	TGATGGGGGC	GACACTCCAC	CATGAATCAC	TCCCCTGTGA	50
GGAACTACTG	TCTTCACGCA	GAAAGCGTCT	AGCCATGGCG	TTAGTATGAG	100
TGTCGTGCAG	CCTCCAGGAC	CCCCCCTCCC	GGGAGAGCCA	TAGTGGTCTG	150
CGGAACCGGT	GAGTACACCG	GAATTGCCAG	GACGACCGGG	TCCTTTCTTG	200
GATCAACCCG	CTCAATGCCT	GGAGATTTGG	GCGTGCCCCC	GCGAGACTGC	250
TAGCCGAGTA	GTGTTGGGTC	GCGAAAGGCC	TTGTGGTACT	GCCTGATAGG	300
GTGCTTGCGA	GTGCCCCGGG	AGGTCTCGTA	GACCGTGCAC	CATGAGCACG	350
AATCCTAAAC	CTCAAAGAAA	AACCAAACGT	AACACCAACC	GCCGCCCACA	400
GGACGTCAAG	TTCCCGGGCG	GTGGTCAGAT	CGTTGGTGGA	GTTTACCTGT	450
TGCCGCGCAG	GGGCCCCAGG	TTGGGTGTGC	GCGCGACTAG	GAAGGCTTCC	500
GAGCGGTCGC	AACCTCGTGG	AAGGCGACAA	CCTATCCCAA	AGGCTCGCCG	550
ACCCGAGGGC	AGGGCCTGGG	CTCAGCCCGG	GTACCCTTGG	CCCCTCTATG	600
GCAATGAGGG	CCTGGGGTGG	GCAGGATGGC	TCCTGTCACC	CCGCGGCTCC	650
CGGCCTAGTT	GGGGCCCCAC	GGACCCCCGG	CGTAGGTCGC	GTAACTTGGG	700
TAAGGTCATC	GATACCCTTA	CATGCGGCTT	CGCCGATCTC	ATGGGGTACA	750
TTCCGCTCGT	CGGCGCCCCC	CTAGGGGGCG	CTGCCAGGGC	CTTGGCACAC	800
GGTGTCCGGG	TTCTGGAGGA	CGGCGTGAAC	TATGCAACAG	GGAACTTGCC	850
CGGTTGCTCT	TTCTCTATCT	TCCTCTTGGC	TCTGCTGTCC	TGTTTGACCA	900
TCCCAGCTTC	CGCTTATGAA	GTGCGCAACG	TGTCCGGGAT	ATACCATGTC	950
ACGAACGACT	GCTCCAACTC	AAGCATTGTG	TATGAGGCAG	CGGACGTGAT	1000
CATGCATACT	CCCGGGTGCG	TGCCCTGTGT	TCAGGAGGGT	AACAGCTCCC	1050
GTTGCTGGGT	AGCGCTCACT	CCCACGCTCG	CGGCCAGGAA	TGCCAGCGTC	1100
CCCACTACGA	CAATACGACG	CCACGTCGAC	TTGCTCGTTG	GGACGGCTGC	1150
TTTCTGCTCC	GCTATGTACG	TGGGGGATCT	CTGCGGATCT	ATTTTCCTCG	1200
TCTCCCAGCT	GTTCACCTTC	TCGCCTCGCC	GGCATGAGAC	AGTGCAGGAC	1250
TGCAACTGCT	CAATCTATCC	CGGCCATGTA	TCAGGTCACC	GCATGGCTTG	1300
GGATATGATG	ATGAACTGGT	CACCTACAAC	AGCCCTAGTG	GTGTCGCAGT	1350
TGCTCCGGAT	CCCACAAGCT	GTCGTGGACA	TGGTGGCGGG	GGCCCACTGG	1400
GGAGTCCTGG	CGGGCCTTGC	CTACTATTCC	ATGGTAGGGA	ACTGGGCTAA	1450
GGTTCTGATT	GTGGCGCTAC	TCTTTGCCGG	CGTTGACGGG	GAGACCCACA	1500
CGACGGGGAG	GGTGGCCGGC	CACACCACCT	CCGGGTTCAC	GTCCCTTTTC	1550
TCATCTGGGG	CGTCTCAGAA	AATCCAGCTT	GTGAATACCA	ACGGCAGCTG	1600
GCACATCAAC	AGGACTGCCC	TAAATTGCAA	TGACTCCCTC	CAAACTGGGT	1650
TCTTTGCCGC	GCTGTTTTAC	GCACACAAGT	TCAACTCGTC	CGGGTGCCCG	1700
GAGCGCATGG	CCAGCTGCCG	CCCCATTGAC	TGGTTCGCCC	AGGGGTGGGG	1750
CCCCATCACC	TATACTAAGC	CTAACAGCTC	GGATCAGAGG	CCTTATTGCT	1800
GGCATTACGC	GCCTCGACCG	TGTGGTGTCG	TACCCGCGTC	GCAGGTGTGT	1850
GGTCCAGTGT	ATTGTTTCAC	CCCAAGCCCT	GTTGTGGTGG	GGACCACCGA	1900

FIG. 7A

HC-J4

10	20	30	40	50	
1234567890	1234567890	1234567890	1234567890	1234567890	
TCGTTCCGGT	GTCCCTACGT	ATAGCTGGGG	GGAGAATGAG	ACAGACGTGA	1950
TGCTCCTCAA	CAACACGCGT	CCGCCACAAG	GCAACTGGTT	CGGCTGTACA	2000
TGGATGAATA	GTACTGGGTT	CACTAAGACG	TGCGGAGGTC	CCCCGTGTAA	2050
CATCGGGGGG	GTCGGTAACC	GCACCTTGAT	CTGCCCCACG	GACTGCTTCC	2100
GGAAGCACCC	CGAGGCTACT	TACACAAAAT	GTGGCTCGGG	GCCCTGGTTG	2150
ACACCTAGGT	GCCTAGTAGA	CTACCCATAC	AGGCTTTGGC	ACTACCCCTG	2200
CACTCTCAAT	TTTTCCATCT	TTAAGGTTAG	GATGTATGTG	GGGGCCGTGG	2250
AGCACAGGCT	CAATGCCGCA	TGCAATTGGA	CTCGAGGAGA	CCGCTGTAAC	2300
TTGGAGGACA	GGGATAGGTC	AGAACTCAGC	CCGCTGCTGC	TGTCTACAAC	2350
AGAGTGGCAG	ATACTGCCCT	GTGCTTTCAC	CACCCTACCG	GCTTTATCCA	2400
CTGGTTTGAT	CCATCTCCAT	CAGAACATCG	TGGACGTGCA	ATACCTGTAC	2450
GGTGTAGGGT	CAGCGTTTGT	CTCCTTTGCA	ATCAAATGGG	AGTACATCCT	2500
GTTGCTTTTC	CTTCTCCTGG	CAGACCCCCG	CGTGTGTGCC	TGCTTGTGGA	2550
TGATGCTGCT	GATAGCCCAG	GCTGAGGCCG	CCTTAGAGAA	CTTGGTGGTC	2600
CTCAATGCGG	CGTCCGTGGC	CGGAGCGCAT	GGTATTCTCT	CCTTTCTTGT	2650
GTTCTTCTGC	GCCGCCTGGT	ACATTAAGGG	CAGGCTGGCT	CCTGGGCCGG	2700
CGTATGCTTT	TTATGGCGTA	TGGCCGCTGC	TCCTGCTCCT	ACTGGCGTTA	2750
CCACCACGAG	CTTACGCCTT	GGACCGGGAG	ATGGCTGCAT	CGTGCGGGGG	2800
TGCGGTTCTT	GTAGGTCTGG	TATTCTTGAC	CTTGTCACCA	TACTACAAAG	2850
TGTTTCTCAC	TAGGCTCATA	TGGTGGTTAC	AATACTTTAT	CACCAGAGCC	2900
GAGGCGCACA	TGCAAGTGTG	GGTCCCCCCC	CTCAACGTTC	GGGGAGGCCG	2950
CGATGCCATC	ATCCTCCTCA	CGTGTGCGGT	TCATCCAGAG	TTAATTTTTG	3000
ACATCACCAA	ACTCCTGCTC	GCCATACTCG	GCCCGCTCAT	GGTGCTCCAG	3050
GCTGGCATAA	CGAGAGTGCC	GTACTTCGTG	CGCGCTCAAG	GGCTCATTCG	3100
TGCATGCATG	TTAGTGCGAA	AAGTCGCCGG	GGGTCATTAT	GTCCAAATGG	3150
TCTTCATGAA	GCTGGGCGCG	CTGACAGGTA	CGTACGTTTA	TAACCATCTT	3200
ACCCCACTGC	GGGACTGGGC	CCACGCGGGC	CTACGAGACC	TTGCGGTGGC	3250
GGTAGAGCCC	GTCGTCTTCT	CCGCCATGGA	GACCAAGGTC	ATCACCTGGG	3300
GAGCAGACAC	CGCTGCGTGT	GGGGACATCA	TCTTGGGTCT	ACCCGTCTCC	3350
GCCCGAAGGG	GGAAGGAGAT	ATTTTTGGGA	CCGGCTGATA	GTCTCGAAGG	3400
GCAAGGGTGG	CGACTCCTTG	CGCCCATCAC	GGCCTACTCC	CAACAAACGC	3450
GGGGCGTACT	TGGTTGCATC	ATCACTAGCC	TCACAGGCCG	GGACAAGAAC	3500
CAGGTCGAAG	GGGAGGTTCA	AGTGGTTTCT	ACCGCAACAC	AATCTTTCCT	3550
GGCGACCTGC	ATCAACGGCG	TGTGCTGGAC	TGTCTACCAT	GGCGCTGGCT	3600
CGAAGACCCT	AGCCGGTCCA	AAAGGTCCAA	TCACCCAAAT	GTACACCAAT	3650
GTAGACCTGG	ACCTCGTCGG	CTGGCAGGCG	CCCCCCGGGG	CGCGCTCCAT	3700
GACACCATGC	AGCTGTGGCA	GCTCGGACCT	TTACTTGGTC	ACGAGACATG	3750
CTGATGTCAT	TCCGGTGCGC	CGGCGAGGCG	ACAGCAGGGG	AAGTCTACTC	3800

FIG. 7B

HC-J4

10	20	30	40	50	
1234567890	1234567890	1234567890	1234567890	1234567890	
TCCCCCAGGC	CCGTCTCCTA	CCTGAAAGGC	TCCTCGGGTG	GTCCATTGCT	3850
TTGCCCTTCG	GGGCACGTCG	TGGGCGTCTT	CCGGGCTGCT	GTGTGCACCC	3900
GGGGGGTCGC	GAAGGCGGTG	GACTTCATAC	CCGTTGAGTC	TATGGAAACT	3950
ACCATGCGGT	CTCCGGTCTT	CACAGACAAC	TCAACCCCCC	CGGCTGTACC	4000
GCAGACATTC	CAAGTGGCAC	ATCTGCACGC	TCCTACTGGC	AGCGGCAAGA	4050
GCACCAAAGT	GCCGGCTGCG	TATGCAGCCC	AAGGGTACAA	GGTGCTCGTC	4100
CTGAACCCGT	CCGTTGCCGC	CACCTTAGGG	TTTGGGGCGT	ATATGTCCAA	4150
GGCACACGGT	ATCGACCCTA	ACATCAGAAC	TGGGGTAAGG	ACCATTACCA	4200
CGGGCGGCTC	CATTACGTAC	TCCACCTATG	GCAAGTTCCT	TGCCGACGGT	4250
GGCTGTTCTG	GGGGCGCCTA	TGACATCATA	ATATGTGATG	AGTGCCACTC	4300
AACTGACTCG	ACTACCATCT	TGGGCATCGG	CACAGTCCTG	GACCAAGCGG	4350
AGACGGCTGG	AGCGCGGCTC	GTCGTGCTCG	CCACCGCTAC	ACCTCCGGGA	4400
TCGGTTACCG	TGCCACACCC	CAATATCGAG	GAAATAGGCC	TGTCCAACAA	4450
TGGAGAGATC	CCCTTCTATG	GCAAAGCCAT	CCCCATTGAG	GCCATCAAGG	4500
GGGGGAGGCA	TCTCATTTTC	TGCCATTCCA	AGAAGAAATG	TGACGAGCTC	4550
GCCGCAAAGC	TGACAGGCCT	CGGACTGAAC	GCTGTAGCAT	ATTACCGGGG	4600
CCTTGATGTG	TCCGTCATAC	CGCCTATCGG	AGACGTCGTT	GTCGTGGCAA	4650
CAGACGCTCT	AATGACGGGT	TTCACCGGCG	ATTTTGACTC	AGTGATCGAC	4700
TGCAATACAT	GTGTCACCCA	GACAGTCGAC	TTCAGCTTGG	ATCCCACCTT	4750
CACCATTGAG	ACGACGACCG	TGCCCCAAGA	CGCGGTGTCG	CGCTCGCAAC	4800
GGCGAGGTAG	AACTGGCAGG	GGTAGGAGTG	GCATCTACAG	GTTTGTGACT	4850
CCAGGAGAAC	GGCCCTCGGG	CATGTTCGAT	TCTTCGGTCC	TGTGTGAGTG	4900
CTATGACGCG	GGCTGTGCTT	GGTATGAGCT	CACGCCCGCT	GAGACCTCGG	4950
TTAGGTTGCG	GGCTTACCTA	AATACACCAG	GGTTGCCCGT	CTGCCAGGAC	5000
CATCTGGAGT	TCTGGGAGAG	CGTCTTCACA	GGCCTCACCC	ACATAGATGC	5050
CCACTTCCTG	TCCCAGACTA	AACAGGCAGG	AGACAACTTT	CCTTACCTGG	5100
TGGCATATCA	AGCTACAGTG	TGCGCCAGGG	CTCAAGCTCC	ACCTCCATCG	5150
TGGGACCAAA	TGTGGAAGTG	TCTCATACGG	CTGAAACCTA	CACTGCACGG	5200
GCCAACACCC	CTGCTGTATA	GGCTAGGAGC	CGTCCAAAAT	GAGGTCATCC	5250
TCACACACCC	CATAACTAAA	TACATCATGG	CATGCATGTC	GGCTGACCTG	5300
GAGGTCGTCA	CTAGCACCTG	GGTGCTGGTA	GGCGGAGTCC	TTGCAGCTTT	5350
GGCCGCATAC	TGCCTGACGA	CAGGCAGTGT	GGTCATTGTG	GGCAGGATCA	5400
TCTTGTCCGG	GAAGCCAGCT	GTCGTTCCCG	ACAGGGAAGT	CCTCTACCAG	5450
GAGTTCGATG	AGATGGAAGA	GTGTGCCTCA	CAACTTCCTT	ACATCGAGCA	5500
GGGAATGCAG	CTCGCCGAGC	AATTCAAGCA	AAAGGCGCTC	GGGTTGTTGC	5550
AAACGGCCAC	CAAGCAAGCG	GAGGCTGCTG	CTCCCGTGGT	GGAGTCCAAG	5600
TGGCGAGCCC	TTGAGACCTT	CTGGGCGAAG	CACATGTGGA	ATTTCATCAG	5650
CGGAATACAG	TACCTAGCAG	GCTTATCCAC	TCTGCCTGGA	AACCCCGCGA	5700

FIG. 7C

HC-J4

10	20	30	40	50	
1234567890	1234567890	1234567890	1234567890	1234567890	
TAGCATCATT	GATGGCATTT	ACAGCTTCTA	TCACTAGCCC	GCTCACCACC	5750
CAAAACACCC	TCCTGTTTAA	CATCTTGGGG	GGATGGGTGG	CTGCCCAACT	5800
CGCTCCTCCC	AGCGCTGCGT	CAGCTTTCGT	GGGCGCCGGC	ATCGCCGGAG	5850
CGGCTGTTGG	CAGCATAGGC	CTTGGGAAGG	TGCTCGTGGA	CATCTTGGCG	5900
GGCTATGGGG	CAGGGGTAGC	CGGCGCACTC	GTGGCCTTTA	AGGTCATGAG	5950
CGGCGAGGTG	CCCTCCACCG	AGGACCTGGT	CAACTTACTC	CCTGCCATCC	6000
TCTCTCCTGG	TGCCCTGGTC	GTCGGGGTCG	TGTGCGCAGC	AATACTGCGT	6050
CGGCACGTGG	GCCCGGGAGA	GGGGGCTGTG	CAGTGGATGA	ACCGGCTGAT	6100
AGCGTTCGCT	TCGCGGGGTA	ACCACGTCTC	CCCTACGCAC	TATGTGCCTG	6150
AGAGCGACGC	TGCAGCACGT	GTCACTCAGA	TCCTCTCTAG	CCTTACCATC	6200
ACTCAACTGC	TGAAGCGGCT	CCACCAGTGG	ATTAATGAGG	ACTGCTCTAC	6250
GCCATGCTCC	GGCTCGTGGC	TAAGGGATGT	TTGGGATTGG	ATATGCACGG	6300
TGTTGACTGA	CTTCAAGACC	TGGCTCCAGT	CCAAACTCCT	GCCGCGGTTA	6350
CCGGGAGTCC	CTTTCCTGTC	ATGCCAACGC	GGGTACAAGG	GAGTCTGGCG	6400
GGGGGACGGC	ATCATGCAAA	CCACCTGCCC	ATGCGGAGCA	CAGATCGCCG	6450
GACATGTCAA	AAACGGTTCC	ATGAGGATCG	TAGGGCCTAG	AACCTGCAGC	6500
AACACGTGGC	ACGGAACGTT	CCCCATCAAC	GCATACACCA	CGGGACCTTG	6550
CACACCCTCC	CCGGCGCCCA	ACTATTCCAG	GGCGCTATGG	CGGGTGGCTG	6600
CTGAGGAGTA	CGTGGAGGTT	ACGCGTGTGG	GGGATTTCCA	CTACGTGACG	6650
GGCATGACCA	CTGACAACGT	AAAGTGCCCA	TGCCAGGTTC	CGGCCCCCGA	6700
ATTCTTCACG	GAGGTGGATG	GAGTGCGGTT	GCACAGGTAC	GCTCCGGCGT	6750
GCAAACCTCT	TCTACGGGAG	GACGTCACGT	TCCAGGTCGG	GCTCAACCAA	6800
TACTTGGTCG	GGTCGCAGCT	CCCATGCGAG	CCCGAACCGG	ACGTAACAGT	6850
GCTTACTTCC	ATGCTCACCG	ATCCCTCCCA	CATTACAGCA	GAGACGGCTA	6900
AGCGTAGGCT	GGCTAGAGGG	TCTCCCCCCT	CTTTAGCCAG	CTCATCAGCT	6950
AGCCAGTTGT	CTGCGCCTTC	TTTGAAGGCG	ACATGCACTA	CCCACCATGA	7000
CTCCCCGGAC	GCTGACCTCA	TCGAGGCCAA	CCTCTTGTGG	CGGCAGGAGA	7050
TGGGCGGAAA	CATCACTCGC	GTGGAGTCAG	AGAATAAGGT	AGTAATTCTG	7100
GACTCTTTCG	AACCGCTTCA	CGCGGAGGGG	GATGAGAGGG	AGATATCCGT	7150
CGCGGCGGAG	ATCCTGCGAA	AATCCAGGAA	GTTCCCCTCA	GCGTTGCCCA	7200
TATGGGCACG	CCCGGACTAC	AATCCTCCAC	TGCTAGAGTC	CTGGAAGGAC	7250
CCGGACTACG	TCCCTCCGGT	GGTACACGGA	TGCCCATTGC	CACCTACCAA	7300
GGCTCCTCCA	ATACCACCTC	CACGGAGAAA	GAGGACGGTT	GTCCTGACAG	7350
AATCCAATGT	GTCTTCTGCC	TTGGCGGAGC	TCGCCACTAA	GACCTTCGGT	7400
AGCTCCGGAT	CGTCGGCCGT	TGATAGCGGC	ACGGCGACCG	CCCTTCCTGA	7450
CCTGGCCTCC	GACGACGGTG	ACAAAGGATC	CGACGTTGAG	TCGTACTCCT	7500
CCATGCCCCC	CCTTGAAGGG	GAGCCGGGGG	ACCCCGATCT	CAGCGACGGG	7550
TCTTGGTCTA	CCGTGAGTGA	GGAGGCTAGT	GAGGATGTCG	TCTGCTGCTC	7600

FIG. 7D

HC-J4

10	20	30	40	50	
1234567890	1234567890	1234567890	1234567890	1234567890	
AATGICCIAT	ACGIGGACAG	GCGCCCIGAT	CACGCCATGC	GCIGCGGAGG	7650
AAAGIAAGCT	GCCCATCAAC	CCGITGAGCA	ACICTTIGCT	GCGICACCAC	7700
AACATGGICT	ACGCCACAAC	ATCCCGCAGC	GCAAGCCICC	GGCAGAAGAA	7750
GGICACCTTT	GACAGATTGC	AAGICCIGGA	TGATCATTAC	CGGGACGTAC	7800
TCAAGGAGAT	GAAGGCGAAG	GCGICCACAG	TTAAGGCIAA	GCTICIATCT	7850
ATAGAGGAGG	CCIGCAAGCT	GACGCCCCCA	CATICGGCCA	AATCCAAATT	7900
TGGCIATGGG	GCAAAGGACG	TCCGGAACCT	ATCCAGCAGG	GCCGITAACC	7950
ACATCCGCIC	CGIGIGGGAG	GACTIGCIGG	AAGACACIGA	AACACCAATT	8000
GACACCACCA	TCATGGCAAA	AAGIGAGGIT	TICIGCGICC	AACCAGAGAA	8050
GGGAGGCCGC	AAGCCAGCIC	GCCTTATCGT	ATTCCCAGAC	CIGGGAGTTC	8100
GIGIATGCGA	GAAGATGGCC	CTTTACGACG	TGGICICCAC	CCTICCICAG	8150
GCCGIGATGG	GCICCICATA	CGGATTTCAA	TACICCCCCA	AGCAGCGGGT	8200
CGAGTICCIG	GIGAATACCT	GGAAATCAAA	GAAATGCCCT	ATGGGCTTCT	8250
CATATGACAC	CCGCIGTTTT	GACICAACGG	TCACIGAGAG	TGACATICGT	8300
GTTGAGGAGT	CAATTTACCA	ATGTTGIGAC	TIGGCCCCCG	AGGCCAGACA	8350
GGCCATAAGG	TCGCTCACAG	AGCGGCTTTA	CATCGGGGGT	CCCCTGACTA	8400
ACTCAAAAGG	GCAGAACTGC	GGTTATCGCC	GGTGCCGCGC	AAGTGGCGTG	8450
CTGACGACTA	GCTGCGGTAA	TACCCTCACA	TGTTACTTGA	AGGCCACTGC	8500
AGCCTGTCGA	GCTGCAAAGC	TCCAGGACTG	CACGATGCTC	GTGAACGGAG	8550
ACGACCTTGT	CGTTATCTGT	GAAAGCGCGG	GAACCCAGGA	GGATGCGGCG	8600
GCCCTACGAG	CCTTCACGGA	GGCTATGACT	AGGTATTCCG	CCCCCCCCGG	8650
GGATCCGCCC	CAACCAGAAT	ACGACCTGGA	GCTGATAACA	TCATGTTCCT	8700
CCAATGTGTC	AGTCGCGCAC	GATGCATCTG	GCAAAAGGGT	ATACTACCTC	8750
ACCCGTGACC	CCACCACCCC	CCTTGCACGG	GCTGCGTGGG	AGACAGCTAG	8800
ACACACTCCA	ATCAACTCTT	GGCTAGGCAA	TATCATCATG	TATGCGCCCA	8850
CCCTATGGGC	AAGGATGATT	CTGATGACTC	ACTTTTTCTC	CATCCTTCTA	8900
GCTCAAGAGC	AACTTGAAAA	AGCCCTGGAT	TGTCAGATCT	ACGGGGCTTG	8950
CTACTCCATT	GAGCCACTTG	ACCTACCTCA	GATCATTGAA	CGACTCCATG	9000
GTCTTAGCGC	ATTTACACTC	CACAGTTACT	CTCCAGGTGA	GATCAATAGG	9050
GTGGCTTCAT	GCCTCAGGAA	ACTTGGGGTA	CCACCCTTGC	GAACCTGGAG	9100
ACATCGGGCC	AGAAGTGTCC	GCGCTAAGCT	ACTGTCCCAG	GGGGGGAGGG	9150
CCGCCACTTG	TGGCAGATAC	CTCTTTAACT	GGGCAGTAAG	GACCAAGCTT	9200
AAACTCACTC	CAATCCCGGC	CGCGTCCCAG	CTGGACTTGT	CTGGCTGGTT	9250
CGTCGCTGGT	TACAGCGGGG	GAGACATATA	TCACAGCCTG	TCTCGTGCCC	9300
GACCCCGCTG	GTTTCCGTTG	TGCCTACTCC	TACTTTCTGT	AGGGGTAGGC	9350
ATTTACCTGC	TCCCCAACCG	ATGAACGGGG	AGCTAACCAC	TCCAGGCCTT	9400
AAGCCATTTC	CTGTTTTTTT	TTTTTTTTTT	TTTTTTTTTT	TCTTTTTTTT	9450
TTTCTTTCCT	TTCCTTCTTT	TTTTCCTTTC	TTTTTCCCTT	CTTTAATGGT	9500

FIG. 7E

10	20	30	40	50	
1234567890	1234567890	1234567890	1234567890	1234567890	
GGCTCCATCT	TAGCCCTAGT	CACGGCTAGC	TGTGAAAGGT	CCGTGAGCCG	9550
CATGACTGCA	GAGAGTGCTG	ATACTGGCCT	CTCTGCAGAT	CATGT	9595

FIG. 7F

```
        10         20         30         40         50
1234567890 1234567890 1234567890 1234567890 1234567890
MSINPKPQRK TKRNINRRPQ DVKFPGGGQI VGGVYLLPRR GPRLGVRATR     50
KASERSQPRG RRQPIPKARR PEGRAWAQPG YPWPLYGNEG LGWAGWLLSP    100
RGSRPSWGPT DPRRRSRNLG KVIDTLTCGF ADLMGYIPLV GAPLGGAARA    150
LAHGVRVLED GVNYATGNLP GCSFSIFLLA LLSCLTIPAS AYEVRNVSGI    200
YHVINDCSNS SIVYEAADVI MHTPGCVPCV QEGNSSRCWV ALTPTLAARN    250
ASVPTTTIRR HVDLLVGAAA FCSAMYVGDL CGSIFLVSQL FTFSPRRHET    300
VQDCNCSIYP GHVSGHRMAW DMMMNWSPTT ALVVSQLLRI PQAVVDMVAG    350
AHWGVLAGLA YYSMVGNWAK VLIVALLFAG VDGETHTTGR VAGHTTSGFT    400
SLFSSGASQK IQLVNTNGSW HINRTALNCN DSLQTGFFAA LFYAHKFNSS    450
GCPERMASCR PIDWFAQGWG PITYTKPNSS DQRPYCWHYA PRPCGVVPAS    500
QVCGPVYCFT PSPVVVGTTD RSGVPTYSWG ENETDVMLLN NTRPPQGNWF    550
GCTWMNSTGF TKTCGGPPCN IGGVGNRTLI CPTDCFRKHP EATYTKCGSG    600
PWLTPRCLVD YPYRLWHYPC TLNFSIFKVR MYVGGVEHRL NAACNWTRGE    650
RCNLEDRDRS ELSPLLLSTT EWQILPCAFT TLPALSTGLI HLHQNIVDVQ    700
YLYGVGSAFV SFAIKWEYIL LLFLLLADAR VCACLWMMLL IAQAEAALEN    750
LVVLNAASVA GAHGILSFLV FFCAAWYIKG RLAPGAAYAF YGVWPLLLLL    800
LALPPRAYAL DREMAASCGG AVLVGLVFLT LSPYYKVFLT RLIWWLQYFI    850
TRAEAHMQVW VPPLNVRGGR DAILLLTCAV HPELIFDITK LLLAILGPLM    900
VLQAGITRVP YFVRAQGLIR ACMLVRKVAG GHYVQMVFMK LGALTGTYVY    950
NHLTPLRDWA HAGLRDLAVA VEPVVFSAME TKVITWGADT AACGDIILGL   1000
PVSARRGKEI FLGPADSLEG QGWRLLAPIT AYSQQTRGVL GCIITSLTGR   1050
DKNQVEGEVQ VVSTATQSFL ATCINGVCWT VYHGAGSKTL AGPKGPITQM   1100
YTNVDLDLVG WQAPPGARSM TPCSCGSSDL YLVTRHADVI PVRRRGDSRG   1150
SLLSPRPVSY LKGSSGGPLL CPSGHVVGVF RAAVCTRGVA KAVDFIPVES   1200
METTMRSPVF TDNSTPPAVP QTFQVAHLHA PTGSGKSTKV PAAYAAQGYK   1250
VLVLNPSVAA TLGFGAYMSK AHGIDPNIRT GVRTITTGGS ITYSTYGKFL   1300
ADGGCSGGAY DIIICDECHS TDSTTILGIG TVLDQAETAG ARLVVLATAT   1350
PPGSVTVPHP NIEEIGLSNN GEIPFYGKAI PIEAIKGGRH LIFCHSKKKC   1400
DELAAKLTGL GLNAVAYYRG LDVSVIPPIG DVVVVATDAL MTGFTGDFDS   1450
VIDCNTCVTQ TVDFSLDPTF TIETTTVPQD AVSRSQRRGR TGRGRSGIYR   1500
FVTPGERPSG MFDSSVLCEC YDAGCAWYEL TPAETSVRLR AYLNTPGLPV   1550
CQDHLEFWES VFTGLTHIDA HFLSQTKQAG DNFPYLVAYQ ATVCARAQAP   1600
PPSWDQMWKC LIRLKPTLHG PTPLLYRLGA VQNEVILTHP ITKYIMACMS   1650
ADLEVVTSTW VLVGGVLAAL AAYCLTTGSV VIVGRIILSG KPAVVPDREV   1700
LYQEFDEMEE CASQLPYIEQ GMQLAEQFKQ KALGLLQTAT KQAEAAAPVV   1750
ESKWRALETF WAKHMWNFIS GIQYLAGLST LPGNPAIASL MAFTASITSP   1800
LTTQNTLLFN ILGGWVAAQL APPSAASAFV GAGIAGAAVG SIGLGKVLVD   1850
ILAGYGAGVA GALVAFKVMS GEVPSTEDLV NLLPAILSPG ALVVGVVCAA   1900
```

FIG. 7G

10	20	30	40	50	
1234567890	1234567890	1234567890	1234567890	1234567890	
ILRRHVGPGE	GAVQWMNRLI	AFASRGNHVS	PIHYVPESDA	AARVIQILSS	1950
LITIQLLKRL	HQWINEDCST	PCSGSWLRDV	WDWICTVLTD	FKIWLQSKLL	2000
PRLPGVPFLS	CQRGYKGVWR	GDGIMQTTCP	CGAQIAGHVK	NGSMRIVGPR	2050
TCSNIWHGTF	PINAYTTGPC	TPSPAPNYSR	ALWRVAAEEY	VEVIRVGDFH	2100
YVTGMTTDNV	KCPCQVPAPE	FFTEVDGVRL	HRYAPACKPL	LREDVTFQVG	2150
LNQYLVGSQL	PCEPEPDVTV	LTSMLTDPSH	ITAETAKRRL	ARGSPPSLAS	2200
SSASQLSAPS	LKATCTTHHD	SPDADLIEAN	LLWRQEMGGN	ITRVESENKV	2250
VILDSFEPLH	AEGDEREISV	AAEILRKSRK	FPSALPIWAR	PDYNPPLLES	2300
WKDPDYVPPV	VHGCPLPPIK	APPIPPPRRK	RTVVLTESNV	SSALAELATK	2350
TFGSSGSSAV	DSGIATALPD	LASDDGDKGS	DVESYSSMPP	LEGEPGDPDL	2400
SDGSWSTVSE	EASEDVVCCS	MSYTWTGALI	TPCAAEESKL	PINPLSNSLL	2450
RHHNMVYATT	SRSASLRQKK	VTFDRLQVLD	DHYRDVLKEM	KAKASTVKAK	2500
LLSIEEACKL	TPPHSAKSKF	GYGAKDVRNL	SSRAVNHIRS	VWEDLLEDTE	2550
TPIDTTIMAK	SEVFCVQPEK	GGRKPARLIV	FPDLGVRVCE	KMALYDVVST	2600
LPQAVMGSSY	GFQYSPKQRV	EFLVNTWKSK	KCPMGFSYDT	RCFDSTVTES	2650
DIRVEESIYQ	CCDLAPEARQ	AIRSLTERLY	IGGPLTNSKG	QNCGYRRCRA	2700
SGVLTTSCGN	TLTCYLKATA	ACRAAKLQDC	TMLVNGDDLV	VICESAGTQE	2750
DAAALRAFTE	AMTRYSAPPG	DPPQPEYDLE	LITSCSSNVS	VAHDASGKRV	2800
YYLTRDPTTP	LARAAWETAR	HTPINSWLGN	IIMYAPTLWA	RMILMTHFFS	2850
ILLAQEQLEK	ALDCQIYGAC	YSIEPLDLPQ	IIERLHGLSA	FTLHSYSPGE	2900
INRVASCLRK	LGVPPLRTWR	HRARSVRAKL	LSQGGRAATC	GRYLFNWAVR	2950
TKLKLTPIPA	ASQLDLSGWF	VAGYSGGDIY	HSLSRARPRW	FPLCLLLLSV	3000
GVGIYLLPNR					3010

FIG. 7H

SEQUENCE LISTING

<110> Yanagi, Masayuki
Emerson, Suzanne
Bukh, Jens
Purcell, Robert

<120> Cloned Genome of Infectious Hepatitis C Viruses of Genotype 2a and Uses Thereof

<130> 20264302PC

<140> TBA
<141> 2000-06-02

<150> 60/137,693
<151> 1999-06-04

<160> 39

<170> PatentIn Ver. 2.1

<210> 1
<211> 9711
<212> DNA
<213> Hepatitis C virus

<400> 1
acccgccccc aataggggcg acactccgcc atgaatcact cccctgtgag gaactactgt 60
cttcacgcag aaagcgtcta gccatggcgt tagtatgagt gtcgtacagc ctccaggccc 120
ccccctcccg ggagagccat agtggtctgc ggaaccggtg agtacaccgg aattgccggg 180
aagactgggt cctttcttgg ataaacccac tctatgcccg gccatttggg cgtgcccccg 240
caagactgct agccgagtag cgttgggttg cgaaaggcct tgtggtactg cctgataggg 300
tgcttgcgag tgccccggga ggtctcgtag accgtgcacc atgagcacaa atcctaaacc 360
tcaaagaaaa accaaaagaa acaccaaccg tcgcccacaa gacgttaagt ttccgggcgg 420
cggccagatc gttggcggag tatacttgtt gccgcgcagg ggccccaggt tgggtgtgcg 480
cgcgacaagg aagacttcgg agcggtccca gccacgtgga aggcgccagc ccatccctaa 540
agatcggcgc tccactggca aatcctgggg aaaaccagga tacccctggc ccctatacgg 600
gaatgaggga ctcggctggg caggatggct cctgtccccc cgaggttccc gtccctcttg 660
gggccccaat gacccccggc ataggtcgcg caacgtgggt aaggtcatcg ataccctaac 720
gtgcggcttt gccgacctca tggggtacat ccctgtcgtg ggcgccccgc tcggcggcgt 780
cgccagagct ctcgcgcatg gcgtgagagt cctggaggac ggggttaatt ttgcaacagg 840
gaacttaccc ggttgctcct tttctatctt cttgctggcc ctgctgtcct gcatcaccac 900
cccggtctcc gctgccgaag tgaagaacat cagtaccggc tacatggtga ctaacgactg 960
caccaatgac agcattacct ggcagctcca ggctgctgtc ctccacgtcc ccgggtgcgt 1020
cccgtgcgag aaagtgggga atgcatctca gtgctggata ccggtctcac cgaatgtggc 1080
cgtgcagcgg cccggcgccc tcacgcaggg cttgcggacg cacatcgaca tggttgtgat 1140
gtccgccacg ctctgctctg ccctctacgt gggggacctc tgcggtgggg tgatgctcgc 1200

agcccaaatg ttcattgtct cgccgcagca ccactggttt gtccaagact gcaattgctc 1260
catctaccct ggtaccatca ctggacaccg catggcatgg gacatgatga tgaactggtc 1320
gcccacggct accatgatct tggcgtacgc gatgcgtgtc cccgaggtca ttatagacat 1380
cattagcggg gctcattggg gcgtcatgtt cggcttggcc tacttctcta tgcagggagc 1440
gtgggcgaaa gtcgttgtca tccttctgtt ggccgccggg gtggacgcgc gcacccatac 1500
tgttgggggt tctgccgcgc agaccaccgg gcgcctcacc agcttatttg acatgggccc 1560
caggcagaaa atccagctcg ttaacaccaa tggcagctgg cacatcaacc gcaccgccct 1620
gaactgcaat gactccttgc acaccggctt tatcgcgtct ctgttctaca cccacagctt 1680
caactcgtca ggatgtcccg aacgcatgtc cgcctgccgc agtatcgagg ccttccgggt 1740
gggatggggc gccttgcaat atgaggataa tgtcaccaat ccagaggata tgagacccta 1800
ttgctggcac tacccaccaa ggcagtgtgg cgtggtctcc gcgaagactg tgtgtggccc 1860
agtgtactgt ttcaccccca gcccagtggt agtgggcacg accgacaggc ttggagcgcc 1920
cacttacacg tgggggggaga atgagacaga tgtcttccta ttgaacagca ctcgaccacc 1980
gctggggtca tggttcggct gcacgtggat gaactcttct ggctacacca agacttgcgg 2040
cgcaccaccc tgccgtacta gagctgactt caacgccagc acggacctgt tgtgccccac 2100
ggactgtttt aggaagcatc ctgataccac ttacctcaaa tgcggctctg ggccctggct 2160
cacgccaagg tgcctgatcg actaccccta caggctctgg cattaccccct gcacagttaa 2220
ctataccatc ttcaaaataa ggatgtatgt gggaggggtt gagcacaggc tcacggctgc 2280
atgcaatttc actcgtgggg atcgttgcaa cttggaggac agagacagaa gtcaactgtc 2340
tcctttgttg cactccacca cggaatgggc cattttacct tgctcttact cggacctgcc 2400
cgccttgtcg actggtcttc tccacctcca ccaaaacatc gtggacgtac aattcatgta 2460
tggcctatca cctgccctca caaaatacat cgtccgatgg gagtgggtaa tactcttatt 2520
cctgctctta gcggacgcca gggtttgcgc ctgcttatgg atgctcatct tgttgggcca 2580
ggccgaagca gcactagaga agctggtcat cttgcacgct gcgagcgcag ctagctgcaa 2640
tggcttccta tattttgtca tcttttcgt ggctgcttgg tacatcaagg gtcgggtagt 2700
ccccttagct acctattccc tcactggcct gtggtccttt agcctactgc tcctagcatt 2760
gccccaacag gcttatgctt atgacgcatc tgtgcatggc cagataggag cggctctgct 2820
ggtaatgatc actctcttta ctctcacccc cgggtataag acccttctca gccggttttt 2880
gtggtggttg tgctatcttc tgaccctggg ggaagctatg gtccaggagt gggcaccacc 2940
tatgcaggtg cgcggtggcc gtgatggcat catatgggcc gtcgccatat tctacccagg 3000
tgtggtgttt gacataacca agtggctctt ggcggtgctt gggcctgctt acctcctaaa 3060
aggtgctttg acgcgcgtgc cgtacttcgt cagggctcac gctctactga ggatgtgcac 3120
catggcaagg catctcgcgg ggggcaggta cgtccagatg gcgctactag cccttggcag 3180
gtggactggc acttacatct atgaccacct caccctatg tcggattggg ctgctagtgg 3240
cctgcgggac ctggcggtcg ccgttgagcc tatcatcttc agtccgatgg agaagaaagt 3300
cattgtctgg ggagcggaga cagctgcttg tggggacatt ttacacggac ttcccgtgtc 3360
cgcccgactt ggtcgggagg tcctccttgg cccagctgat ggctatacct ccaaggggtg 3420
gagtcttctc gcccccatca ctgcttacgc ccagcagaca cgtggccttt tgggcaccat 3480
agtggtgagc atgacggggc gcgacaagac agaacaggct ggggaaattc aggtcctgtc 3540
cacagtcact cagtccttcc tcggaacatc catctcgggg gttttgtgga ctgtctacca 3600
tggagctggc aacaagactc tggccggctc acggggtccg gtcacgcaga tgtactccag 3660
tgctgagggg gacttagtag ggtggcccag ccccccctggg actaaatctt tggagccgtg 3720
cacgtgtgga gcggtcgacc tgtacctggt cacgcggaac gctgatgtca tcccggctcg 3780
aagacgcggg gacaaacggg gagcgctact ctccccgaga cctctttcca ccttgaaggg 3840
gtcctcagga ggcccggtgc tatgccccag gggccacgct gtcggagtct tccgggcagc 3900
tgtgtgctct cggggcgtgg ctaagtccat agatttcatc cccgttgaga cactcgacat 3960
cgtcacgcgg tcccccacct ttagtgacaa cagcacacca cctgctgtgc cccagaccta 4020
tcaggtcggg tacttgcatg ccccgactgg cagtggaaag agcaccaaag ttcctgtcgc 4080

atatgctgct caggggtata aagtgctagt gcttaatccc tcagtggctg ccaccctggg 4140
gtttggggcg tacttgtcta aggcacatgg catcaatccc aacattagga ctggagtcag 4200
gactgtgacg accggggcgc ccatcacgta ctccacatat ggcaaattcc tcgccgatgg 4260
gggctgtgcg ggcggcgcct acgacatcat catatgtgat gaatgccatg ccgtggactc 4320
taccaccatc cttggcatcg gaacagtcct tgatcaagca gagacagctg gggtcagact 4380
aactgtgctg gctacagcta cgccccctgg gtcagtgaca acccccacc ccaacataga 4440
ggaggtggcc cttgggcagg agggcgagat ccccttctat gggagggcga ttcccctgtc 4500
ttacatcaag ggaggaagac atctgatctt ctgccattca aagaaaaagt gtgacgagct 4560
cgcggcggcc cttcggggta tgggcttgaa ctcagtggca tactacagag ggttggacgt 4620
ctccgtaata ccaactcagg gagacgtagt ggtcgtcgcc accgacgccc tcatgacagg 4680
gtatactggg gactttgact ccgtgatcga ctgcaacgta gcggtcactc aagttgtaga 4740
cttcagttta gaccccacat tcaccataac cacacagatt gtccctcaag acgctgtctc 4800
acgtagccag cgccggggtc gcacgggtag gggaagactg ggcatttata ggtatgtttc 4860
cactggtgag cgagcctcag gaatgtttga cagtgtagtg ctctgtgagt gctacgacgc 4920
aggggccgca tggtatgagc tcacaccatc ggagaccacc gtcaggctca gggcgtattt 4980
caacacgccc ggtttgcctg tgtgccaaga ccatcttgag ttttgggagg cagttttcac 5040
cggcctcaca cacatagatg cccacttcct ttcccaaaca aagcaatcgg gggaaaattt 5100
cgcatactta acagcctacc aggctacagt gtgcgctagg gccaaagccc ccccccgtc 5160
ctgggacgtc atgtggaagt gtttgactcg actcaagccc acactcgtgg gccccacacc 5220
tctcctgtac cgcttgggct ctgttaccaa cgaggtcacc ctcacacatc ccgtgacgaa 5280
atacatcgcc acctgcatgc aagccgacct tgaggtcatg accagcacat gggtcttggc 5340
aggggagtc ttggcggccg tcgccgcgta ttgcctggcg accgggtgtg tttgcatcat 5400
cggccgcttg cacattaacc agcgagccgt cgttgcgccg gacaaggagg tcctctatga 5460
ggcttttgat gagatggagg aatgtgcctc tagggcggct ctcattgaag aggggcagcg 5520
gatagccgag atgctgaagt ccaagatcca aggcttattg cagcaagctt ccaaacaagc 5580
tcaagacata caacccactg tgcaggcttc atggcccaag gtagaacaat tctgggccaa 5640
acacatgtgg aacttcatta gcggcatcca atacctcgca ggactatcaa cactgccagg 5700
gaaccctgca gtagcttcca tgatggcgtt cagtgccgcc ctcaccagtc cgctgtcaac 5760
aagcaccact atccttctca acattttggg gggctggcta gcatcccaaa ttgcaccacc 5820
cgcgggggcc actggcttcg ttgtcagtgg cctagtggga gctgccgtag gcagtatagg 5880
cttaggtaag gtgctagtgg acatcctggc agggtatggt gcgggcattt cgggggctct 5940
cgtcgcattc aagatcatgt ctggcgagaa gccctccatg gaggatgtcg tcaacttgct 6000
gcctggaatt ctgtctccgg gtgccttggt agtgggagtc atctgcgcgg ccattctgcg 6060
ccgacacgtg ggaccggggg aaggcgccgt ccaatggatg aatagactca ttgcctttgc 6120
ttccagagga aatcacgtcg cccccaccca ctacgtgacg gagtcggatg cgtcgcagcg 6180
tgtgacccaa ctacttggct cccttaccat aaccagcctg ctcagaagac tccacaactg 6240
gattactgag gactgcccca tcccatgcgg cggctcgtgg ctccgcgatg tgtgggactg 6300
ggtttgcacc atcctaacag actttaaaaa ttggctgacc tccaaattat tcccaaagat 6360
gcccggcctc ccctttgtct cctgtcaaaa ggggtacaag ggcgtgtggg ccggcactgg 6420
catcatgacc acacggtgtc cttgcggcgc caatatctct ggcaatgtcc gcttgggctc 6480
catgagaatc acggggccta agacctgcat gaatatctgg caggggacct ttcctatcaa 6540
ttgttacacg gagggccagt gcgtgccgaa acccgcgcca aactttaagg tcgccatctg 6600
gagggtggcg gcctcagagt acgcggaggt gacgcagcac gggtcatacc actacataac 6660
aggactcacc actgataact tgaaagtccc ctgccaacta ccctctcccg agttcttttc 6720
ctgggtggac ggagtgcaga tccataggtt tgcccccaca ccgaagccgt ttttccggga 6780
tgaggtctcg ttctgcgttg ggcttaattc atttgtcgtc gggtcccagc ttccttgcga 6840
ccctgaaccc gacacagacg tattgatgtc catgctaaca gatccatctc atatcacggc 6900
ggagactgca gcgcggcgtt tagcgcgggg gtcaccccca tccgaggcaa gctcctcggc 6960

gagccagcta tcggcaccat cgctgcgagc cacctgcacc acccacggca aagcctatga 7020
tgtggacatg gtggatgcta acctgttcat ggggggcgat gtgactcgga tagagtctgg 7080
gtccaaagtg gtcgttctgg actctctcga cccaatggtc gaagaaagga gcgaccttga 7140
gccttcgata ccatcagaat acatgctccc caagaagagg ttcccaccag ctttaccggc 7200
ctgggcacgg cctgattaca acccaccgct tgtggaatcg tggaaaaggc cagattacca 7260
accggccact gttgcgggct gtgctctccc tcctcctagg aaaaccccga cgcctccccc 7320
aaggaggcgc cggacagtgg gcctaagtga ggactccata ggagatgccc ttcaacagct 7380
ggccattaag tcctttggcc agcccccccc aagcggcgat tcaggccttt ccacgggggc 7440
gggcgctgcc gattccggca gtcagacgcc tcctgatgag ttggcccttt cggagacagg 7500
ttccatctct tccatgcccc ccctcgaggg ggagcttgga gatccagacc tggagcctga 7560
gcaggtagag ccccaacccc ccccccaggg gggggtggca gctcccggct cggactcggg 7620
gtcctggtct acttgctccg aggaggacga ctccgtcgtg tgctgctcca tgtcatactc 7680
ctggaccggg gctctaataa ctccttgtag tcccgaagag gagaagttac cgattaaccc 7740
cttgagcaac tccctgttgc gatatcacaa caaggtgtac tgtaccacaa caaagagcgc 7800
ctcactaagg gctaaaaagg taacttttga taggatgcaa gtgctcgact cctactacga 7860
ctcagtctta aaggacatta agctagcggc ctccaaggtc accgcaaggc tcctcaccat 7920
ggaggaggct tgccagttaa ccccacccca ttctgcaaga tctaaatatg ggtttggggc 7980
taaggaggtc cgcagcttgt ccgggagggc cgttaaccac atcaagtccg tgtggaagga 8040
cctcctggag gactcagaaa caccaattcc cacaaccatt atggccaaaa atgaggtgtt 8100
ctgcgtggac cccaccaagg ggggcaagaa agcagctcgc cttatcgttt accctgacct 8160
cggcgtcagg gtctgcgaga agatggccct ttatgacatt acacaaaaac ttcctcaggc 8220
ggtgatgggg gcttcttatg gattccagta ttcccccgct cagcgggtag agtttctctt 8280
gaaagcatgg gcggaaaaga aggaccctat gggtttttcg tatgataccc gatgctttga 8340
ctcaaccgtc actgagagag acatcaggac tgaggagtcc atatatcggg cctgctcctt 8400
gcccgaggag gcccacactg ccatacactc gctaactgag agactttacg tgggagggcc 8460
tatgttcaac agcaagggcc aaacctgcgg gtacaggcgt tgccgcgcca gcggggtgct 8520
caccactagc atggggaaca ccatcacatg ctacgtgaaa gccttagcgg cttgtaaagc 8580
tgcagggata atcgcgccca caatgctggt atgcggcgat gacttggttg tcatctcaga 8640
aagccagggg accgaggagg acgagcggaa cctgagagcc ttcacggagg ctatgaccag 8700
gtattctgcc cctcctggtg acccccccag accggagtat gatctggagc tgataacatc 8760
ttgctcctca aatgtgtctg tggcgctggg cccacaaggc cgccgcagat actacctgac 8820
cagagaccct accactccaa tcgcccgggc tgcctgggaa acagttagac actcccctgt 8880
caattcatgg ctgggaaaca tcatccagta cgccccgacc atatgggctc gcatggtcct 8940
gatgacacac ttcttctcca ttctcatggc tcaagacacg ctggaccaga acctcaactt 9000
tgagatgtac ggagcggtgt actccgtgag tcccttggac ctcccagcta taattgaaag 9060
gttacatggg cttgacgctt tttctctgca cacatacact ccccacgaac tgacacgggt 9120
ggcttcagcc ctcagaaaac ttggggcgcc acccctcaga gcgtggaaga gccgggcacg 9180
tgcagtcagg gcgtccctca tctcccgtgg ggggagagcg gccgtttgcg gtcgatatct 9240
cttcaattgg gcggtgaaga ccaagctcaa actcactcca ttgccggaag cgcgcctcct 9300
ggatttatcc agctggttca ccgtcggcgc cggcgggggc gacatttatc acagcgtgtc 9360
gcgtgcccga ccccgcttat tgctctttgg cctactccta ctttttgtag gggtaggcct 9420
tttcctactc cccgctcggt agagcggcac acattagcta cactccatag ctaactgtcc 9480
ctttttttct ttttttttct ttttttttct ttttttttct ttttttttct ttttttttct 9540
ttttttttct ttttttttct ttttctcttt tttctctttt ccttctttct taccttattt 9600
tactttcttt cctggtggct ccatcttagc cctagtcacg gctagctgtg aaaggtccgt 9660
gagccgcatg actgcagaga gtgccgtaac tggtctctct gcagatcatg t 9711

<210> 2
<211> 3033
<212> PRT
<213> Hepatitis C virus

<400> 2

```
Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn
  1               5                  10                  15

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly
             20                  25                  30

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala
         35                  40                  45

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro
     50                  55                  60

Ile Pro Lys Asp Arg Arg Ser Thr Gly Lys Ser Trp Gly Lys Pro Gly
 65                  70                  75                  80

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Leu Gly Trp Ala Gly Trp
                 85                  90                  95

Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Asn Asp Pro
            100                 105                 110

Arg His Arg Ser Arg Asn Val Gly Lys Val Ile Asp Thr Leu Thr Cys
        115                 120                 125

Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Val Val Gly Ala Pro Leu
    130                 135                 140

Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp
145                 150                 155                 160

Gly Val Asn Phe Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile
                165                 170                 175

Phe Leu Leu Ala Leu Leu Ser Cys Ile Thr Thr Pro Val Ser Ala Ala
            180                 185                 190

Glu Val Lys Asn Ile Ser Thr Gly Tyr Met Val Thr Asn Asp Cys Thr
        195                 200                 205

Asn Asp Ser Ile Thr Trp Gln Leu Gln Ala Ala Val Leu His Val Pro
    210                 215                 220
```

```
Gly Cys Val Pro Cys Glu Lys Val Gly Asn Ala Ser Gln Cys Trp Ile
225                 230                 235                 240

Pro Val Ser Pro Asn Val Ala Val Gln Arg Pro Gly Ala Leu Thr Gln
                245                 250                 255

Gly Leu Arg Thr His Ile Asp Met Val Val Met Ser Ala Thr Leu Cys
            260                 265                 270

Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Gly Val Met Leu Ala Ala
        275                 280                 285

Gln Met Phe Ile Val Ser Pro Gln His His Trp Phe Val Gln Asp Cys
    290                 295                 300

Asn Cys Ser Ile Tyr Pro Gly Thr Ile Thr Gly His Arg Met Ala Trp
305                 310                 315                 320

Asp Met Met Met Asn Trp Ser Pro Thr Ala Thr Met Ile Leu Ala Tyr
                325                 330                 335

Ala Met Arg Val Pro Glu Val Ile Ile Asp Ile Ile Ser Gly Ala His
            340                 345                 350

Trp Gly Val Met Phe Gly Leu Ala Tyr Phe Ser Met Gln Gly Ala Trp
        355                 360                 365

Ala Lys Val Val Val Ile Leu Leu Leu Ala Ala Gly Val Asp Ala Arg
    370                 375                 380

Thr His Thr Val Gly Gly Ser Ala Ala Gln Thr Thr Gly Arg Leu Thr
385                 390                 395                 400

Ser Leu Phe Asp Met Gly Pro Arg Gln Lys Ile Gln Leu Val Asn Thr
                405                 410                 415

Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser
            420                 425                 430

Leu His Thr Gly Phe Ile Ala Ser Leu Phe Tyr Thr His Ser Phe Asn
        435                 440                 445

Ser Ser Gly Cys Pro Glu Arg Met Ser Ala Cys Arg Ser Ile Glu Ala
    450                 455                 460

Phe Arg Val Gly Trp Gly Ala Leu Gln Tyr Glu Asp Asn Val Thr Asn
465                 470                 475                 480
```

```
Pro Glu Asp Met Arg Pro Tyr Cys Trp His Tyr Pro Pro Arg Gln Cys
                485                 490                 495

Gly Val Val Ser Ala Lys Thr Val Cys Gly Pro Val Tyr Cys Phe Thr
            500                 505                 510

Pro Ser Pro Val Val Val Gly Thr Thr Asp Arg Leu Gly Ala Pro Thr
        515                 520                 525

Tyr Thr Trp Gly Glu Asn Glu Thr Asp Val Phe Leu Leu Asn Ser Thr
    530                 535                 540

Arg Pro Pro Leu Gly Ser Trp Phe Gly Cys Thr Trp Met Asn Ser Ser
545                 550                 555                 560

Gly Tyr Thr Lys Thr Cys Gly Ala Pro Pro Cys Arg Thr Arg Ala Asp
                565                 570                 575

Phe Asn Ala Ser Thr Asp Leu Leu Cys Pro Thr Asp Cys Phe Arg Lys
            580                 585                 590

His Pro Asp Thr Thr Tyr Leu Lys Cys Gly Ser Gly Pro Trp Leu Thr
        595                 600                 605

Pro Arg Cys Leu Ile Asp Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys
    610                 615                 620

Thr Val Asn Tyr Thr Ile Phe Lys Ile Arg Met Tyr Val Gly Gly Val
625                 630                 635                 640

Glu His Arg Leu Thr Ala Ala Cys Asn Phe Thr Arg Gly Asp Arg Cys
                645                 650                 655

Asn Leu Glu Asp Arg Asp Arg Ser Gln Leu Ser Pro Leu Leu His Ser
            660                 665                 670

Thr Thr Glu Trp Ala Ile Leu Pro Cys Ser Tyr Ser Asp Leu Pro Ala
        675                 680                 685

Leu Ser Thr Gly Leu Leu His Leu His Gln Asn Ile Val Asp Val Gln
    690                 695                 700

Phe Met Tyr Gly Leu Ser Pro Ala Leu Thr Lys Tyr Ile Val Arg Trp
705                 710                 715                 720

Glu Trp Val Ile Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Val Cys
                725                 730                 735
```

```
Ala Cys Leu Trp Met Leu Ile Leu Leu Gly Gln Ala Glu Ala Ala Leu
            740                 745                 750

Glu Lys Leu Val Ile Leu His Ala Ala Ser Ala Ala Ser Cys Asn Gly
        755                 760                 765

Phe Leu Tyr Phe Val Ile Phe Phe Val Ala Ala Trp Tyr Ile Lys Gly
    770                 775                 780

Arg Val Val Pro Leu Ala Thr Tyr Ser Leu Thr Gly Leu Trp Ser Phe
785                 790                 795                 800

Ser Leu Leu Leu Leu Ala Leu Pro Gln Gln Ala Tyr Ala Tyr Asp Ala
                805                 810                 815

Ser Val His Gly Gln Ile Gly Ala Ala Leu Leu Val Met Ile Thr Leu
            820                 825                 830

Phe Thr Leu Thr Pro Gly Tyr Lys Thr Leu Leu Ser Arg Phe Leu Trp
        835                 840                 845

Trp Leu Cys Tyr Leu Leu Thr Leu Gly Glu Ala Met Val Gln Glu Trp
    850                 855                 860

Ala Pro Pro Met Gln Val Arg Gly Gly Arg Asp Gly Ile Ile Trp Ala
865                 870                 875                 880

Val Ala Ile Phe Tyr Pro Gly Val Val Phe Asp Ile Thr Lys Trp Leu
                885                 890                 895

Leu Ala Val Leu Gly Pro Ala Tyr Leu Leu Lys Gly Ala Leu Thr Arg
            900                 905                 910

Val Pro Tyr Phe Val Arg Ala His Ala Leu Leu Arg Met Cys Thr Met
        915                 920                 925

Ala Arg His Leu Ala Gly Gly Arg Tyr Val Gln Met Ala Leu Leu Ala
    930                 935                 940

Leu Gly Arg Trp Thr Gly Thr Tyr Ile Tyr Asp His Leu Thr Pro Met
945                 950                 955                 960

Ser Asp Trp Ala Ala Ser Gly Leu Arg Asp Leu Ala Val Ala Val Glu
                965                 970                 975

Pro Ile Ile Phe Ser Pro Met Glu Lys Lys Val Ile Val Trp Gly Ala
            980                 985                 990
```

Glu Thr Ala Ala Cys Gly Asp Ile Leu His Gly Leu Pro Val Ser Ala
995 1000 1005

Arg Leu Gly Arg Glu Val Leu Leu Gly Pro Ala Asp Gly Tyr Thr Ser
1010 1015 1020

Lys Gly Trp Ser Leu Leu Ala Pro Ile Thr Ala Tyr Ala Gln Gln Thr
1025 1030 1035 1040

Arg Gly Leu Leu Gly Thr Ile Val Val Ser Met Thr Gly Arg Asp Lys
1045 1050 1055

Thr Glu Gln Ala Gly Glu Ile Gln Val Leu Ser Thr Val Thr Gln Ser
1060 1065 1070

Phe Leu Gly Thr Ser Ile Ser Gly Val Leu Trp Thr Val Tyr His Gly
1075 1080 1085

Ala Gly Asn Lys Thr Leu Ala Gly Ser Arg Gly Pro Val Thr Gln Met
1090 1095 1100

Tyr Ser Ser Ala Glu Gly Asp Leu Val Gly Trp Pro Ser Pro Pro Gly
1105 1110 1115 1120

Thr Lys Ser Leu Glu Pro Cys Thr Cys Gly Ala Val Asp Leu Tyr Leu
1125 1130 1135

Val Thr Arg Asn Ala Asp Val Ile Pro Ala Arg Arg Arg Gly Asp Lys
1140 1145 1150

Arg Gly Ala Leu Leu Ser Pro Arg Pro Leu Ser Thr Leu Lys Gly Ser
1155 1160 1165

Ser Gly Gly Pro Val Leu Cys Pro Arg Gly His Ala Val Gly Val Phe
1170 1175 1180

Arg Ala Ala Val Cys Ser Arg Gly Val Ala Lys Ser Ile Asp Phe Ile
1185 1190 1195 1200

Pro Val Glu Thr Leu Asp Ile Val Thr Arg Ser Pro Thr Phe Ser Asp
1205 1210 1215

Asn Ser Thr Pro Pro Ala Val Pro Gln Thr Tyr Gln Val Gly Tyr Leu
1220 1225 1230

His Ala Pro Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Val Ala Tyr
1235 1240 1245

Ala Ala Gln Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala
1250 1255 1260

Thr Leu Gly Phe Gly Ala Tyr Leu Ser Lys Ala His Gly Ile Asn Pro
1265 1270 1275 1280

Asn Ile Arg Thr Gly Val Arg Thr Val Thr Thr Gly Ala Pro Ile Thr
1285 1290 1295

Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys Ala Gly Gly
1300 1305 1310

Ala Tyr Asp Ile Ile Ile Cys Asp Glu Cys His Ala Val Asp Ser Thr
1315 1320 1325

Thr Ile Leu Gly Ile Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Gly
1330 1335 1340

Val Arg Leu Thr Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr
1345 1350 1355 1360

Thr Pro His Pro Asn Ile Glu Glu Val Ala Leu Gly Gln Glu Gly Glu
1365 1370 1375

Ile Pro Phe Tyr Gly Arg Ala Ile Pro Leu Ser Tyr Ile Lys Gly Gly
1380 1385 1390

Arg His Leu Ile Phe Cys His Ser Lys Lys Lys Cys Asp Glu Leu Ala
1395 1400 1405

Ala Ala Leu Arg Gly Met Gly Leu Asn Ser Val Ala Tyr Tyr Arg Gly
1410 1415 1420

Leu Asp Val Ser Val Ile Pro Thr Gln Gly Asp Val Val Val Val Ala
1425 1430 1435 1440

Thr Asp Ala Leu Met Thr Gly Tyr Thr Gly Asp Phe Asp Ser Val Ile
1445 1450 1455

Asp Cys Asn Val Ala Val Thr Gln Val Val Asp Phe Ser Leu Asp Pro
1460 1465 1470

Thr Phe Thr Ile Thr Thr Gln Ile Val Pro Gln Asp Ala Val Ser Arg
1475 1480 1485

Ser Gln Arg Arg Gly Arg Thr Gly Arg Gly Arg Leu Gly Ile Tyr Arg
1490 1495 1500

```
Tyr Val Ser Thr Gly Glu Arg Ala Ser Gly Met Phe Asp Ser Val Val
1505                1510                1515                1520

Leu Cys Glu Cys Tyr Asp Ala Gly Ala Ala Trp Tyr Glu Leu Thr Pro
                1525                1530                1535

Ser Glu Thr Thr Val Arg Leu Arg Ala Tyr Phe Asn Thr Pro Gly Leu
            1540                1545                1550

Pro Val Cys Gln Asp His Leu Glu Phe Trp Glu Ala Val Phe Thr Gly
        1555                1560                1565

Leu Thr His Ile Asp Ala His Phe Leu Ser Gln Thr Lys Gln Ser Gly
    1570                1575                1580

Glu Asn Phe Ala Tyr Leu Thr Ala Tyr Gln Ala Thr Val Cys Ala Arg
1585                1590                1595                1600

Ala Lys Ala Pro Pro Pro Ser Trp Asp Val Met Trp Lys Cys Leu Thr
                1605                1610                1615

Arg Leu Lys Pro Thr Leu Val Gly Pro Thr Pro Leu Leu Tyr Arg Leu
            1620                1625                1630

Gly Ser Val Thr Asn Glu Val Thr Leu Thr His Pro Val Thr Lys Tyr
        1635                1640                1645

Ile Ala Thr Cys Met Gln Ala Asp Leu Glu Val Met Thr Ser Thr Trp
    1650                1655                1660

Val Leu Ala Gly Gly Val Leu Ala Ala Val Ala Ala Tyr Cys Leu Ala
1665                1670                1675                1680

Thr Gly Cys Val Cys Ile Ile Gly Arg Leu His Ile Asn Gln Arg Ala
                1685                1690                1695

Val Val Ala Pro Asp Lys Glu Val Leu Tyr Glu Ala Phe Asp Glu Met
            1700                1705                1710

Glu Glu Cys Ala Ser Arg Ala Ala Leu Ile Glu Glu Gly Gln Arg Ile
        1715                1720                1725

Ala Glu Met Leu Lys Ser Lys Ile Gln Gly Leu Leu Gln Gln Ala Ser
    1730                1735                1740

Lys Gln Ala Gln Asp Ile Gln Pro Thr Val Gln Ala Ser Trp Pro Lys
1745                1750                1755                1760
```

Val Glu Gln Phe Trp Ala Lys His Met Trp Asn Phe Ile Ser Gly Ile
1765 1770 1775

Gln Tyr Leu Ala Gly Leu Ser Thr Leu Pro Gly Asn Pro Ala Val Ala
1780 1785 1790

Ser Met Met Ala Phe Ser Ala Ala Leu Thr Ser Pro Leu Ser Thr Ser
1795 1800 1805

Thr Thr Ile Leu Leu Asn Ile Leu Gly Gly Trp Leu Ala Ser Gln Ile
1810 1815 1820

Ala Pro Pro Ala Gly Ala Thr Gly Phe Val Val Ser Gly Leu Val Gly
1825 1830 1835 1840

Ala Ala Val Gly Ser Ile Gly Leu Gly Lys Val Leu Val Asp Ile Leu
1845 1850 1855

Ala Gly Tyr Gly Ala Gly Ile Ser Gly Ala Leu Val Ala Phe Lys Ile
1860 1865 1870

Met Ser Gly Glu Lys Pro Ser Met Glu Asp Val Val Asn Leu Leu Pro
1875 1880 1885

Gly Ile Leu Ser Pro Gly Ala Leu Val Val Gly Val Ile Cys Ala Ala
1890 1895 1900

Ile Leu Arg Arg His Val Gly Pro Gly Glu Gly Ala Val Gln Trp Met
1905 1910 1915 1920

Asn Arg Leu Ile Ala Phe Ala Ser Arg Gly Asn His Val Ala Pro Thr
1925 1930 1935

His Tyr Val Thr Glu Ser Asp Ala Ser Gln Arg Val Thr Gln Leu Leu
1940 1945 1950

Gly Ser Leu Thr Ile Thr Ser Leu Leu Arg Arg Leu His Asn Trp Ile
1955 1960 1965

Thr Glu Asp Cys Pro Ile Pro Cys Gly Gly Ser Trp Leu Arg Asp Val
1970 1975 1980

Trp Asp Trp Val Cys Thr Ile Leu Thr Asp Phe Lys Asn Trp Leu Thr
1985 1990 1995 2000

Ser Lys Leu Phe Pro Lys Met Pro Gly Leu Pro Phe Val Ser Cys Gln
2005 2010 2015

Lys Gly Tyr Lys Gly Val Trp Ala Gly Thr Gly Ile Met Thr Thr Arg
2020 2025 2030

Cys Pro Cys Gly Ala Asn Ile Ser Gly Asn Val Arg Leu Gly Ser Met
2035 2040 2045

Arg Ile Thr Gly Pro Lys Thr Cys Met Asn Ile Trp Gln Gly Thr Phe
2050 2055 2060

Pro Ile Asn Cys Tyr Thr Glu Gly Gln Cys Val Pro Lys Pro Ala Pro
2065 2070 2075 2080

Asn Phe Lys Val Ala Ile Trp Arg Val Ala Ala Ser Glu Tyr Ala Glu
2085 2090 2095

Val Thr Gln His Gly Ser Tyr His Tyr Ile Thr Gly Leu Thr Thr Asp
2100 2105 2110

Asn Leu Lys Val Pro Cys Gln Leu Pro Ser Pro Glu Phe Phe Ser Trp
2115 2120 2125

Val Asp Gly Val Gln Ile His Arg Phe Ala Pro Thr Pro Lys Pro Phe
2130 2135 2140

Phe Arg Asp Glu Val Ser Phe Cys Val Gly Leu Asn Ser Phe Val Val
2145 2150 2155 2160

Gly Ser Gln Leu Pro Cys Asp Pro Glu Pro Asp Thr Asp Val Leu Met
2165 2170 2175

Ser Met Leu Thr Asp Pro Ser His Ile Thr Ala Glu Thr Ala Ala Arg
2180 2185 2190

Arg Leu Ala Arg Gly Ser Pro Pro Ser Glu Ala Ser Ser Ser Ala Ser
2195 2200 2205

Gln Leu Ser Ala Pro Ser Leu Arg Ala Thr Cys Thr Thr His Gly Lys
2210 2215 2220

Ala Tyr Asp Val Asp Met Val Asp Ala Asn Leu Phe Met Gly Gly Asp
2225 2230 2235 2240

Val Thr Arg Ile Glu Ser Gly Ser Lys Val Val Val Leu Asp Ser Leu
2245 2250 2255

Asp Pro Met Val Glu Glu Arg Ser Asp Leu Glu Pro Ser Ile Pro Ser
2260 2265 2270

Glu Tyr Met Leu Pro Lys Lys Arg Phe Pro Pro Ala Leu Pro Ala Trp
2275 2280 2285

Ala Arg Pro Asp Tyr Asn Pro Pro Leu Val Glu Ser Trp Lys Arg Pro
2290 2295 2300

Asp Tyr Gln Pro Ala Thr Val Ala Gly Cys Ala Leu Pro Pro Pro Arg
2305 2310 2315 2320

Lys Thr Pro Thr Pro Pro Pro Arg Arg Arg Arg Thr Val Gly Leu Ser
2325 2330 2335

Glu Asp Ser Ile Gly Asp Ala Leu Gln Gln Leu Ala Ile Lys Ser Phe
2340 2345 2350

Gly Gln Pro Pro Pro Ser Gly Asp Ser Gly Leu Ser Thr Gly Ala Gly
2355 2360 2365

Ala Ala Asp Ser Gly Ser Gln Thr Pro Pro Asp Glu Leu Ala Leu Ser
2370 2375 2380

Glu Thr Gly Ser Ile Ser Ser Met Pro Pro Leu Glu Gly Glu Leu Gly
2385 2390 2395 2400

Asp Pro Asp Leu Glu Pro Glu Gln Val Glu Pro Gln Pro Pro Pro Gln
2405 2410 2415

Gly Gly Val Ala Ala Pro Gly Ser Asp Ser Gly Ser Trp Ser Thr Cys
2420 2425 2430

Ser Glu Glu Asp Asp Ser Val Val Cys Cys Ser Met Ser Tyr Ser Trp
2435 2440 2445

Thr Gly Ala Leu Ile Thr Pro Cys Ser Pro Glu Glu Glu Lys Leu Pro
2450 2455 2460

Ile Asn Pro Leu Ser Asn Ser Leu Leu Arg Tyr His Asn Lys Val Tyr
2465 2470 2475 2480

Cys Thr Thr Thr Lys Ser Ala Ser Leu Arg Ala Lys Lys Val Thr Phe
2485 2490 2495

Asp Arg Met Gln Val Leu Asp Ser Tyr Tyr Asp Ser Val Leu Lys Asp
2500 2505 2510

Ile Lys Leu Ala Ala Ser Lys Val Thr Ala Arg Leu Leu Thr Met Glu
2515 2520 2525

Glu Ala Cys Gln Leu Thr Pro Pro His Ser Ala Arg Ser Lys Tyr Gly
2530 2535 2540

Phe Gly Ala Lys Glu Val Arg Ser Leu Ser Gly Arg Ala Val Asn His
2545 2550 2555 2560

Ile Lys Ser Val Trp Lys Asp Leu Leu Glu Asp Ser Glu Thr Pro Ile
2565 2570 2575

Pro Thr Thr Ile Met Ala Lys Asn Glu Val Phe Cys Val Asp Pro Thr
2580 2585 2590

Lys Gly Gly Lys Lys Ala Ala Arg Leu Ile Val Tyr Pro Asp Leu Gly
2595 2600 2605

Val Arg Val Cys Glu Lys Met Ala Leu Tyr Asp Ile Thr Gln Lys Leu
2610 2615 2620

Pro Gln Ala Val Met Gly Ala Ser Tyr Gly Phe Gln Tyr Ser Pro Ala
2625 2630 2635 2640

Gln Arg Val Glu Phe Leu Leu Lys Ala Trp Ala Glu Lys Lys Asp Pro
2645 2650 2655

Met Gly Phe Ser Tyr Asp Thr Arg Cys Phe Asp Ser Thr Val Thr Glu
2660 2665 2670

Arg Asp Ile Arg Thr Glu Glu Ser Ile Tyr Arg Ala Cys Ser Leu Pro
2675 2680 2685

Glu Glu Ala His Thr Ala Ile His Ser Leu Thr Glu Arg Leu Tyr Val
2690 2695 2700

Gly Gly Pro Met Phe Asn Ser Lys Gly Gln Thr Cys Gly Tyr Arg Arg
2705 2710 2715 2720

Cys Arg Ala Ser Gly Val Leu Thr Thr Ser Met Gly Asn Thr Ile Thr
2725 2730 2735

Cys Tyr Val Lys Ala Leu Ala Ala Cys Lys Ala Ala Gly Ile Ile Ala
2740 2745 2750

Pro Thr Met Leu Val Cys Gly Asp Asp Leu Val Val Ile Ser Glu Ser
2755 2760 2765

Gln Gly Thr Glu Glu Asp Glu Arg Asn Leu Arg Ala Phe Thr Glu Ala
2770 2775 2780

```
Met Thr Arg Tyr Ser Ala Pro Pro Gly Asp Pro Pro Arg Pro Glu Tyr
2785                2790                2795                2800

Asp Leu Glu Leu Ile Thr Ser Cys Ser Ser Asn Val Ser Val Ala Leu
                2805                2810                2815

Gly Pro Gln Gly Arg Arg Arg Tyr Tyr Leu Thr Arg Asp Pro Thr Thr
            2820                2825                2830

Pro Ile Ala Arg Ala Ala Trp Glu Thr Val Arg His Ser Pro Val Asn
        2835                2840                2845

Ser Trp Leu Gly Asn Ile Ile Gln Tyr Ala Pro Thr Ile Trp Ala Arg
    2850                2855                2860

Met Val Leu Met Thr His Phe Phe Ser Ile Leu Met Ala Gln Asp Thr
2865                2870                2875                2880

Leu Asp Gln Asn Leu Asn Phe Glu Met Tyr Gly Ala Val Tyr Ser Val
                2885                2890                2895

Ser Pro Leu Asp Leu Pro Ala Ile Ile Glu Arg Leu His Gly Leu Asp
            2900                2905                2910

Ala Phe Ser Leu His Thr Tyr Thr Pro His Glu Leu Thr Arg Val Ala
        2915                2920                2925

Ser Ala Leu Arg Lys Leu Gly Ala Pro Pro Leu Arg Ala Trp Lys Ser
    2930                2935                2940

Arg Ala Arg Ala Val Arg Ala Ser Leu Ile Ser Arg Gly Gly Arg Ala
2945                2950                2955                2960

Ala Val Cys Gly Arg Tyr Leu Phe Asn Trp Ala Val Lys Thr Lys Leu
                2965                2970                2975

Lys Leu Thr Pro Leu Pro Glu Ala Arg Leu Leu Asp Leu Ser Ser Trp
            2980                2985                2990

Phe Thr Val Gly Ala Gly Gly Gly Asp Ile Tyr His Ser Val Ser Arg
        2995                3000                3005

Ala Arg Pro Arg Leu Leu Leu Phe Gly Leu Leu Leu Leu Phe Val Gly
    3010                3015                3020

Val Gly Leu Phe Leu Leu Pro Ala Arg
3025                3030
```

<210> 3
<211> 9611
<212> DNA
<213> Hepatitis C virus

<400> 3
gccagccccc tgatgggggc gacactccac catgaatcac tcccctgtga ggaactactg 60
tcttcacgca gaaagcgtct agccatggcg ttagtatgag tgtcgtgcag cctccaggac 120
ccccccteee gggagagcca tagtggtctg cggaaccggt gagtacaccg gaattgccag 180
gacgaccggg tcctttcttg gataaacccg ctcaatgcct ggagatttgg gcgtgccccc 240
gcaagactgc tagccgagta gtgttgggtc gcgaaaggcc ttgtggtact gcctgatagg 300
gtgcttgcga gtgccccggg aggtctcgta gaccgtgcac catgagcaca aatcctaaac 360
ctcaaagaaa aaccaaaaga aacaccaacc gtcgcccaca agacgttaag tttccgggcg 420
gcggccagat cgttggcgga gtatacttgt tgccgcgcag gggccccagg ttgggtgtgc 480
gcgcgacaag gaagacttcg gagcggtccc agccacgtgg aaggcgccag cccatcccta 540
aagatcggcg ctccactggc aaatcctggg gaaaaccagg atacccctgg cccctatacg 600
ggaatgaggg actcggctgg gcaggatggc tcctgtcccc ccgaggttcc cgtccctctt 660
ggggccccaa tgacccccgg cataggtcgc gcaacgtggg taaggtcatc gataccctaa 720
cgtgcggctt tgccgacctc atggggtaca tccctgtcgt gggcgccccg ctcggcggcg 780
tcgccagagc tctcgcgcat ggcgtgagag tcctggagga cggggttaat tttgcaacag 840
ggaacttacc cggttgctcc ttttctatct tcttgctggc cctgctgtcc tgcatcacca 900
ccccggtctc cgctgccgaa gtgaagaaca tcagtaccgg ctacatggtg actaacgact 960
gcaccaatga cagcattacc tggcagctcc aggctgctgt cctccacgtc cccgggtgcg 1020
tcccgtgcga gaaagtgggg aatgcatctc agtgctggat accggtctca ccgaatgtgg 1080
ccgtgcagcg gcccggcgcc ctcacgcagg gcttgcggac gcacatcgac atggttgtga 1140
tgtccgccac gctctgctct gccctctacg tgggggacct ctgcggtggg gtgatgctcg 1200
cagcccaaat gttcattgtc tcgccgcagc accactggtt tgtccaagac tgcaattgct 1260
ccatctaccc tggtaccatc actggacacc gcatggcatg ggacatgatg atgaactggt 1320
cgcccacggc taccatgatc ttggcgtacg cgatgcgtgt ccccgaggtc attatagaca 1380
tcattagcgg ggctcattgg ggcgtcatgt tcggcttggc ctacttctct atgcagggag 1440
cgtgggcgaa agtcgttgtc atccttctgt tggccgccgg ggtggacgcg cgcacccata 1500
ctgttggggg ttctgccgcg cagaccaccg ggcgcctcac cagcttattt gacatgggcc 1560
ccaggcagaa aatccagctc gttaacacca atggcagctg gcacatcaac cgcaccgccc 1620
tgaactgcaa tgactccttg cacaccggct ttatcgcgtc tctgttctac acccacagct 1680
tcaactcgtc aggatgtccc gaacgcatgt ccgcctgccg cagtatcgag gccttccggg 1740
tgggatgggg cgccttgcaa tatgaggata atgtcaccaa tccagaggat atgagaccct 1800
attgctggca ctacccacca aggcagtgtg gcgtggtctc cgcgaagact gtgtgtggcc 1860
cagtgtactg tttcaccccc agcccagtgg tagtgggcac gaccgacagg cttggagcgc 1920
ccacttacac gtgggggggag aatgagacag atgtcttcct attgaacagc actcgaccac 1980
cgctggggtc atggttcggc tgcacgtgga tgaactcttc tggctacacc aagacttgcg 2040
gcgcaccacc ctgccgtact agagctgact tcaacgccag cacggacctg ttgtgcccca 2100
cggactgttt taggaagcat cctgatacca cttacctcaa atgcggctct gggccctggc 2160
tcacgccaag gtgcctgatc gactacccct acaggctctg gcattacccc tgcacagtta 2220
actataccat cttcaaaata aggatgtatg tgggaggggt tgagcacagg ctcacggctg 2280
catgcaattt cactcgtggg gatcgttgca acttggagga cagagacaga agtcaactgt 2340
ctcctttgtt gcactccacc acggaatggg ccattttacc ttgctcttac tcggacctgc 2400
ccgccttgtc gactggtctt ctccacctcc accaaaacat cgtggacgta caattcatgt 2460

atggcctatc acctgccctc acaaaatacа tcgtccgatg ggagtgggta atactcttat 2520
tcctgctctt agcggacgcc agggtttgcg cctgcttatg gatgctcatc ttgttgggcc 2580
aggccgaagc agcactagag aagctggtca tcttgcacgc tgcgagcgca gctagctgca 2640
atggcttcct atattttgtc atctttttcg tggctgcttg gtacatcaag ggtcgggtag 2700
tcccccttagc tacctattcc ctcactggcc tgtggtcctt tagcctactg ctcctagcat 2760
tgccccaaca ggcatatgca ctggacacgg aggtggccgc gtcgtgtggc ggcgttgttc 2820
ttgtcgggtt aatggcgctg actctgtcgc catattacaa gcgctatatc agctggtgca 2880
tgtggtggct tcagtatttt ctgaccagag tagaagcgca actgcacgtg tgggttcccc 2940
ccctcaacgt ccgggggggg cgcgatgccg tcatcttact catgtgtgta gtacacccga 3000
ccctggtatt tgacatcacc aaactactcc tggccatctt cggacccctt tggattcttc 3060
aagccagttt gcttaaagtc ccctacttcg tgcgcgttca aggccttctc cggatctgcg 3120
cgctagcgcg gaagatagcc ggaggtcatt acgtgcaaat ggccatcatc aagttagggg 3180
cgcttactgg cacctatgtg tataaccatc tcacccctct tcgagactgg gcgcacaacg 3240
gcctgcgaga tctggccgtg gctgtggaac cagtcgtctt ctcccgaatg gagaccaagc 3300
tcatcacgtg gggggcagat accgccgcgt gcggtgacat catcaacggc ttgcccgtct 3360
ctgcccgtag gggccaggag atactgcttg ggccagccga cggaatggtc tccaaggggt 3420
ggaggttgct ggcgcccatc acggcgtacg cccagcagac gagaggcctc ctagggtgta 3480
taatcaccag cctgactggc cgggacaaaa accaagtgga gggtgaggtc cagatcgtgt 3540
caactgctac ccaaaccttc ctggcaacgt gcatcaatgg ggtatgctgg actgtctacc 3600
acggggccgg aacgaggacc atcgcatcac ccaagggtcc tgtcatccag atgtatacca 3660
atgtggacca agaccttgtg ggctggcccg ctcctcaagg ttcccgctca ttgacaccct 3720
gtacctgcgg ctcctcggac ctttacctgg tcacgaggca cgccgatgtc attcccgtgc 3780
gccggcgagg tgatagcagg ggtagcctgc tttcgccccg gcccatttcc tacttgaaag 3840
gctcctcggg gggtccgctg ttgtgccccg cgggacacgc cgtgggccta ttcagggccg 3900
cggtgtgcac ccgtggagtg gctaaagcgg tggactttat ccctgtggag aacctaggga 3960
caaccatgag atccccggtg ttcacggaca actcctctcc accagcagtg ccccagagct 4020
tccaggtggc ccacctgcat gctcccaccg gcagcggtaa gagcaccaag gtcccggctg 4080
cgtacgcagc ccagggctac aaggtgttgg tgctcaaccc ctctgttgct gcaacgctgg 4140
gctttggtgc ttacatgtcc aaggcccatg gggttgatcc taatatcagg accggggtga 4200
gaacaattac cactggcagc cccatcacgt actccaccta cggcaagttc cttgccgacg 4260
gcgggtgctc aggaggtgct tatgacataa taatttgtga cgagtgccac tccacggatg 4320
ccacatccat cttgggcatc ggcactgtcc ttgaccaagc agagactgcg ggggcgagac 4380
tggttgtgct cgccactgct acccctccgg gctccgtcac tgtgtcccat cctaacatcg 4440
aggaggttgc tctgtccacc accggagaga tccccctttа cggcaaggct atccccctcg 4500
aggtgatcaa ggggggaaga catctcatct tctgccactc aaagaagaag tgcgacgagc 4560
tcgccgcgaa gctggtcgca ttgggcatca atgccgtggc ctactaccgc ggtcttgacg 4620
tgtctgtcat cccgaccagc ggcgatgttg tcgtcgtgtc gaccgatgct ctcatgactg 4680
gctttaccgg cgacttcgac tctgtgatag actgcaacac gtgtgtcact cagacagtcg 4740
atttcagcct tgaccctacc tttaccattg agacaaccac gctcccccag gatgctgtct 4800
ccaggactca acgccggggc aggactggca gggggaagcc aggcatctat agatttgtgg 4860
caccgggggа gcgccctcc ggcatgttcg actcgtccgt cctctgtgag tgctatgacg 4920
cgggctgtgc ttggtatgag ctcacgcccg ccgagactac agttaggcta cgagcgtaca 4980
tgaacacccc ggggcttccc gtgtgccagg accatcttga attttgggag ggcgtcttta 5040
cgggcctcac tcatatagat gcccactttt tatcccagac aaagcagagt ggggagaact 5100
ttccttacct ggtagcgtac caagccaccg tgtgcgctag ggctcaagcc cctcccccat 5160
cgtgggacca gatgtggaag tgtttgatcc gccttaaacc caccctccat gggccaacac 5220
ccctgctata cagactgggc gctgttcaga atgaagtcac cctgacgcac ccaatcacca 5280
aatacatcat gacatgcatg tcggccgacc tggaggtcgt cacgagcacc tgggtgctcg 5340

ttggcggcgt cctggctgct ctggccgcgt attgcctgtc aacaggctgc gtggtcatag 5400
tgggcaggat cgtcttgtcc gggaagccgg caattatacc tgacagggag gttctctacc 5460
aggagttcga tgagatggaa gagtgctctc agcacttacc gtacatcgag caagggatga 5520
tgctcgctga gcagttcaag cagaaggccc tcggcctcct gcagaccgcg tcccgccatg 5580
cagaggttat caccctgct gtccagacca actggcagaa actcgaggtc ttttgggcga 5640
agcacatgtg gaatttcatc agtgggatac aatacttggc gggcctgtca acgctgcctg 5700
gtaaccccgc cattgcttca ttgatggctt ttacagctgc cgtcaccagc ccactaacca 5760
ctggccaaac cctcctcttc aacatattgg gggggtgggt ggctgcccag ctcgccgccc 5820
ccggtgccgc tactgccttt gtgggtgctg gcctagctgg cgccgccatc ggcagcgttg 5880
gactggggaa ggtcctcgtg gacattcttg cagggtatgg cgcgggcgtg gcgggagctc 5940
ttgtagcatt caagatcatg agcggtgagg tcccctccac ggaggacctg gtcaatctgc 6000
tgcccgccat cctctcgcct ggagcccttg tagtcggtgt ggtctgcgca gcaatactgc 6060
gccggcacgt tggccgggc gaggggcag tgcaatggat gaaccggcta atagccttcg 6120
cctcccgggg gaaccatgtt tcccccacgc actacgtgcc ggagagcgat gcagccgccc 6180
gcgtcactgc catactcagc agcctcactg taacccagct cctgaggcga ctgcatcagt 6240
ggataagctc ggagtgtacc actccatgct ccggttcctg gctaagggac atctgggact 6300
ggatatgcga ggtgctgagc gactttaaga cctggctgaa agccaagctc atgccacaac 6360
tgcctgggat tccctttgtg tcctgccagc gcgggtatag gggggtctgg cgaggagacg 6420
gcattatgca cactcgctgc cactgtggag ctgagatcac tggacatgtc aaaaacggga 6480
cgatgaggat cgtcggtcct aggacctgca ggaacatgtg gagtgggacg ttccccatta 6540
acgcctacac cacgggcccc tgtactcccc ttcctgcgcc gaactataag ttcgcgctgt 6600
ggagggtgtc tgcagaggaa tacgtggaga taaggcgggt gggggacttc cactacgtat 6660
cgggtatgac tactgacaat cttaaatgcc cgtgccagat cccatcgccc gaatttttca 6720
cagaattgga cggggtgcgc ctacacaggt ttgcgccccc ttgcaagccc ttgctgcggg 6780
aggaggtatc attcagagta ggactccacg agtacccggt ggggtcgcaa ttaccttgcg 6840
agcccgaacc ggacgtagcc gtgttgacgt ccatgctcac tgatccctcc catataacag 6900
cagaggcggc cgggagaagg ttggcgagag ggtcaccccc ttctatggcc agctcctcgg 6960
ctagccagct gtccgctcca tctctcaagg caacttgcac cgccaaccat gactcccctg 7020
acgccgagct catagaggct aacctcctgt ggaggcagga gatgggcggc aacatcacca 7080
gggttgagtc agagaacaaa gtggtgattc tggactcctt cgatccgctt gtggcagagg 7140
aggatgagcg ggaggtctcc gtacctgcag aaattctgcg gaagtctcgg agattcgccc 7200
gggccctgcc cgtctgggcg cggccggact acaaccccccc gctagtagag acgtggaaaa 7260
agcctgacta cgaaccacct gtggtccatg gctgcccgct accacctcca cggtcccctc 7320
ctgtgcctcc gcctcggaaa aagcgtacgg tggtcctcac cgaatcaacc ctatctactg 7380
ccttggccga gcttgccacc aaaagttttg gcagctcctc aacttccggc attacgggcg 7440
acaatacgac aacatcctct gagcccgccc cttctggctg ccccccccgac tccgacgttg 7500
agtcctattc ttccatgccc cccctggagg gggagcctgg ggatccggat ctcagcgacg 7560
ggtcatggtc gacggtcagt agtggggccg acacggaaga tgtcgtgtgc tgctcaatgt 7620
cttattcctg gacaggcgca ctcgtcaccc cgtgcgctgc ggaagaacaa aaactgccca 7680
tcaacgcact gagcaactcg ttgctacgcc atcacaatct ggtgtattcc accacttcac 7740
gcagtgcttg ccaaaggcag aagaaagtca catttgacag actgcaagtt ctggacagcc 7800
attaccagga cgtgctcaag gaggtcaaag cagcggcgtc aaaagtgaag gctaacttgc 7860
tatccgtaga ggaagcttgc agcctgacgc ccccacattc agccaaatcc aagtttggct 7920
atggggcaaa agacgtccgt tgccatgcca gaaaggccgt agcccacatc aactccgtgt 7980
ggaaagacct tctggaagac agtgtaacac caatagacac taccatcatg gccaagaacg 8040
aggttttctg cgttcagcct gagaaggggg gtcgtaagcc agctcgtctc atcgtgttcc 8100
ccgacctggg cgtgcgcgtg tgcgagaaga tggccctgta cgacgtggtt agcaagctcc 8160
ccctggccgt gatgggaagc tcctacggat tccaatactc accaggacag cgggttgaat 8220

tcctcgtgca agcgtggaag tccaagaaga ccccgatggg gttctcgtat gatacccgct 8280
gttttgactc cacagtcact gagagcgaca tccgtacgga ggaggcaatt taccaatgtt 8340
gtgacctgga cccccaagcc cgcgtggcca tcaagtccct cactgagagg ctttatgttg 8400
ggggcccctct taccaattca agggggaaa actgcggcta ccgcaggtgc cgcgcgagcg 8460
gcgtactgac aactagctgt ggtaacaccc tcacttgcta catcaaggcc cgggcagcct 8520
gtcgagccgc agggctccag gactgcacca tgctcgtgtg tggcgacgac ttagtcgtta 8580
tctgtgaaag tgcgggggtc caggaggacg cggcgagcct gagagccttc acggaggcta 8640
tgaccaggta ctccgccccc cccggggacc ccccacaacc agaatacgac ttggagctta 8700
taacatcatg ctcctccaac gtgtcagtcg cccacgacgg cgctggaaag agggtctact 8760
accttacccg tgaccctaca acccccctcg cgagagccgc gtgggagaca gcaagacaca 8820
ctccagtcaa ttcctggcta ggcaacataa tcatgtttgc ccccacactg tgggcgagga 8880
tgatactgat gacccatttc tttagcgtcc tcatagccag ggatcagctt gaacaggctc 8940
ttaactgtga gatctacgga gcctgctact ccatagaacc actggatcta cctccaatca 9000
ttcaaagact ccatggcctc agcgcatttt cactccacag ttactctcca ggtgaaatca 9060
atagggtggc cgcatgcctc agaaaacttg gggtcccgcc cttgcgagct tggagacacc 9120
gggcccggag cgtccgcgct aggcttctgt ccagaggagg cagggctgct atatgtggca 9180
agtacctctt caactgggca gtaagaacaa agctcaaact cactccaata gcggccgctg 9240
gccggctgga cttgtccggt tggttcacgg ctggctacag cgggggagac atttatcaca 9300
gcgtgtctca tgcccggccc cgctggttct ggttttgcct actcctgctc gctgcagggg 9360
taggcatcta cctcctcccc aaccgatgaa ggttggggta aacactccgg cctcttaagc 9420
catttcctgt ttttttttt ttttttttt ttttttcctt ttttttttc tttcctttcc 9480
ttctttttt cctttctttt tcccttcttt aatggtggct ccatcttagc cctagtcacg 9540
gctagctgtg aaaggtccgt gagccgcatg actgcagaga gtgctgatac tggcctctct 9600
gcagatcatg t 9611

<210> 4
<211> 3015
<212> PRT
<213> Hepatitis C virus

<400> 4

Met	Ser	Thr	Asn	Pro	Lys	Pro	Gln	Arg	Lys	Thr	Lys	Arg	Asn	Thr	Asn
1					5				10					15	

Arg	Arg	Pro	Gln	Asp	Val	Lys	Phe	Pro	Gly	Gly	Gly	Gln	Ile	Val	Gly
			20					25					30		

Gly	Val	Tyr	Leu	Leu	Pro	Arg	Arg	Gly	Pro	Arg	Leu	Gly	Val	Arg	Ala
		35					40					45			

Thr	Arg	Lys	Thr	Ser	Glu	Arg	Ser	Gln	Pro	Arg	Gly	Arg	Arg	Gln	Pro
	50					55					60				

Ile	Pro	Lys	Asp	Arg	Arg	Ser	Thr	Gly	Lys	Ser	Trp	Gly	Lys	Pro	Gly
65					70					75					80

Tyr	Pro	Trp	Pro	Leu	Tyr	Gly	Asn	Glu	Gly	Leu	Gly	Trp	Ala	Gly	Trp

85 90 95

Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Asn Asp Pro
100 105 110

Arg His Arg Ser Arg Asn Val Gly Lys Val Ile Asp Thr Leu Thr Cys
115 120 125

Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Val Val Gly Ala Pro Leu
130 135 140

Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp
145 150 155 160

Gly Val Asn Phe Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile
165 170 175

Phe Leu Leu Ala Leu Leu Ser Cys Ile Thr Thr Pro Val Ser Ala Ala
180 185 190

Glu Val Lys Asn Ile Ser Thr Gly Tyr Met Val Thr Asn Asp Cys Thr
195 200 205

Asn Asp Ser Ile Thr Trp Gln Leu Gln Ala Ala Val Leu His Val Pro
210 215 220

Gly Cys Val Pro Cys Glu Lys Val Gly Asn Ala Ser Gln Cys Trp Ile
225 230 235 240

Pro Val Ser Pro Asn Val Ala Val Gln Arg Pro Gly Ala Leu Thr Gln
245 250 255

Gly Leu Arg Thr His Ile Asp Met Val Val Met Ser Ala Thr Leu Cys
260 265 270

Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Gly Val Met Leu Ala Ala
275 280 285

Gln Met Phe Ile Val Ser Pro Gln His His Trp Phe Val Gln Asp Cys
290 295 300

Asn Cys Ser Ile Tyr Pro Gly Thr Ile Thr Gly His Arg Met Ala Trp
305 310 315 320

Asp Met Met Met Asn Trp Ser Pro Thr Ala Thr Met Ile Leu Ala Tyr
325 330 335

Ala Met Arg Val Pro Glu Val Ile Ile Asp Ile Ile Ser Gly Ala His

340 345 350

Trp Gly Val Met Phe Gly Leu Ala Tyr Phe Ser Met Gln Gly Ala Trp
355 360 365

Ala Lys Val Val Val Ile Leu Leu Leu Ala Ala Gly Val Asp Ala Arg
370 375 380

Thr His Thr Val Gly Gly Ser Ala Ala Gln Thr Thr Gly Arg Leu Thr
385 390 395 400

Ser Leu Phe Asp Met Gly Pro Arg Gln Lys Ile Gln Leu Val Asn Thr
405 410 415

Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser
420 425 430

Leu His Thr Gly Phe Ile Ala Ser Leu Phe Tyr Thr His Ser Phe Asn
435 440 445

Ser Ser Gly Cys Pro Glu Arg Met Ser Ala Cys Arg Ser Ile Glu Ala
450 455 460

Phe Arg Val Gly Trp Gly Ala Leu Gln Tyr Glu Asp Asn Val Thr Asn
465 470 475 480

Pro Glu Asp Met Arg Pro Tyr Cys Trp His Tyr Pro Pro Arg Gln Cys
485 490 495

Gly Val Val Ser Ala Lys Thr Val Cys Gly Pro Val Tyr Cys Phe Thr
500 505 510

Pro Ser Pro Val Val Val Gly Thr Thr Asp Arg Leu Gly Ala Pro Thr
515 520 525

Tyr Thr Trp Gly Glu Asn Glu Thr Asp Val Phe Leu Leu Asn Ser Thr
530 535 540

Arg Pro Pro Leu Gly Ser Trp Phe Gly Cys Thr Trp Met Asn Ser Ser
545 550 555 560

Gly Tyr Thr Lys Thr Cys Gly Ala Pro Pro Cys Arg Thr Arg Ala Asp
565 570 575

Phe Asn Ala Ser Thr Asp Leu Leu Cys Pro Thr Asp Cys Phe Arg Lys
580 585 590

His Pro Asp Thr Thr Tyr Leu Lys Cys Gly Ser Gly Pro Trp Leu Thr

595 600 605

Pro Arg Cys Leu Ile Asp Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys
610 615 620

Thr Val Asn Tyr Thr Ile Phe Lys Ile Arg Met Tyr Val Gly Gly Val
625 630 635 640

Glu His Arg Leu Thr Ala Ala Cys Asn Phe Thr Arg Gly Asp Arg Cys
645 650 655

Asn Leu Glu Asp Arg Asp Arg Ser Gln Leu Ser Pro Leu Leu His Ser
660 665 670

Thr Thr Glu Trp Ala Ile Leu Pro Cys Ser Tyr Ser Asp Leu Pro Ala
675 680 685

Leu Ser Thr Gly Leu Leu His Leu His Gln Asn Ile Val Asp Val Gln
690 695 700

Phe Met Tyr Gly Leu Ser Pro Ala Leu Thr Lys Tyr Ile Val Arg Trp
705 710 715 720

Glu Trp Val Ile Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Val Cys
725 730 735

Ala Cys Leu Trp Met Leu Ile Leu Leu Gly Gln Ala Glu Ala Ala Leu
740 745 750

Glu Lys Leu Val Ile Leu His Ala Ala Ser Ala Ala Ser Cys Asn Gly
755 760 765

Phe Leu Tyr Phe Val Ile Phe Phe Val Ala Ala Trp Tyr Ile Lys Gly
770 775 780

Arg Val Val Pro Leu Ala Thr Tyr Ser Leu Thr Gly Leu Trp Ser Phe
785 790 795 800

Ser Leu Leu Leu Leu Ala Leu Pro Gln Gln Ala Tyr Ala Leu Asp Thr
805 810 815

Glu Val Ala Ala Ser Cys Gly Gly Val Val Leu Val Gly Leu Met Ala
820 825 830

Leu Thr Leu Ser Pro Tyr Tyr Lys Arg Tyr Ile Ser Trp Cys Met Trp
835 840 845

Trp Leu Gln Tyr Phe Leu Thr Arg Val Glu Ala Gln Leu His Val Trp

```
    850                 855                 860

Val Pro Pro Leu Asn Val Arg Gly Gly Arg Asp Ala Val Ile Leu Leu
865                 870                 875                 880

Met Cys Val Val His Pro Thr Leu Val Phe Asp Ile Thr Lys Leu Leu
                885                 890                 895

Leu Ala Ile Phe Gly Pro Leu Trp Ile Leu Gln Ala Ser Leu Leu Lys
            900                 905                 910

Val Pro Tyr Phe Val Arg Val Gln Gly Leu Leu Arg Ile Cys Ala Leu
        915                 920                 925

Ala Arg Lys Ile Ala Gly Gly His Tyr Val Gln Met Ala Ile Ile Lys
    930                 935                 940

Leu Gly Ala Leu Thr Gly Thr Tyr Val Tyr Asn His Leu Thr Pro Leu
945                 950                 955                 960

Arg Asp Trp Ala His Asn Gly Leu Arg Asp Leu Ala Val Ala Val Glu
                965                 970                 975

Pro Val Val Phe Ser Arg Met Glu Thr Lys Leu Ile Thr Trp Gly Ala
            980                 985                 990

Asp Thr Ala Ala Cys Gly Asp Ile Ile Asn Gly Leu Pro Val Ser Ala
        995                1000                1005

Arg Arg Gly Gln Glu Ile Leu Leu Gly Pro Ala Asp Gly Met Val Ser
   1010                1015                1020

Lys Gly Trp Arg Leu Leu Ala Pro Ile Thr Ala Tyr Ala Gln Gln Thr
1025                1030                1035                1040

Arg Gly Leu Leu Gly Cys Ile Ile Thr Ser Leu Thr Gly Arg Asp Lys
                1045                1050                1055

Asn Gln Val Glu Gly Glu Val Gln Ile Val Ser Thr Ala Thr Gln Thr
            1060                1065                1070

Phe Leu Ala Thr Cys Ile Asn Gly Val Cys Trp Thr Val Tyr His Gly
        1075                1080                1085

Ala Gly Thr Arg Thr Ile Ala Ser Pro Lys Gly Pro Val Ile Gln Met
   1090                1095                1100

Tyr Thr Asn Val Asp Gln Asp Leu Val Gly Trp Pro Ala Pro Gln Gly
```

1105 1110 1115 1120

Ser Arg Ser Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu
1125 1130 1135

Val Thr Arg His Ala Asp Val Ile Pro Val Arg Arg Arg Gly Asp Ser
1140 1145 1150

Arg Gly Ser Leu Leu Ser Pro Arg Pro Ile Ser Tyr Leu Lys Gly Ser
1155 1160 1165

Ser Gly Gly Pro Leu Leu Cys Pro Ala Gly His Ala Val Gly Leu Phe
1170 1175 1180

Arg Ala Ala Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Ile
1185 1190 1195 1200

Pro Val Glu Asn Leu Gly Thr Thr Met Arg Ser Pro Val Phe Thr Asp
1205 1210 1215

Asn Ser Ser Pro Pro Ala Val Pro Gln Ser Phe Gln Val Ala His Leu
1220 1225 1230

His Ala Pro Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr
1235 1240 1245

Ala Ala Gln Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala
1250 1255 1260

Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala His Gly Val Asp Pro
1265 1270 1275 1280

Asn Ile Arg Thr Gly Val Arg Thr Ile Thr Thr Gly Ser Pro Ile Thr
1285 1290 1295

Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly
1300 1305 1310

Ala Tyr Asp Ile Ile Ile Cys Asp Glu Cys His Ser Thr Asp Ala Thr
1315 1320 1325

Ser Ile Leu Gly Ile Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Gly
1330 1335 1340

Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr
1345 1350 1355 1360

Val Ser His Pro Asn Ile Glu Glu Val Ala Leu Ser Thr Thr Gly Glu

1365 1370 1375

Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu Val Ile Lys Gly Gly
1380 1385 1390

Arg His Leu Ile Phe Cys His Ser Lys Lys Lys Cys Asp Glu Leu Ala
1395 1400 1405

Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly
1410 1415 1420

Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp Val Val Val Val Ser
1425 1430 1435 1440

Thr Asp Ala Leu Met Thr Gly Phe Thr Gly Asp Phe Asp Ser Val Ile
1445 1450 1455

Asp Cys Asn Thr Cys Val Thr Gln Thr Val Asp Phe Ser Leu Asp Pro
1460 1465 1470

Thr Phe Thr Ile Glu Thr Thr Thr Leu Pro Gln Asp Ala Val Ser Arg
1475 1480 1485

Thr Gln Arg Arg Gly Arg Thr Gly Arg Gly Lys Pro Gly Ile Tyr Arg
1490 1495 1500

Phe Val Ala Pro Gly Glu Arg Pro Ser Gly Met Phe Asp Ser Ser Val
1505 1510 1515 1520

Leu Cys Glu Cys Tyr Asp Ala Gly Cys Ala Trp Tyr Glu Leu Thr Pro
1525 1530 1535

Ala Glu Thr Thr Val Arg Leu Arg Ala Tyr Met Asn Thr Pro Gly Leu
1540 1545 1550

Pro Val Cys Gln Asp His Leu Glu Phe Trp Glu Gly Val Phe Thr Gly
1555 1560 1565

Leu Thr His Ile Asp Ala His Phe Leu Ser Gln Thr Lys Gln Ser Gly
1570 1575 1580

Glu Asn Phe Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg
1585 1590 1595 1600

Ala Gln Ala Pro Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile
1605 1610 1615

Arg Leu Lys Pro Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu

1620 1625 1630

Gly Ala Val Gln Asn Glu Val Thr Leu Thr His Pro Ile Thr Lys Tyr
1635 1640 1645

Ile Met Thr Cys Met Ser Ala Asp Leu Glu Val Val Thr Ser Thr Trp
1650 1655 1660

Val Leu Val Gly Gly Val Leu Ala Ala Leu Ala Ala Tyr Cys Leu Ser
1665 1670 1675 1680

Thr Gly Cys Val Val Ile Val Gly Arg Ile Val Leu Ser Gly Lys Pro
1685 1690 1695

Ala Ile Ile Pro Asp Arg Glu Val Leu Tyr Gln Glu Phe Asp Glu Met
1700 1705 1710

Glu Glu Cys Ser Gln His Leu Pro Tyr Ile Glu Gln Gly Met Met Leu
1715 1720 1725

Ala Glu Gln Phe Lys Gln Lys Ala Leu Gly Leu Leu Gln Thr Ala Ser
1730 1735 1740

Arg His Ala Glu Val Ile Thr Pro Ala Val Gln Thr Asn Trp Gln Lys
1745 1750 1755 1760

Leu Glu Val Phe Trp Ala Lys His Met Trp Asn Phe Ile Ser Gly Ile
1765 1770 1775

Gln Tyr Leu Ala Gly Leu Ser Thr Leu Pro Gly Asn Pro Ala Ile Ala
1780 1785 1790

Ser Leu Met Ala Phe Thr Ala Ala Val Thr Ser Pro Leu Thr Thr Gly
1795 1800 1805

Gln Thr Leu Leu Phe Asn Ile Leu Gly Gly Trp Val Ala Ala Gln Leu
1810 1815 1820

Ala Ala Pro Gly Ala Ala Thr Ala Phe Val Gly Ala Gly Leu Ala Gly
1825 1830 1835 1840

Ala Ala Ile Gly Ser Val Gly Leu Gly Lys Val Leu Val Asp Ile Leu
1845 1850 1855

Ala Gly Tyr Gly Ala Gly Val Ala Gly Ala Leu Val Ala Phe Lys Ile
1860 1865 1870

Met Ser Gly Glu Val Pro Ser Thr Glu Asp Leu Val Asn Leu Leu Pro

1875 1880 1885

Ala Ile Leu Ser Pro Gly Ala Leu Val Val Gly Val Val Cys Ala Ala
1890 1895 1900

Ile Leu Arg Arg His Val Gly Pro Gly Glu Gly Ala Val Gln Trp Met
1905 1910 1915 1920

Asn Arg Leu Ile Ala Phe Ala Ser Arg Gly Asn His Val Ser Pro Thr
1925 1930 1935

His Tyr Val Pro Glu Ser Asp Ala Ala Ala Arg Val Thr Ala Ile Leu
1940 1945 1950

Ser Ser Leu Thr Val Thr Gln Leu Leu Arg Arg Leu His Gln Trp Ile
1955 1960 1965

Ser Ser Glu Cys Thr Thr Pro Cys Ser Gly Ser Trp Leu Arg Asp Ile
1970 1975 1980

Trp Asp Trp Ile Cys Glu Val Leu Ser Asp Phe Lys Thr Trp Leu Lys
1985 1990 1995 2000

Ala Lys Leu Met Pro Gln Leu Pro Gly Ile Pro Phe Val Ser Cys Gln
2005 2010 2015

Arg Gly Tyr Arg Gly Val Trp Arg Gly Asp Gly Ile Met His Thr Arg
2020 2025 2030

Cys His Cys Gly Ala Glu Ile Thr Gly His Val Lys Asn Gly Thr Met
2035 2040 2045

Arg Ile Val Gly Pro Arg Thr Cys Arg Asn Met Trp Ser Gly Thr Phe
2050 2055 2060

Pro Ile Asn Ala Tyr Thr Thr Gly Pro Cys Thr Pro Leu Pro Ala Pro
2065 2070 2075 2080

Asn Tyr Lys Phe Ala Leu Trp Arg Val Ser Ala Glu Glu Tyr Val Glu
2085 2090 2095

Ile Arg Arg Val Gly Asp Phe His Tyr Val Ser Gly Met Thr Thr Asp
2100 2105 2110

Asn Leu Lys Cys Pro Cys Gln Ile Pro Ser Pro Glu Phe Phe Thr Glu
2115 2120 2125

Leu Asp Gly Val Arg Leu His Arg Phe Ala Pro Pro Cys Lys Pro Leu

2130 2135 2140

Leu Arg Glu Glu Val Ser Phe Arg Val Gly Leu His Glu Tyr Pro Val
2145 2150 2155 2160

Gly Ser Gln Leu Pro Cys Glu Pro Glu Pro Asp Val Ala Val Leu Thr
2165 2170 2175

Ser Met Leu Thr Asp Pro Ser His Ile Thr Ala Glu Ala Ala Gly Arg
2180 2185 2190

Arg Leu Ala Arg Gly Ser Pro Pro Ser Met Ala Ser Ser Ser Ala Ser
2195 2200 2205

Gln Leu Ser Ala Pro Ser Leu Lys Ala Thr Cys Thr Ala Asn His Asp
2210 2215 2220

Ser Pro Asp Ala Glu Leu Ile Glu Ala Asn Leu Leu Trp Arg Gln Glu
2225 2230 2235 2240

Met Gly Gly Asn Ile Thr Arg Val Glu Ser Glu Asn Lys Val Val Ile
2245 2250 2255

Leu Asp Ser Phe Asp Pro Leu Val Ala Glu Glu Asp Glu Arg Glu Val
2260 2265 2270

Ser Val Pro Ala Glu Ile Leu Arg Lys Ser Arg Arg Phe Ala Arg Ala
2275 2280 2285

Leu Pro Val Trp Ala Arg Pro Asp Tyr Asn Pro Pro Leu Val Glu Thr
2290 2295 2300

Trp Lys Lys Pro Asp Tyr Glu Pro Pro Val Val His Gly Cys Pro Leu
2305 2310 2315 2320

Pro Pro Pro Arg Ser Pro Pro Val Pro Pro Pro Arg Lys Lys Arg Thr
2325 2330 2335

Val Val Leu Thr Glu Ser Thr Leu Ser Thr Ala Leu Ala Glu Leu Ala
2340 2345 2350

Thr Lys Ser Phe Gly Ser Ser Ser Thr Ser Gly Ile Thr Gly Asp Asn
2355 2360 2365

Thr Thr Thr Ser Ser Glu Pro Ala Pro Ser Gly Cys Pro Pro Asp Ser
2370 2375 2380

Asp Val Glu Ser Tyr Ser Ser Met Pro Pro Leu Glu Gly Glu Pro Gly

2385 2390 2395 2400

Asp Pro Asp Leu Ser Asp Gly Ser Trp Ser Thr Val Ser Ser Gly Ala
2405 2410 2415

Asp Thr Glu Asp Val Val Cys Cys Ser Met Ser Tyr Ser Trp Thr Gly
2420 2425 2430

Ala Leu Val Thr Pro Cys Ala Ala Glu Glu Gln Lys Leu Pro Ile Asn
2435 2440 2445

Ala Leu Ser Asn Ser Leu Leu Arg His His Asn Leu Val Tyr Ser Thr
2450 2455 2460

Thr Ser Arg Ser Ala Cys Gln Arg Gln Lys Lys Val Thr Phe Asp Arg
2465 2470 2475 2480

Leu Gln Val Leu Asp Ser His Tyr Gln Asp Val Leu Lys Glu Val Lys
2485 2490 2495

Ala Ala Ala Ser Lys Val Lys Ala Asn Leu Leu Ser Val Glu Glu Ala
2500 2505 2510

Cys Ser Leu Thr Pro Pro His Ser Ala Lys Ser Lys Phe Gly Tyr Gly
2515 2520 2525

Ala Lys Asp Val Arg Cys His Ala Arg Lys Ala Val Ala His Ile Asn
2530 2535 2540

Ser Val Trp Lys Asp Leu Leu Glu Asp Ser Val Thr Pro Ile Asp Thr
2545 2550 2555 2560

Thr Ile Met Ala Lys Asn Glu Val Phe Cys Val Gln Pro Glu Lys Gly
2565 2570 2575

Gly Arg Lys Pro Ala Arg Leu Ile Val Phe Pro Asp Leu Gly Val Arg
2580 2585 2590

Val Cys Glu Lys Met Ala Leu Tyr Asp Val Val Ser Lys Leu Pro Leu
2595 2600 2605

Ala Val Met Gly Ser Ser Tyr Gly Phe Gln Tyr Ser Pro Gly Gln Arg
2610 2615 2620

Val Glu Phe Leu Val Gln Ala Trp Lys Ser Lys Lys Thr Pro Met Gly
2625 2630 2635 2640

Phe Ser Tyr Asp Thr Arg Cys Phe Asp Ser Thr Val Thr Glu Ser Asp

2645 2650 2655

Ile Arg Thr Glu Glu Ala Ile Tyr Gln Cys Cys Asp Leu Asp Pro Gln
2660 2665 2670

Ala Arg Val Ala Ile Lys Ser Leu Thr Glu Arg Leu Tyr Val Gly Gly
2675 2680 2685

Pro Leu Thr Asn Ser Arg Gly Glu Asn Cys Gly Tyr Arg Arg Cys Arg
2690 2695 2700

Ala Ser Gly Val Leu Thr Thr Ser Cys Gly Asn Thr Leu Thr Cys Tyr
2705 2710 2715 2720

Ile Lys Ala Arg Ala Ala Cys Arg Ala Ala Gly Leu Gln Asp Cys Thr
2725 2730 2735

Met Leu Val Cys Gly Asp Asp Leu Val Val Ile Cys Glu Ser Ala Gly
2740 2745 2750

Val Gln Glu Asp Ala Ala Ser Leu Arg Ala Phe Thr Glu Ala Met Thr
2755 2760 2765

Arg Tyr Ser Ala Pro Pro Gly Asp Pro Pro Gln Pro Glu Tyr Asp Leu
2770 2775 2780

Glu Leu Ile Thr Ser Cys Ser Ser Asn Val Ser Val Ala His Asp Gly
2785 2790 2795 2800

Ala Gly Lys Arg Val Tyr Tyr Leu Thr Arg Asp Pro Thr Thr Pro Leu
2805 2810 2815

Ala Arg Ala Ala Trp Glu Thr Ala Arg His Thr Pro Val Asn Ser Trp
2820 2825 2830

Leu Gly Asn Ile Ile Met Phe Ala Pro Thr Leu Trp Ala Arg Met Ile
2835 2840 2845

Leu Met Thr His Phe Phe Ser Val Leu Ile Ala Arg Asp Gln Leu Glu
2850 2855 2860

Gln Ala Leu Asn Cys Glu Ile Tyr Gly Ala Cys Tyr Ser Ile Glu Pro
2865 2870 2875 2880

Leu Asp Leu Pro Pro Ile Ile Gln Arg Leu His Gly Leu Ser Ala Phe
2885 2890 2895

Ser Leu His Ser Tyr Ser Pro Gly Glu Ile Asn Arg Val Ala Ala Cys

2900 2905 2910

Leu Arg Lys Leu Gly Val Pro Pro Leu Arg Ala Trp Arg His Arg Ala
2915 2920 2925

Arg Ser Val Arg Ala Arg Leu Leu Ser Arg Gly Gly Arg Ala Ala Ile
2930 2935 2940

Cys Gly Lys Tyr Leu Phe Asn Trp Ala Val Arg Thr Lys Leu Lys Leu
2945 2950 2955 2960

Thr Pro Ile Ala Ala Ala Gly Arg Leu Asp Leu Ser Gly Trp Phe Thr
2965 2970 2975

Ala Gly Tyr Ser Gly Gly Asp Ile Tyr His Ser Val Ser His Ala Arg
2980 2985 2990

Pro Arg Trp Phe Trp Phe Cys Leu Leu Leu Leu Ala Ala Gly Val Gly
2995 3000 3005

Ile Tyr Leu Leu Pro Asn Arg
3010 3015

<210> 5
<211> 9611
<212> DNA
<213> Hepatitis C virus

<400> 5
gccagccccc tgatgggggc gacactccac catgaatcac tcccctgtga ggaactactg 60
tcttcacgca gaaagcgtct agccatggcg ttagtatgag tgtcgtgcag cctccaggac 120
cccccctccc gggagagcca tagtggtctg cggaaccggt gagtacaccg gaattgccgg 180
gaagactggg tcctttcttg gataaaccca ctctatgccc ggccatttgg gcgtgccccc 240
gcaagactgc tagccgagta gcgttgggtt gcgaaaggcc ttgtggtact gcctgatagg 300
gtgcttgcga gtgccccggg aggtctcgta gaccgtgcac catgagcaca aatcctaaac 360
ctcaaagaaa aaccaaaaga aacaccaacc gtcgcccaca agacgttaag tttccgggcg 420
gcggccagat cgttggcgga gtatacttgt tgccgcgcag gggccccagg ttgggtgtgc 480
gcgcgacaag gaagacttcg gagcggtccc agccacgtgg aaggcgccag cccatcccta 540
aagatcggcg ctccactggc aaatcctggg gaaaaccagg atacccctgg cccctatacg 600
ggaatgaggg actcggctgg gcaggatggc tcctgtcccc ccgaggttcc cgtcctctt 660
ggggccccaa tgacccccgg cataggtcgc gcaacgtggg taaggtcatc gataccctaa 720
cgtgcggctt tgccgacctc atggggtaca tccctgtcgt gggcgccccg ctcggcggcg 780
tcgccagagc tctcgcgcat ggcgtgagag tcctggagga cggggttaat tttgcaacag 840
ggaacttacc cggttgctcc ttttctatct tcttgctggc cctgctgtcc tgcatcacca 900
ccccggtctc cgctgccgaa gtgaagaaca tcagtaccgg ctacatggtg actaacgact 960
gcaccaatga cagcattacc tggcagctcc aggctgctgt cctccacgtc cccgggtgcg 1020
tcccgtgcga gaaagtgggg aatgcatctc agtgctggat accggtctca ccgaatgtgg 1080

ccgtgcagcg gcccggcgcc ctcacgcagg gcttgcggac gcacatcgac atggttgtga 1140
tgtccgccac gctctgctct gccctctacg tgggggacct ctgcggtggg gtgatgctcg 1200
cagcccaaat gttcattgtc tcgccgcagc accactggtt tgtccaagac tgcaattgct 1260
ccatctaccc tggtaccatc actggacacc gcatggcatg ggacatgatg atgaactggt 1320
cgcccacggc taccatgatc ttggcgtacg cgatgcgtgt ccccgaggtc attatagaca 1380
tcattagcgg ggctcattgg ggcgtcatgt tcggcttggc ctacttctct atgcagggag 1440
cgtgggcgaa agtcgttgtc atccttctgt tggccgccgg ggtggacgcg cgcacccata 1500
ctgttggggg ttctgccgcg cagaccaccg ggcgcctcac cagcttattt gacatgggcc 1560
ccaggcagaa aatccagctc gttaacacca atggcagctg gcacatcaac cgcaccgccc 1620
tgaactgcaa tgactccttg cacaccggct ttatcgcgtc tctgttctac acccacagct 1680
tcaactcgtc aggatgtccc gaacgcatgt ccgcctgccg cagtatcgag gccttccggg 1740
tgggatgggg cgccttgcaa tatgaggata atgtcaccaa tccagaggat atgagaccct 1800
attgctggca ctacccacca aggcagtgtg gcgtggtctc cgcgaagact gtgtgtggcc 1860
cagtgtactg tttcaccccc agcccagtgg tagtgggcac gaccgacagg cttggagcgc 1920
ccacttacac gtgggggggag aatgagacag atgtcttcct attgaacagc actcgaccac 1980
cgctggggtc atggttcggc tgcacgtgga tgaactcttc tggctacacc aagacttgcg 2040
gcgcaccacc ctgccgtact agagctgact tcaacgccag cacggacctg ttgtgcccca 2100
cggactgttt taggaagcat cctgatacca cttacctcaa atgcggctct gggccctggc 2160
tcacgccaag gtgcctgatc gactacccct acaggctctg gcattacccc tgcacagtta 2220
actataccat cttcaaaata aggatgtatg tgggaggggt tgagcacagg ctcacggctg 2280
catgcaattt cactcgtggg gatcgttgca acttggagga cagagacaga agtcaactgt 2340
ctcctttgtt gcactccacc acggaatggg ccattttacc ttgctcttac tcggacctgc 2400
ccgccttgtc gactggtctt ctccacctcc accaaaaacat cgtggacgta caattcatgt 2460
atggcctatc acctgccctc acaaaataca tcgtccgatg ggagtgggta atactcttat 2520
tcctgctctt agcggacgcc agggtttgcg cctgcttatg gatgctcatc ttgttgggcc 2580
aggccgaagc agctttggag aacctcgtaa tactcaatgc agcatccctg gccgggacgc 2640
acggtcttgt gtccttcctc gtgttcttct gctttgcgtg gtatctgaag ggtaggtggg 2700
tgcccggagc ggtctacgcc ctctacggga tgtggcctct cctcctgctc ctgctggcgt 2760
tgcctcagcg ggcatatgca ctggacacgg aggtggccgc gtcgtgtggc ggcgttgttc 2820
ttgtcgggtt aatggcgctg actctgtcgc catattacaa gcgctatatc agctggtgca 2880
tgtggtggct tcagtatttt ctgaccagag tagaagcgca actgcacgtg tgggttcccc 2940
ccctcaacgt ccgggggggg cgcgatgccg tcatcttact catgtgtgta gtacacccga 3000
ccctggtatt tgacatcacc aaactactcc tggccatctt cggacccctt tggattcttc 3060
aagccagttt gcttaaagtc ccctacttcg tgcgcgttca aggccttctc cggatctgcg 3120
cgctagcgcg gaagatagcc ggaggtcatt acgtgcaaat ggccatcatc aagttagggg 3180
cgcttactgg cacctatgtg tataaccatc tcacccctct tcgagactgg gcgcacaacg 3240
gcctgcgaga tctggccgtg gctgtggaac cagtcgtctt ctcccgaatg gagaccaagc 3300
tcatcacgtg gggggcagat accgccgcgt gcggtgacat catcaacggc ttgcccgtct 3360
ctgcccgtag gggccaggag atactgcttg ggccagccga cggaatggtc tccaaggggt 3420
ggaggttgct ggcgcccatc acggcgtacg cccagcagac gagaggcctc ctagggtgta 3480
taatcaccag cctgactggc cgggacaaaa accaagtgga gggtgaggtc cagatcgtgt 3540
caactgctac ccaaaccttc ctggcaacgt gcatcaatgg ggtatgctgg actgtctacc 3600
acggggccgg aacgaggacc atcgcatcac ccaagggtcc tgtcatccag atgtatacca 3660
atgtggacca agaccttgtg ggctggcccg ctcctcaagg ttcccgctca ttgacaccct 3720
gtacctgcgg ctcctcggac ctttacctgg tcacgaggca cgccgatgtc attcccgtgc 3780
gccggcgagg tgatagcagg ggtagcctgc tttcgccccg gcccatttcc tacttgaaag 3840
gctcctcggg gggtccgctg ttgtgccccg cgggacacgc cgtgggccta ttcagggccg 3900
cggtgtgcac ccgtggagtg gctaaagcgg tggactttat ccctgtggag aacctaggga 3960

caaccatgag atccccggtg ttcacggaca actcctctcc accagcagtg ccccagagct 4020
tccaggtggc ccacctgcat gctcccaccg gcagcggtaa gagcaccaag gtcccggctg 4080
cgtacgcagc ccagggctac aaggtgttgg tgctcaaccc ctctgttgct gcaacgctgg 4140
gctttggtgc ttacatgtcc aaggcccatg gggttgatcc taatatcagg accggggtga 4200
gaacaattac cactggcagc cccatcacgt actccaccta cggcaagttc cttgccgacg 4260
gcgggtgctc aggaggtgct tatgacataa taatttgtga cgagtgccac tccacggatg 4320
ccacatccat cttgggcatc ggcactgtcc ttgaccaagc agagactgcg ggggcgagac 4380
tggttgtgct cgccactgct acccctccgg gctccgtcac tgtgtcccat cctaacatcg 4440
aggaggttgc tctgtccacc accggagaga tccccttta cggcaaggct atccccctcg 4500
aggtgatcaa gggggaaga catctcatct tctgccactc aaagaagaag tgcgacgagc 4560
tcgccgcgaa gctggtcgca ttgggcatca atgccgtggc ctactaccgc ggtcttgacg 4620
tgtctgtcat cccgaccagc ggcgatgttg tcgtcgtgtc gaccgatgct ctcatgactg 4680
gctttaccgg cgacttcgac tctgtgatag actgcaacac gtgtgtcact cagacagtcg 4740
atttcagcct tgaccctacc tttaccattg agacaaccac gctcccccag gatgctgtct 4800
ccaggactca acgccgggge aggactggca gggggaagcc aggcatctat agatttgtgg 4860
caccgggggа gcgcccctcc ggcatgttcg actcgtccgt cctctgtgag tgctatgacg 4920
cgggctgtgc ttggtatgag ctcacgcccg ccgagactac agttaggcta cgagcgtaca 4980
tgaacacccc ggggcttccc gtgtgccagg accatcttga attttgggag ggcgtcttta 5040
cgggcctcac tcatatagat gcccacтttt tatcccagac aaagcagagt ggggagaact 5100
ttccttacct ggtagcgtac caagccaccg tgtgcgctag ggctcaagcc cctcccccat 5160
cgtgggacca gatgtggaag tgtttgatcc gccttaaacc caccctccat gggccaacac 5220
ccctgctata cagactgggc gctgttcaga atgaagtcac cctgacgcac ccaatcacca 5280
aatacatcat gacatgcatg tcggccgacc tggaggtcgt cacgagcacc tgggtgctcg 5340
ttggcggcgt cctggctgct ctggccgcgt attgcctgtc aacaggctgc gtggtcatag 5400
tgggcaggat cgtcttgtcc gggaagccgg caattatacc tgacagggag gttctctacc 5460
aggagttcga tgagatggaa gagtgctctc agcacttacc gtacatcgag caagggatga 5520
tgctcgctga gcagttcaag cagaaggccc tcggcctcct gcagaccgcg tcccgccatg 5580
cagaggttat caccccctgct gtccagacca actggcagaa actcgaggtc ttttgggcga 5640
agcacatgtg gaatttcatc agtgggatac aatacttggc gggcctgtca acgctgcctg 5700
gtaaccccgc cattgcttca ttgatggctt ttacagctgc cgtcaccagc ccactaacca 5760
ctggccaaac cctcctcttc aacatattgg gggggtgggt ggctgcccag ctcgccgccc 5820
ccggtgccgc tactgccttt gtgggtgctg gcctagctgg cgccgccatc ggcagcgttg 5880
gactggggaa ggtcctcgtg gacattcttg cagggtatgg cgcgggcgtg gcgggagctc 5940
ttgtagcatt caagatcatg agcggtgagg tcccctccac ggaggacctg gtcaatctgc 6000
tgcccgccat cctctcgcct ggagcccttg tagtcggtgt ggtctgcgca gcaatactgc 6060
gccggcacgt tggcccgggc gaggggggcag tgcaatggat gaaccggcta atagccttcg 6120
cctcccgggg gaaccatgtt tcccccacgc actacgtgcc ggagagcgat gcagccgccc 6180
gcgtcactgc catactcagc agcctcactg taacccagct cctgaggcga ctgcatcagt 6240
ggataagctc ggagtgtacc actccatgct ccggttcctg gctaagggac atctgggact 6300
ggatatgcga ggtgctgagc gactttaaga cctggctgaa agccaagctc atgccacaac 6360
tgcctgggat tcccttttgtg tcctgccagc gcgggtatag gggggtctgg cgaggagacg 6420
gcattatgca cactcgctgc cactgtggag ctgagatcac tggacatgtc aaaaacggga 6480
cgatgaggat cgtcggtcct aggacctgca ggaacatgtg gagtgggacg ttccccatta 6540
acgcctacac cacgggcccc tgtactcccc ttcctgcgcc gaactataag ttcgcgctgt 6600
ggagggtgtc tgcagaggaa tacgtggaga taaggcgggt gggggacttc cactacgtat 6660
cgggtatgac tactgacaat cttaaatgcc cgtgccagat cccatcgccc gaatttttca 6720
cagaattgga cggggtgcgc ctacacaggt ttgcgccccc ttgcaagccc ttgctgcggg 6780
aggaggtatc attcagagta ggactccacg agtacccggt ggggtcgcaa ttaccttgcg 6840

agcccgaacc ggacgtagcc gtgttgacgt ccatgctcac tgatccctcc catataacag 6900
cagaggcggc cgggagaagg ttggcgagag ggtcaccccc ttctatggcc agctcctcgg 6960
ctagccagct gtccgctcca tctctcaagg caacttgcac cgccaaccat gactcccctg 7020
acgccgagct catagaggct aacctcctgt ggaggcagga gatgggcggc aacatcacca 7080
gggttgagtc agagaacaaa gtggtgattc tggactcctt cgatccgctt gtggcagagg 7140
aggatgagcg ggaggtctcc gtacctgcag aaattctgcg gaagtctcgg agattcgccc 7200
gggccctgcc cgtctgggcg cggccggact acaacccccc gctagtagag acgtggaaaa 7260
agcctgacta cgaaccacct gtggtccatg gctgcccgct accacctcca cggtcccctc 7320
ctgtgcctcc gcctcggaaa aagcgtacgg tggtcctcac cgaatcaacc ctatctactg 7380
ccttggccga gcttgccacc aaaagttttg gcagctcctc aacttccggc attacgggcg 7440
acaatacgac aacatcctct gagcccgccc cttctggctg ccccccccgac tccgacgttg 7500
agtcctattc ttccatgccc cccctggagg gggagcctgg ggatccggat ctcagcgacg 7560
ggtcatggtc gacggtcagt agtggggccg acacggaaga tgtcgtgtgc tgctcaatgt 7620
cttattcctg gacaggcgca ctcgtcaccc cgtgcgctgc ggaagaacaa aaactgccca 7680
tcaacgcact gagcaactcg ttgctacgcc atcacaatct ggtgtattcc accacttcac 7740
gcagtgcttg ccaaaggcag aagaaagtca catttgacag actgcaagtt ctggacagcc 7800
attaccagga cgtgctcaag gaggtcaaag cagcggcgtc aaaagtgaag gctaacttgc 7860
tatccgtaga ggaagcttgc agcctgacgc ccccacattc agccaaatcc aagtttggct 7920
atggggcaaa agacgtccgt tgccatgcca gaaaggccgt agcccacatc aactccgtgt 7980
ggaaagacct tctggaagac agtgtaacac caatagacac taccatcatg gccaagaacg 8040
aggttttctg cgttcagcct gagaaggggg gtcgtaagcc agctcgtctc atcgtgttcc 8100
ccgacctggg cgtgcgcgtg tgcgagaaga tggccctgta cgacgtggtt agcaagctcc 8160
ccctggccgt gatgggaagc tcctacggat tccaatactc accaggacag cgggttgaat 8220
tcctcgtgca agcgtggaag tccaagaaga ccccgatggg gttctcgtat gatacccgct 8280
gttttgactc cacagtcact gagagcgaca tccgtacgga ggaggcaatt taccaatgtt 8340
gtgacctgga cccccaagcc cgcgtggcca tcaagtccct cactgagagg ctttatgttg 8400
ggggccctct taccaattca agggggggaaa actgcggcta ccgcaggtgc cgcgcgagcg 8460
gcgtactgac aactagctgt ggtaacaccc tcacttgcta catcaaggcc cgggcagcct 8520
gtcgagccgc agggctccag gactgcacca tgctcgtgtg tggcgacgac ttagtcgtta 8580
tctgtgaaag tgcgggggtc caggaggacg cggcgagcct gagagccttc acggaggcta 8640
tgaccaggta ctccgccccc cccggggacc ccccacaacc agaatacgac ttggagctta 8700
taacatcatg ctcctccaac gtgtcagtcg cccacgacgg cgctggaaag agggtctact 8760
accttacccg tgaccctaca acccccctcg cgagagccgc gtgggagaca gcaagacaca 8820
ctccagtcaa ttcctggcta ggcaacataa tcatgtttgc ccccacactg tgggcgagga 8880
tgatactgat gacccatttc tttagcgtcc tcatagccag ggatcagctt gaacaggctc 8940
ttaactgtga gatctacgga gcctgctact ccatagaacc actggatcta cctccaatca 9000
ttcaaagact ccatggcctc agcgcatttt cactccacag ttactctcca ggtgaaatca 9060
atagggtggc cgcatgcctc agaaaacttg gggtcccgcc cttgcgagct tggagacacc 9120
gggcccggag cgtccgcgct aggcttctgt ccagaggagg cagggctgct atatgtggca 9180
agtacctctt caactgggca gtaagaacaa agctcaaact cactccaata gcggccgctg 9240
gccggctgga cttgtccggt tggttcacgg ctggctacag cgggggagac atttatcaca 9300
gcgtgtctca tgcccggccc cgctggttct ggttttgcct actcctgctc gctgcagggg 9360
taggcatcta cctcctcccc aaccgatgaa ggttggggta aacactccgg cctcttaagc 9420
catttcctgt ttttttttt ttttttttt ttttttcctt ttttttttc tttcctttcc 9480
ttctttttt cctttctttt tcccttcttt aatggtggct ccatcttagc cctagtcacg 9540
gctagctgtg aaaggtccgt gagccgcatg actgcagaga gtgctgatac tggcctctct 9600
gcagatcatg t 9611

<210> 6
<211> 3015
<212> PRT
<213> Hepatitis C virus

<400> 6

```
Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn
  1               5                  10                  15

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly
             20                  25                  30

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala
         35                  40                  45

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro
     50                  55                  60

Ile Pro Lys Asp Arg Arg Ser Thr Gly Lys Ser Trp Gly Lys Pro Gly
 65                  70                  75                  80

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Leu Gly Trp Ala Gly Trp
                 85                  90                  95

Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Asn Asp Pro
            100                 105                 110

Arg His Arg Ser Arg Asn Val Gly Lys Val Ile Asp Thr Leu Thr Cys
        115                 120                 125

Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Val Val Gly Ala Pro Leu
    130                 135                 140

Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp
145                 150                 155                 160

Gly Val Asn Phe Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile
                165                 170                 175

Phe Leu Leu Ala Leu Leu Ser Cys Ile Thr Thr Pro Val Ser Ala Ala
            180                 185                 190

Glu Val Lys Asn Ile Ser Thr Gly Tyr Met Val Thr Asn Asp Cys Thr
        195                 200                 205

Asn Asp Ser Ile Thr Trp Gln Leu Gln Ala Ala Val Leu His Val Pro
    210                 215                 220
```

```
Gly Cys Val Pro Cys Glu Lys Val Gly Asn Ala Ser Gln Cys Trp Ile
225                 230                 235                 240

Pro Val Ser Pro Asn Val Ala Val Gln Arg Pro Gly Ala Leu Thr Gln
                245                 250                 255

Gly Leu Arg Thr His Ile Asp Met Val Val Met Ser Ala Thr Leu Cys
            260                 265                 270

Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Gly Val Met Leu Ala Ala
        275                 280                 285

Gln Met Phe Ile Val Ser Pro Gln His His Trp Phe Val Gln Asp Cys
    290                 295                 300

Asn Cys Ser Ile Tyr Pro Gly Thr Ile Thr Gly His Arg Met Ala Trp
305                 310                 315                 320

Asp Met Met Met Asn Trp Ser Pro Thr Ala Thr Met Ile Leu Ala Tyr
                325                 330                 335

Ala Met Arg Val Pro Glu Val Ile Ile Asp Ile Ile Ser Gly Ala His
            340                 345                 350

Trp Gly Val Met Phe Gly Leu Ala Tyr Phe Ser Met Gln Gly Ala Trp
        355                 360                 365

Ala Lys Val Val Val Ile Leu Leu Leu Ala Ala Gly Val Asp Ala Arg
    370                 375                 380

Thr His Thr Val Gly Gly Ser Ala Ala Gln Thr Thr Gly Arg Leu Thr
385                 390                 395                 400

Ser Leu Phe Asp Met Gly Pro Arg Gln Lys Ile Gln Leu Val Asn Thr
                405                 410                 415

Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser
            420                 425                 430

Leu His Thr Gly Phe Ile Ala Ser Leu Phe Tyr Thr His Ser Phe Asn
        435                 440                 445

Ser Ser Gly Cys Pro Glu Arg Met Ser Ala Cys Arg Ser Ile Glu Ala
    450                 455                 460

Phe Arg Val Gly Trp Gly Ala Leu Gln Tyr Glu Asp Asn Val Thr Asn
465                 470                 475                 480
```

Pro Glu Asp Met Arg Pro Tyr Cys Trp His Tyr Pro Pro Arg Gln Cys
485 490 495

Gly Val Val Ser Ala Lys Thr Val Cys Gly Pro Val Tyr Cys Phe Thr
500 505 510

Pro Ser Pro Val Val Val Gly Thr Thr Asp Arg Leu Gly Ala Pro Thr
515 520 525

Tyr Thr Trp Gly Glu Asn Glu Thr Asp Val Phe Leu Leu Asn Ser Thr
530 535 540

Arg Pro Pro Leu Gly Ser Trp Phe Gly Cys Thr Trp Met Asn Ser Ser
545 550 555 560

Gly Tyr Thr Lys Thr Cys Gly Ala Pro Pro Cys Arg Thr Arg Ala Asp
565 570 575

Phe Asn Ala Ser Thr Asp Leu Leu Cys Pro Thr Asp Cys Phe Arg Lys
580 585 590

His Pro Asp Thr Thr Tyr Leu Lys Cys Gly Ser Gly Pro Trp Leu Thr
595 600 605

Pro Arg Cys Leu Ile Asp Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys
610 615 620

Thr Val Asn Tyr Thr Ile Phe Lys Ile Arg Met Tyr Val Gly Gly Val
625 630 635 640

Glu His Arg Leu Thr Ala Ala Cys Asn Phe Thr Arg Gly Asp Arg Cys
645 650 655

Asn Leu Glu Asp Arg Asp Arg Ser Gln Leu Ser Pro Leu Leu His Ser
660 665 670

Thr Thr Glu Trp Ala Ile Leu Pro Cys Ser Tyr Ser Asp Leu Pro Ala
675 680 685

Leu Ser Thr Gly Leu Leu His Leu His Gln Asn Ile Val Asp Val Gln
690 695 700

Phe Met Tyr Gly Leu Ser Pro Ala Leu Thr Lys Tyr Ile Val Arg Trp
705 710 715 720

Glu Trp Val Ile Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Val Cys
725 730 735

```
Ala Cys Leu Trp Met Leu Ile Leu Leu Gly Gln Ala Glu Ala Ala Leu
            740                 745                 750

Glu Asn Leu Val Ile Leu Asn Ala Ala Ser Leu Ala Gly Thr His Gly
        755                 760                 765

Leu Val Ser Phe Leu Val Phe Phe Cys Phe Ala Trp Tyr Leu Lys Gly
    770                 775                 780

Arg Trp Val Pro Gly Ala Val Tyr Ala Leu Tyr Gly Met Trp Pro Leu
785                 790                 795                 800

Leu Leu Leu Leu Leu Ala Leu Pro Gln Arg Ala Tyr Ala Leu Asp Thr
                805                 810                 815

Glu Val Ala Ala Ser Cys Gly Gly Val Val Leu Val Gly Leu Met Ala
            820                 825                 830

Leu Thr Leu Ser Pro Tyr Tyr Lys Arg Tyr Ile Ser Trp Cys Met Trp
        835                 840                 845

Trp Leu Gln Tyr Phe Leu Thr Arg Val Glu Ala Gln Leu His Val Trp
    850                 855                 860

Val Pro Pro Leu Asn Val Arg Gly Gly Arg Asp Ala Val Ile Leu Leu
865                 870                 875                 880

Met Cys Val Val His Pro Thr Leu Val Phe Asp Ile Thr Lys Leu Leu
                885                 890                 895

Leu Ala Ile Phe Gly Pro Leu Trp Ile Leu Gln Ala Ser Leu Leu Lys
            900                 905                 910

Val Pro Tyr Phe Val Arg Val Gln Gly Leu Leu Arg Ile Cys Ala Leu
        915                 920                 925

Ala Arg Lys Ile Ala Gly Gly His Tyr Val Gln Met Ala Ile Ile Lys
    930                 935                 940

Leu Gly Ala Leu Thr Gly Thr Tyr Val Tyr Asn His Leu Thr Pro Leu
945                 950                 955                 960

Arg Asp Trp Ala His Asn Gly Leu Arg Asp Leu Ala Val Ala Val Glu
                965                 970                 975

Pro Val Val Phe Ser Arg Met Glu Thr Lys Leu Ile Thr Trp Gly Ala
            980                 985                 990
```

Asp Thr Ala Ala Cys Gly Asp Ile Ile Asn Gly Leu Pro Val Ser Ala
995 1000 1005

Arg Arg Gly Gln Glu Ile Leu Leu Gly Pro Ala Asp Gly Met Val Ser
1010 1015 1020

Lys Gly Trp Arg Leu Leu Ala Pro Ile Thr Ala Tyr Ala Gln Gln Thr
1025 1030 1035 1040

Arg Gly Leu Leu Gly Cys Ile Ile Thr Ser Leu Thr Gly Arg Asp Lys
1045 1050 1055

Asn Gln Val Glu Gly Glu Val Gln Ile Val Ser Thr Ala Thr Gln Thr
1060 1065 1070

Phe Leu Ala Thr Cys Ile Asn Gly Val Cys Trp Thr Val Tyr His Gly
1075 1080 1085

Ala Gly Thr Arg Thr Ile Ala Ser Pro Lys Gly Pro Val Ile Gln Met
1090 1095 1100

Tyr Thr Asn Val Asp Gln Asp Leu Val Gly Trp Pro Ala Pro Gln Gly
1105 1110 1115 1120

Ser Arg Ser Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu
1125 1130 1135

Val Thr Arg His Ala Asp Val Ile Pro Val Arg Arg Arg Gly Asp Ser
1140 1145 1150

Arg Gly Ser Leu Leu Ser Pro Arg Pro Ile Ser Tyr Leu Lys Gly Ser
1155 1160 1165

Ser Gly Gly Pro Leu Leu Cys Pro Ala Gly His Ala Val Gly Leu Phe
1170 1175 1180

Arg Ala Ala Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Ile
1185 1190 1195 1200

Pro Val Glu Asn Leu Gly Thr Thr Met Arg Ser Pro Val Phe Thr Asp
1205 1210 1215

Asn Ser Ser Pro Pro Ala Val Pro Gln Ser Phe Gln Val Ala His Leu
1220 1225 1230

His Ala Pro Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr
1235 1240 1245

```
Ala Ala Gln Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala
   1250                1255                1260

Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala His Gly Val Asp Pro
1265                1270                1275                1280

Asn Ile Arg Thr Gly Val Arg Thr Ile Thr Thr Gly Ser Pro Ile Thr
                1285                1290                1295

Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly
           1300                1305                1310

Ala Tyr Asp Ile Ile Ile Cys Asp Glu Cys His Ser Thr Asp Ala Thr
       1315                1320                1325

Ser Ile Leu Gly Ile Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Gly
   1330                1335                1340

Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr
1345                1350                1355                1360

Val Ser His Pro Asn Ile Glu Glu Val Ala Leu Ser Thr Thr Gly Glu
                1365                1370                1375

Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu Val Ile Lys Gly Gly
           1380                1385                1390

Arg His Leu Ile Phe Cys His Ser Lys Lys Lys Cys Asp Glu Leu Ala
       1395                1400                1405

Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly
   1410                1415                1420

Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp Val Val Val Val Ser
1425                1430                1435                1440

Thr Asp Ala Leu Met Thr Gly Phe Thr Gly Asp Phe Asp Ser Val Ile
                1445                1450                1455

Asp Cys Asn Thr Cys Val Thr Gln Thr Val Asp Phe Ser Leu Asp Pro
           1460                1465                1470

Thr Phe Thr Ile Glu Thr Thr Thr Leu Pro Gln Asp Ala Val Ser Arg
       1475                1480                1485

Thr Gln Arg Arg Gly Arg Thr Gly Arg Gly Lys Pro Gly Ile Tyr Arg
   1490                1495                1500
```

```
Phe Val Ala Pro Gly Glu Arg Pro Ser Gly Met Phe Asp Ser Ser Val
1505                1510                1515                1520

Leu Cys Glu Cys Tyr Asp Ala Gly Cys Ala Trp Tyr Glu Leu Thr Pro
                1525                1530                1535

Ala Glu Thr Thr Val Arg Leu Arg Ala Tyr Met Asn Thr Pro Gly Leu
            1540                1545                1550

Pro Val Cys Gln Asp His Leu Glu Phe Trp Glu Gly Val Phe Thr Gly
        1555                1560                1565

Leu Thr His Ile Asp Ala His Phe Leu Ser Gln Thr Lys Gln Ser Gly
    1570                1575                1580

Glu Asn Phe Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg
1585                1590                1595                1600

Ala Gln Ala Pro Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile
                1605                1610                1615

Arg Leu Lys Pro Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu
            1620                1625                1630

Gly Ala Val Gln Asn Glu Val Thr Leu Thr His Pro Ile Thr Lys Tyr
        1635                1640                1645

Ile Met Thr Cys Met Ser Ala Asp Leu Glu Val Val Thr Ser Thr Trp
    1650                1655                1660

Val Leu Val Gly Gly Val Leu Ala Ala Leu Ala Ala Tyr Cys Leu Ser
1665                1670                1675                1680

Thr Gly Cys Val Val Ile Val Gly Arg Ile Val Leu Ser Gly Lys Pro
                1685                1690                1695

Ala Ile Ile Pro Asp Arg Glu Val Leu Tyr Gln Glu Phe Asp Glu Met
            1700                1705                1710

Glu Glu Cys Ser Gln His Leu Pro Tyr Ile Glu Gln Gly Met Met Leu
        1715                1720                1725

Ala Glu Gln Phe Lys Gln Lys Ala Leu Gly Leu Leu Gln Thr Ala Ser
    1730                1735                1740

Arg His Ala Glu Val Ile Thr Pro Ala Val Gln Thr Asn Trp Gln Lys
1745                1750                1755                1760
```

```
Leu Glu Val Phe Trp Ala Lys His Met Trp Asn Phe Ile Ser Gly Ile
                1765                1770                1775

Gln Tyr Leu Ala Gly Leu Ser Thr Leu Pro Gly Asn Pro Ala Ile Ala
            1780                1785                1790

Ser Leu Met Ala Phe Thr Ala Ala Val Thr Ser Pro Leu Thr Thr Gly
        1795                1800                1805

Gln Thr Leu Leu Phe Asn Ile Leu Gly Gly Trp Val Ala Ala Gln Leu
    1810                1815                1820

Ala Ala Pro Gly Ala Ala Thr Ala Phe Val Gly Ala Gly Leu Ala Gly
1825                1830                1835                1840

Ala Ala Ile Gly Ser Val Gly Leu Gly Lys Val Leu Val Asp Ile Leu
                1845                1850                1855

Ala Gly Tyr Gly Ala Gly Val Ala Gly Ala Leu Val Ala Phe Lys Ile
            1860                1865                1870

Met Ser Gly Glu Val Pro Ser Thr Glu Asp Leu Val Asn Leu Leu Pro
        1875                1880                1885

Ala Ile Leu Ser Pro Gly Ala Leu Val Val Gly Val Val Cys Ala Ala
    1890                1895                1900

Ile Leu Arg Arg His Val Gly Pro Gly Glu Gly Ala Val Gln Trp Met
1905                1910                1915                1920

Asn Arg Leu Ile Ala Phe Ala Ser Arg Gly Asn His Val Ser Pro Thr
                1925                1930                1935

His Tyr Val Pro Glu Ser Asp Ala Ala Ala Arg Val Thr Ala Ile Leu
            1940                1945                1950

Ser Ser Leu Thr Val Thr Gln Leu Leu Arg Arg Leu His Gln Trp Ile
        1955                1960                1965

Ser Ser Glu Cys Thr Thr Pro Cys Ser Gly Ser Trp Leu Arg Asp Ile
    1970                1975                1980

Trp Asp Trp Ile Cys Glu Val Leu Ser Asp Phe Lys Thr Trp Leu Lys
1985                1990                1995                2000

Ala Lys Leu Met Pro Gln Leu Pro Gly Ile Pro Phe Val Ser Cys Gln
                2005                2010                2015
```

Arg Gly Tyr Arg Gly Val Trp Arg Gly Asp Gly Ile Met His Thr Arg
2020 2025 2030

Cys His Cys Gly Ala Glu Ile Thr Gly His Val Lys Asn Gly Thr Met
2035 2040 2045

Arg Ile Val Gly Pro Arg Thr Cys Arg Asn Met Trp Ser Gly Thr Phe
2050 2055 2060

Pro Ile Asn Ala Tyr Thr Thr Gly Pro Cys Thr Pro Leu Pro Ala Pro
2065 2070 2075 2080

Asn Tyr Lys Phe Ala Leu Trp Arg Val Ser Ala Glu Glu Tyr Val Glu
2085 2090 2095

Ile Arg Arg Val Gly Asp Phe His Tyr Val Ser Gly Met Thr Thr Asp
2100 2105 2110

Asn Leu Lys Cys Pro Cys Gln Ile Pro Ser Pro Glu Phe Phe Thr Glu
2115 2120 2125

Leu Asp Gly Val Arg Leu His Arg Phe Ala Pro Pro Cys Lys Pro Leu
2130 2135 2140

Leu Arg Glu Glu Val Ser Phe Arg Val Gly Leu His Glu Tyr Pro Val
2145 2150 2155 2160

Gly Ser Gln Leu Pro Cys Glu Pro Glu Pro Asp Val Ala Val Leu Thr
2165 2170 2175

Ser Met Leu Thr Asp Pro Ser His Ile Thr Ala Glu Ala Ala Gly Arg
2180 2185 2190

Arg Leu Ala Arg Gly Ser Pro Pro Ser Met Ala Ser Ser Ser Ala Ser
2195 2200 2205

Gln Leu Ser Ala Pro Ser Leu Lys Ala Thr Cys Thr Ala Asn His Asp
2210 2215 2220

Ser Pro Asp Ala Glu Leu Ile Glu Ala Asn Leu Leu Trp Arg Gln Glu
2225 2230 2235 2240

Met Gly Gly Asn Ile Thr Arg Val Glu Ser Glu Asn Lys Val Val Ile
2245 2250 2255

Leu Asp Ser Phe Asp Pro Leu Val Ala Glu Glu Asp Glu Arg Glu Val
2260 2265 2270

```
Ser Val Pro Ala Glu Ile Leu Arg Lys Ser Arg Arg Phe Ala Arg Ala
      2275                2280                2285

Leu Pro Val Trp Ala Arg Pro Asp Tyr Asn Pro Pro Leu Val Glu Thr
   2290                2295                2300

Trp Lys Lys Pro Asp Tyr Glu Pro Pro Val Val His Gly Cys Pro Leu
2305                2310                2315                2320

Pro Pro Pro Arg Ser Pro Pro Val Pro Pro Pro Arg Lys Lys Arg Thr
              2325                2330                2335

Val Val Leu Thr Glu Ser Thr Leu Ser Thr Ala Leu Ala Glu Leu Ala
          2340                2345                2350

Thr Lys Ser Phe Gly Ser Ser Ser Thr Ser Gly Ile Thr Gly Asp Asn
      2355                2360                2365

Thr Thr Thr Ser Ser Glu Pro Ala Pro Ser Gly Cys Pro Pro Asp Ser
   2370                2375                2380

Asp Val Glu Ser Tyr Ser Ser Met Pro Pro Leu Glu Gly Glu Pro Gly
2385                2390                2395                2400

Asp Pro Asp Leu Ser Asp Gly Ser Trp Ser Thr Val Ser Ser Gly Ala
              2405                2410                2415

Asp Thr Glu Asp Val Val Cys Cys Ser Met Ser Tyr Ser Trp Thr Gly
          2420                2425                2430

Ala Leu Val Thr Pro Cys Ala Ala Glu Glu Gln Lys Leu Pro Ile Asn
      2435                2440                2445

Ala Leu Ser Asn Ser Leu Leu Arg His His Asn Leu Val Tyr Ser Thr
   2450                2455                2460

Thr Ser Arg Ser Ala Cys Gln Arg Gln Lys Lys Val Thr Phe Asp Arg
2465                2470                2475                2480

Leu Gln Val Leu Asp Ser His Tyr Gln Asp Val Leu Lys Glu Val Lys
              2485                2490                2495

Ala Ala Ala Ser Lys Val Lys Ala Asn Leu Leu Ser Val Glu Glu Ala
          2500                2505                2510

Cys Ser Leu Thr Pro Pro His Ser Ala Lys Ser Lys Phe Gly Tyr Gly
      2515                2520                2525
```

Ala Lys Asp Val Arg Cys His Ala Arg Lys Ala Val Ala His Ile Asn
2530 2535 2540

Ser Val Trp Lys Asp Leu Leu Glu Asp Ser Val Thr Pro Ile Asp Thr
2545 2550 2555 2560

Thr Ile Met Ala Lys Asn Glu Val Phe Cys Val Gln Pro Glu Lys Gly
2565 2570 2575

Gly Arg Lys Pro Ala Arg Leu Ile Val Phe Pro Asp Leu Gly Val Arg
2580 2585 2590

Val Cys Glu Lys Met Ala Leu Tyr Asp Val Val Ser Lys Leu Pro Leu
2595 2600 2605

Ala Val Met Gly Ser Ser Tyr Gly Phe Gln Tyr Ser Pro Gly Gln Arg
2610 2615 2620

Val Glu Phe Leu Val Gln Ala Trp Lys Ser Lys Lys Thr Pro Met Gly
2625 2630 2635 2640

Phe Ser Tyr Asp Thr Arg Cys Phe Asp Ser Thr Val Thr Glu Ser Asp
2645 2650 2655

Ile Arg Thr Glu Glu Ala Ile Tyr Gln Cys Cys Asp Leu Asp Pro Gln
2660 2665 2670

Ala Arg Val Ala Ile Lys Ser Leu Thr Glu Arg Leu Tyr Val Gly Gly
2675 2680 2685

Pro Leu Thr Asn Ser Arg Gly Glu Asn Cys Gly Tyr Arg Arg Cys Arg
2690 2695 2700

Ala Ser Gly Val Leu Thr Thr Ser Cys Gly Asn Thr Leu Thr Cys Tyr
2705 2710 2715 2720

Ile Lys Ala Arg Ala Ala Cys Arg Ala Ala Gly Leu Gln Asp Cys Thr
2725 2730 2735

Met Leu Val Cys Gly Asp Asp Leu Val Val Ile Cys Glu Ser Ala Gly
2740 2745 2750

Val Gln Glu Asp Ala Ala Ser Leu Arg Ala Phe Thr Glu Ala Met Thr
2755 2760 2765

Arg Tyr Ser Ala Pro Pro Gly Asp Pro Pro Gln Pro Glu Tyr Asp Leu
2770 2775 2780

```
Glu Leu Ile Thr Ser Cys Ser Ser Asn Val Ser Val Ala His Asp Gly
2785                2790                2795                2800

Ala Gly Lys Arg Val Tyr Tyr Leu Thr Arg Asp Pro Thr Thr Pro Leu
                2805                2810                2815

Ala Arg Ala Ala Trp Glu Thr Ala Arg His Thr Pro Val Asn Ser Trp
            2820                2825                2830

Leu Gly Asn Ile Ile Met Phe Ala Pro Thr Leu Trp Ala Arg Met Ile
        2835                2840                2845

Leu Met Thr His Phe Phe Ser Val Leu Ile Ala Arg Asp Gln Leu Glu
    2850                2855                2860

Gln Ala Leu Asn Cys Glu Ile Tyr Gly Ala Cys Tyr Ser Ile Glu Pro
2865                2870                2875                2880

Leu Asp Leu Pro Pro Ile Ile Gln Arg Leu His Gly Leu Ser Ala Phe
                2885                2890                2895

Ser Leu His Ser Tyr Ser Pro Gly Glu Ile Asn Arg Val Ala Ala Cys
            2900                2905                2910

Leu Arg Lys Leu Gly Val Pro Pro Leu Arg Ala Trp Arg His Arg Ala
        2915                2920                2925

Arg Ser Val Arg Ala Arg Leu Leu Ser Arg Gly Gly Arg Ala Ala Ile
    2930                2935                2940

Cys Gly Lys Tyr Leu Phe Asn Trp Ala Val Arg Thr Lys Leu Lys Leu
2945                2950                2955                2960

Thr Pro Ile Ala Ala Ala Gly Arg Leu Asp Leu Ser Gly Trp Phe Thr
                2965                2970                2975

Ala Gly Tyr Ser Gly Gly Asp Ile Tyr His Ser Val Ser His Ala Arg
            2980                2985                2990

Pro Arg Trp Phe Trp Phe Cys Leu Leu Leu Leu Ala Ala Gly Val Gly
        2995                3000                3005

Ile Tyr Leu Leu Pro Asn Arg
    3010                3015
```

<210> 7

<211> 9611
<212> DNA
<213> Hepatitis C virus

<400> 7
gccagccccc tgatgggggc gacactccac catgaatcac tcccctgtga ggaactactg 60
tcttcacgca gaaagcgtct agccatggcg ttagtatgag tgtcgtgcag cctccaggac 120
ccccccteee gggagagcca tagtggtctg cggaaccggt gagtacaccg gaattgccag 180
gacgaccggg tcctttcttg gataaacccg ctcaatgcct ggagatttgg gcgtgccccc 240
gcaagactgc tagccgagta gtgttgggtc gcgaaaggcc ttgtggtact gcctgatagg 300
gtgcttgcga gtgccccggg aggtctcgta gaccgtgcac catgagcaca aatcctaaac 360
ctcaaagaaa aaccaaaaga aacaccaacc gtcgcccaca agacgttaag tttccgggcg 420
gcggccagat cgttggcgga gtatacttgt tgccgcgcag gggccccagg ttgggtgtgc 480
gcgcgacaag gaagacttcg gagcggtccc agccacgtgg aaggcgccag cccatcccta 540
aagatcggcg ctccactggc aaatcctggg gaaaaccagg ataccccctgg cccctatacg 600
ggaatgaggg actcggctgg gcaggatggc tcctgtcccc ccgaggttcc cgtcctctt 660
ggggccccaa tgacccccgg cataggtcgc gcaacgtggg taaggtcatc gataccctaa 720
cgtgcggctt tgccgacctc atggggtaca tccctgtcgt gggcgccccg ctcggcggcg 780
tcgccagagc tctcgcgcat ggcgtgagag tcctggagga cggggttaat tttgcaacag 840
ggaacttacc cggttgctcc ttttctatct tcttgctggc cctgctgtcc tgcatcacca 900
ccccggtctc cgctgccgaa gtgaagaaca tcagtaccgg ctacatggtg actaacgact 960
gcaccaatga cagcattacc tggcagctcc aggctgctgt cctccacgtc cccgggtgcg 1020
tcccgtgcga gaaagtgggg aatgcatctc agtgctggat accggtctca ccgaatgtgg 1080
ccgtgcagcg gcccggcgcc ctcacgcagg gcttgcggac gcacatcgac atggttgtga 1140
tgtccgccac gctctgctct gccctctacg tgggggacct ctgcggtggg gtgatgctcg 1200
cagcccaaat gttcattgtc tcgccgcagc accactggtt tgtccaagac tgcaattgct 1260
ccatctaccc tggtaccatc actggacacc gcatggcatg ggacatgatg atgaactggt 1320
cgcccacggc taccatgatc ttggcgtacg cgatgcgtgt ccccgaggtc attatagaca 1380
tcattagcgg ggctcattgg ggcgtcatgt tcggcttggc ctacttctct atgcagggag 1440
cgtgggcgaa agtcgttgtc atccttctgt tggccgccgg ggtggacgcg cgcacccata 1500
ctgttggggg ttctgccgcg cagaccaccg ggcgcctcac cagcttattt gacatgggcc 1560
ccaggcagaa aatccagctc gttaacacca atggcagctg gcacatcaac cgcaccgccc 1620
tgaactgcaa tgactccttg cacaccggct ttatcgcgtc tctgttctac acccacagct 1680
tcaactcgtc aggatgtccc gaacgcatgt ccgcctgccg cagtatcgag gccttccggg 1740
tgggatgggg cgccttgcaa tatgaggata atgtcaccaa tccagaggat atgagaccct 1800
attgctggca ctacccacca aggcagtgtg gcgtggtctc cgcgaagact gtgtgtggcc 1860
cagtgtactg tttcaccccc agcccagtgg tagtgggcac gaccgacagg cttggagcgc 1920
ccacttacac gtgggggggag aatgagacag atgtcttcct attgaacagc actcgaccac 1980
cgctggggtc atggttcggc tgcacgtgga tgaactcttc tggctacacc aagacttgcg 2040
gcgcaccacc ctgccgtact agagctgact tcaacgccag cacggacctg ttgtgcccca 2100
cggactgttt taggaagcat cctgatacca cttacctcaa atgcggctct gggccctggc 2160
tcacgccaag gtgcctgatc gactaccccc acaggctctg gcattacccc tgcacagtta 2220
actataccat cttcaaaata aggatgtatg tgggaggggt tgagcacagg ctcacggctg 2280
catgcaattt cactcgtggg gatcgttgca acttggagga cagagacaga agtcaactgt 2340
ctcctttgtt gcactccacc acggaatggg ccattttacc ttgctcttac tcggacctgc 2400
ccgccttgtc gactggtctt ctccacctcc accaaaacat cgtggacgta caattcatgt 2460
atggcctatc acctgccctc acaaaataca tcgtccgatg ggagtgggta atactcttat 2520
tcctgctctt agcggacgcc agggtttgcg cctgcttatg gatgctcatc ttgttgggcc 2580

aggccgaagc agcactagag aagctggtca tcttgcacgc tgcgagcgca gctagctgca 2640
atggcttcct atattttgtc atcttttcg tggctgcttg gtacatcaag ggtcgggtag 2700
tcccccttagc tacctattcc ctcactggcc tgtggtcctt tagcctactg ctcctagcat 2760
tgccccaaca ggcatatgca ctggacacgg aggtggccgc gtcgtgtggc ggcgttgttc 2820
ttgtcgggtt aatggcgctg actctgtcgc catattacaa gcgctatatc agctggtgca 2880
tgtggtggct tcagtatttt ctgaccagag tagaagcgca actgcacgtg tgggttcccc 2940
ccctcaacgt ccgggggggg cgcgatgccg tcatcttact catgtgtgta gtacacccga 3000
ccctggtatt tgacatcacc aaactactcc tggccatctt cggacccctt tggattcttc 3060
aagccagttt gcttaaagtc ccctacttcg tgcgcgttca aggccttctc cggatctgcg 3120
cgctagcgcg gaagatagcc ggaggtcatt acgtgcaaat ggccatcatc aagttagggg 3180
cgcttactgg cacctatgtg tataaccatc tcacccctct tcgagactgg gcgcacaacg 3240
gcctgcgaga tctggccgtg gctgtggaac cagtcgtctt ctcccgaatg gagaccaagc 3300
tcatcacgtg gggggcagat accgccgcgt gcggtgacat catcaacggc ttgcccgtct 3360
ctgcccgtag gggccaggag atactgcttg ggccagccga cggaatggtc tccaaggggt 3420
ggaggttgct ggcgcccatc acggcgtacg cccagcagac gagaggcctc ctagggtgta 3480
taatcaccag cctgactggc cgggacaaaa accaagtgga gggtgaggtc cagatcgtgt 3540
caactgctac ccaaaccttc ctggcaacgt gcatcaatgg ggtatgctgg actgtctacc 3600
acggggccgg aacgaggacc atcgcatcac ccaagggtcc tgtcatccag atgtatacca 3660
atgtggacca agaccttgtg ggctggcccg ctcctcaagg ttcccgctca ttgacaccct 3720
gtacctgcgg ctcctcggac ctttacctgg tcacgaggca cgccgatgtc attcccgtgc 3780
gccggcgagg tgatagcagg ggtagcctgc tttcgccccg gcccatttcc tacttgaaag 3840
gctcctcggg gggtccgctg ttgtgccccg cgggacacgc cgtgggccta ttcagggccg 3900
cggtgtgcac ccgtggagtg gctaaagcgg tggactttat ccctgtggag aacctaggga 3960
caaccatgag atccccggtg ttcacggaca actcctctcc accagcagtg ccccagagct 4020
tccaggtggc ccacctgcat gctcccaccg gcagcggtaa gagcaccaag gtcccggctg 4080
cgtacgcagc ccagggctac aaggtgttgg tgctcaaccc ctctgttgct gcaacgctgg 4140
gctttggtgc ttacatgtcc aaggcccatg gggttgatcc taatatcagg accggggtga 4200
gaacaattac cactggcagc cccatcacgt actccaccta cggcaagttc cttgccgacg 4260
gcgggtgctc aggaggtgct tatgacataa taatttgtga cgagtgccac tccacggatg 4320
ccacatccat cttgggcatc ggcactgtcc ttgaccaagc agagactgcg ggggcgagac 4380
tggttgtgct cgccactgct acccctccgg gctccgtcac tgtgtcccat cctaacatcg 4440
aggaggttgc tctgtccacc accggagaga tccccttta cggcaaggct atccccctcg 4500
aggtgatcaa gggggaaga catctcatct tctgccactc aaagaagaag tgcgacgagc 4560
tcgccgcgaa gctggtcgca ttgggcatca atgccgtggc ctactaccgc ggtcttgacg 4620
tgtctgtcat cccgaccagc ggcgatgttg tcgtcgtgtc gaccgatgct ctcatgactg 4680
gctttaccgg cgacttcgac tctgtgatag actgcaacac gtgtgtcact cagacagtcg 4740
atttcagcct tgaccctacc tttaccattg agacaaccac gctcccccag gatgctgtct 4800
ccaggactca acgccggggc aggactggca gggggaagcc aggcatctat agatttgtgg 4860
caccgggga gcgcccctcc ggcatgttcg actcgtccgt cctctgtgag tgctatgacg 4920
cgggctgtgc ttggtatgag ctcacgcccg ccgagactac agttaggcta cgagcgtaca 4980
tgaacacccc ggggcttccc gtgtgccagg accatcttga attttgggag ggcgtcttta 5040
cgggcctcac tcatatagat gcccactttt tatcccagac aaagcagagt ggggagaact 5100
ttccttacct ggtagcgtac caagccaccg tgtgcgctag ggctcaagcc cctcccccat 5160
cgtgggacca gatgtggaag tgtttgatcc gccttaaacc caccctccat gggccaacac 5220
ccctgctata cagactgggc gctgttcaga atgaagtcac cctgacgcac ccaatcacca 5280
aatacatcat gacatgcatg tcggccgacc tggaggtcgt cacgagcacc tgggtgctcg 5340
ttggcggcgt cctggctgct ctggccgcgt attgcctgtc aacaggctgc gtggtcatag 5400
tgggcaggat cgtcttgtcc gggaagccgg caattatacc tgacagggag gttctctacc 5460

aggagttcga tgagatggaa gagtgctctc agcacttacc gtacatcgag caagggatga 5520
tgctcgctga gcagttcaag cagaaggccc tcggcctcct gcagaccgcg tcccgccatg 5580
cagaggttat cacccctgct gtccagacca actggcagaa actcgaggtc ttttgggcga 5640
agcacatgtg gaatttcatc agtgggatac aatacttggc gggcctgtca acgctgcctg 5700
gtaaccccgc cattgcttca ttgatggctt ttacagctgc cgtcaccagc ccactaacca 5760
ctggccaaac cctcctcttc aacatattgg gggggtgggt ggctgcccag ctcgccgccc 5820
ccggtgccgc tactgccttt gtgggtgctg gcctagctgg cgccgccatc ggcagcgttg 5880
gactggggaa ggtcctcgtg gacattcttg cagggtatgg cgcgggcgtg gcgggagctc 5940
ttgtagcatt caagatcatg agcggtgagg tcccctccac ggaggacctg gtcaatctgc 6000
tgcccgccat cctctcgcct ggagcccttg tagtcggtgt ggtctgcgca gcaatactgc 6060
gccggcacgt tggcccgggc gaggggggcag tgcaatggat gaaccggcta atagccttcg 6120
cctcccgggg gaaccatgtt tcccccacgc actacgtgcc ggagagcgat gcagccgccc 6180
gcgtcactgc catactcagc agcctcactg taacccagct cctgaggcga ctgcatcagt 6240
ggataagctc ggagtgtacc actccatgct ccggttcctg gctaagggac atctgggact 6300
ggatatgcga ggtgctgagc gactttaaga cctggctgaa agccaagctc atgccacaac 6360
tgcctgggat tccctttgtg tcctgccagc gcgggtatag gggggtctgg cgaggagacg 6420
gcattatgca cactcgctgc cactgtggag ctgagatcac tggacatgtc aaaaacggga 6480
cgatgaggat cgtcggtcct aggacctgca ggaacatgtg gagtgggacg ttccccatta 6540
acgcctacac cacgggcccc tgtactcccc ttcctgcgcc gaactataag ttcgcgctgt 6600
ggagggtgtc tgcagaggaa tacgtggaga taaggcgggt gggggacttc cactacgtat 6660
cgggtatgac tactgacaat cttaaatgcc cgtgccagat cccatcgccc gaatttttca 6720
cagaattgga cggggtgcgc ctacacaggt ttgcgccccc ttgcaagccc ttgctgcggg 6780
aggaggtatc attcagagta ggactccacg agtacccggt ggggtcgcaa ttaccttgcg 6840
agcccgaacc ggacgtagcc gtgttgacgt ccatgctcac tgatccctcc catataacag 6900
cagaggcggc cgggagaagg ttggcgagag ggtcaccccc ttctatggcc agctcctcgg 6960
ctagccagct gtccgctcca tctctcaagg caacttgcac cgccaaccat gactcccctg 7020
acgccgagct catagaggct aacctcctgt ggaggcagga gatgggcggc aacatcacca 7080
gggttgagtc agagaacaaa gtggtgattc tggactcctt cgatccgctt gtggcagagg 7140
aggatgagcg ggaggtctcc gtacctgcag aaattctgcg gaagtctcgg agattcgccc 7200
gggccctgcc cgtctgggcg cggccggact acaacccccc gctagtagag acgtggaaaa 7260
agcctgacta cgaaccacct gtggtccatg gctgcccgct accacctcca cggtcccctc 7320
ctgtgcctcc gcctcggaaa aagcgtacgg tggtcctcac cgaatcaacc ctatctactg 7380
ccttggccga gcttgccacc aaaagttttg gcagctcctc aacttccggc attacgggcg 7440
acaatacgac aacatcctct gagcccgccc cttctggctg ccccccgac tccgacgttg 7500
agtcctattc ttccatgccc cccctggagg gggagcctgg ggatccggat ctcagcgacg 7560
ggtcatggtc gacggtcagt agtggggccg acacggaaga tgtcgtgtgc tgctcaatgt 7620
cttattcctg gacaggcgca ctcgtcaccc cgtgcgctgc ggaagaacaa aaactgccca 7680
tcaacgcact gagcaactcg ttgctacgcc atcacaatct ggtgtattcc accacttcac 7740
gcagtgcttg ccaaaggcag aagaaagtca catttgacag actgcaagtt ctggacagcc 7800
attaccagga cgtgctcaag gaggtcaaag cagcggcgtc aaaagtgaag gctaacttgc 7860
tatccgtaga ggaagcttgc agcctgacgc ccccacattc agccaaatcc aagtttggct 7920
atggggcaaa agacgtccgt tgccatgcca gaaaggccgt agcccacatc aactccgtgt 7980
ggaaagacct tctggaagac agtgtaacac caatagacac taccatcatg gccaagaacg 8040
aggttttctg cgttcagcct gagaaggggg gtcgtaagcc agctcgtctc atcgtgttcc 8100
ccgacctggg cgtgcgcgtg tgcgagaaga tggccctgta cgacgtggtt agcaagctcc 8160
ccctggccgt gatgggaagc tcctacggat tccaatactc accaggacag cgggttgaat 8220
tcctcgtgca agcgtggaag tccaagaaga ccccgatggg gttctcgtat gatacccgct 8280
gttttgactc cacagtcact gagagcgaca tccgtacgga ggaggcaatt taccaatgtt 8340

gtgacctgga cccccaagcc cgcgtggcca tcaagtccct cactgagagg ctttatgttg 8400
ggggccctct taccaattca agggggggaaa actgcggcta ccgcaggtgc cgcgcgagcg 8460
gcgtactgac aactagctgt ggtaacaccc tcacttgcta catcaaggcc cgggcagcct 8520
gtcgagccgc agggctccag gactgcacca tgctcgtgtg tggcgacgac ttagtcgtta 8580
tctgtgaaag tgcgggggtc caggaggacg cggcgagcct gagagccttc acggaggcta 8640
tgaccaggta ctccgccccc cccggggacc ccccacaacc agaatacgac ttggagctta 8700
taacatcatg ctcctccaac gtgtcagtcg cccacgacgg cgctggaaag agggtctact 8760
accttacccg tgaccctaca acccccctcg cgagagccgc gtgggagaca gcaagacaca 8820
ctccagtcaa ttcctggcta ggcaacataa tcatgtttgc ccccacactg tgggcgagga 8880
tgatactgat gacccatttc tttagcgtcc tcatagccag ggatcagctt gaacaggctc 8940
ttaactgtga gatctacgga gcctgctact ccatagaacc actggatcta cctccaatca 9000
ttcaaagact ccatggcctc agcgcatttt cactccacag ttactctcca ggtgaaatca 9060
atagggtggc cgcatgcctc agaaaacttg gggtcccgcc cttgcgagct tggagacacc 9120
gggcccggag cgtccgcgct aggcttctgt ccagaggagg cagggctgct atatgtggca 9180
agtacctctt caactgggca gtaagaacaa agctcaaact cactccaata gcggccgctg 9240
gccggctgga cttgtccggt tggttcacgg ctggctacag cgggggagac atttatcaca 9300
gcgtgtctca tgcccggccc cgctggttct ggttttgcct actcctgctc gctgcagggg 9360
taggcatcta cctcctcccc aaccgatgaa ggttggggta aacactccgg cctcttaagc 9420
catttcctgt ttttttttt ttttttttt ttttttcctt ttttttttc tttcctttcc 9480
ttctttttt cctttctttt tcccttcttt aatggtggct ccatcttagc cctagtcacg 9540
gctagctgtg aaaggtccgt gagccgcatg actgcagaga gtgctgatac tggcctctct 9600
gcagatcatg t 9611

<210> 8
<211> 3015
<212> PRT
<213> Hepatitis C virus

<400> 8

Met	Ser	Thr	Asn	Pro	Lys	Pro	Gln	Arg	Lys	Thr	Lys	Arg	Asn	Thr	Asn
1				5				10					15		
Arg	Arg	Pro	Gln	Asp	Val	Lys	Phe	Pro	Gly	Gly	Gly	Gln	Ile	Val	Gly
			20					25					30		
Gly	Val	Tyr	Leu	Leu	Pro	Arg	Arg	Gly	Pro	Arg	Leu	Gly	Val	Arg	Ala
		35					40					45			
Thr	Arg	Lys	Thr	Ser	Glu	Arg	Ser	Gln	Pro	Arg	Gly	Arg	Arg	Gln	Pro
	50					55					60				
Ile	Pro	Lys	Asp	Arg	Arg	Ser	Thr	Gly	Lys	Ser	Trp	Gly	Lys	Pro	Gly
65					70					75					80
Tyr	Pro	Trp	Pro	Leu	Tyr	Gly	Asn	Glu	Gly	Leu	Gly	Trp	Ala	Gly	Trp
				85					90					95	

```
Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Asn Asp Pro
            100                 105                 110

Arg His Arg Ser Arg Asn Val Gly Lys Val Ile Asp Thr Leu Thr Cys
        115                 120                 125

Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Val Val Gly Ala Pro Leu
    130                 135                 140

Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp
145                 150                 155                 160

Gly Val Asn Phe Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile
                165                 170                 175

Phe Leu Leu Ala Leu Leu Ser Cys Ile Thr Thr Pro Val Ser Ala Ala
            180                 185                 190

Glu Val Lys Asn Ile Ser Thr Gly Tyr Met Val Thr Asn Asp Cys Thr
        195                 200                 205

Asn Asp Ser Ile Thr Trp Gln Leu Gln Ala Ala Val Leu His Val Pro
    210                 215                 220

Gly Cys Val Pro Cys Glu Lys Val Gly Asn Ala Ser Gln Cys Trp Ile
225                 230                 235                 240

Pro Val Ser Pro Asn Val Ala Val Gln Arg Pro Gly Ala Leu Thr Gln
                245                 250                 255

Gly Leu Arg Thr His Ile Asp Met Val Val Met Ser Ala Thr Leu Cys
            260                 265                 270

Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Gly Val Met Leu Ala Ala
        275                 280                 285

Gln Met Phe Ile Val Ser Pro Gln His His Trp Phe Val Gln Asp Cys
    290                 295                 300

Asn Cys Ser Ile Tyr Pro Gly Thr Ile Thr Gly His Arg Met Ala Trp
305                 310                 315                 320

Asp Met Met Met Asn Trp Ser Pro Thr Ala Thr Met Ile Leu Ala Tyr
                325                 330                 335

Ala Met Arg Val Pro Glu Val Ile Ile Asp Ile Ile Ser Gly Ala His
            340                 345                 350
```

```
Trp Gly Val Met Phe Gly Leu Ala Tyr Phe Ser Met Gln Gly Ala Trp
        355                 360                 365

Ala Lys Val Val Val Ile Leu Leu Leu Ala Ala Gly Val Asp Ala Arg
    370                 375                 380

Thr His Thr Val Gly Gly Ser Ala Ala Gln Thr Thr Gly Arg Leu Thr
385                 390                 395                 400

Ser Leu Phe Asp Met Gly Pro Arg Gln Lys Ile Gln Leu Val Asn Thr
                405                 410                 415

Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser
            420                 425                 430

Leu His Thr Gly Phe Ile Ala Ser Leu Phe Tyr Thr His Ser Phe Asn
        435                 440                 445

Ser Ser Gly Cys Pro Glu Arg Met Ser Ala Cys Arg Ser Ile Glu Ala
    450                 455                 460

Phe Arg Val Gly Trp Gly Ala Leu Gln Tyr Glu Asp Asn Val Thr Asn
465                 470                 475                 480

Pro Glu Asp Met Arg Pro Tyr Cys Trp His Tyr Pro Pro Arg Gln Cys
                485                 490                 495

Gly Val Val Ser Ala Lys Thr Val Cys Gly Pro Val Tyr Cys Phe Thr
            500                 505                 510

Pro Ser Pro Val Val Val Gly Thr Thr Asp Arg Leu Gly Ala Pro Thr
        515                 520                 525

Tyr Thr Trp Gly Glu Asn Glu Thr Asp Val Phe Leu Leu Asn Ser Thr
    530                 535                 540

Arg Pro Pro Leu Gly Ser Trp Phe Gly Cys Thr Trp Met Asn Ser Ser
545                 550                 555                 560

Gly Tyr Thr Lys Thr Cys Gly Ala Pro Pro Cys Arg Thr Arg Ala Asp
                565                 570                 575

Phe Asn Ala Ser Thr Asp Leu Leu Cys Pro Thr Asp Cys Phe Arg Lys
            580                 585                 590

His Pro Asp Thr Thr Tyr Leu Lys Cys Gly Ser Gly Pro Trp Leu Thr
        595                 600                 605
```

```
Pro Arg Cys Leu Ile Asp Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys
    610                 615                 620

Thr Val Asn Tyr Thr Ile Phe Lys Ile Arg Met Tyr Val Gly Gly Val
625                 630                 635                 640

Glu His Arg Leu Thr Ala Ala Cys Asn Phe Thr Arg Gly Asp Arg Cys
                645                 650                 655

Asn Leu Glu Asp Arg Asp Arg Ser Gln Leu Ser Pro Leu Leu His Ser
            660                 665                 670

Thr Thr Glu Trp Ala Ile Leu Pro Cys Ser Tyr Ser Asp Leu Pro Ala
        675                 680                 685

Leu Ser Thr Gly Leu Leu His Leu His Gln Asn Ile Val Asp Val Gln
    690                 695                 700

Phe Met Tyr Gly Leu Ser Pro Ala Leu Thr Lys Tyr Ile Val Arg Trp
705                 710                 715                 720

Glu Trp Val Ile Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Val Cys
                725                 730                 735

Ala Cys Leu Trp Met Leu Ile Leu Leu Gly Gln Ala Glu Ala Ala Leu
            740                 745                 750

Glu Lys Leu Val Ile Leu His Ala Ala Ser Ala Ala Ser Cys Asn Gly
        755                 760                 765

Phe Leu Tyr Phe Val Ile Phe Phe Val Ala Ala Trp Tyr Ile Lys Gly
    770                 775                 780

Arg Val Val Pro Leu Ala Thr Tyr Ser Leu Thr Gly Leu Trp Ser Phe
785                 790                 795                 800

Ser Leu Leu Leu Leu Ala Leu Pro Gln Gln Ala Tyr Ala Leu Asp Thr
                805                 810                 815

Glu Val Ala Ala Ser Cys Gly Gly Val Val Leu Val Gly Leu Met Ala
            820                 825                 830

Leu Thr Leu Ser Pro Tyr Tyr Lys Arg Tyr Ile Ser Trp Cys Met Trp
        835                 840                 845

Trp Leu Gln Tyr Phe Leu Thr Arg Val Glu Ala Gln Leu His Val Trp
    850                 855                 860
```

```
Val Pro Pro Leu Asn Val Arg Gly Gly Arg Asp Ala Val Ile Leu Leu
865                 870                 875                 880

Met Cys Val Val His Pro Thr Leu Val Phe Asp Ile Thr Lys Leu Leu
                885                 890                 895

Leu Ala Ile Phe Gly Pro Leu Trp Ile Leu Gln Ala Ser Leu Leu Lys
            900                 905                 910

Val Pro Tyr Phe Val Arg Val Gln Gly Leu Leu Arg Ile Cys Ala Leu
        915                 920                 925

Ala Arg Lys Ile Ala Gly Gly His Tyr Val Gln Met Ala Ile Ile Lys
    930                 935                 940

Leu Gly Ala Leu Thr Gly Thr Tyr Val Tyr Asn His Leu Thr Pro Leu
945                 950                 955                 960

Arg Asp Trp Ala His Asn Gly Leu Arg Asp Leu Ala Val Ala Val Glu
                965                 970                 975

Pro Val Val Phe Ser Arg Met Glu Thr Lys Leu Ile Thr Trp Gly Ala
            980                 985                 990

Asp Thr Ala Ala Cys Gly Asp Ile Ile Asn Gly Leu Pro Val Ser Ala
        995                1000                1005

Arg Arg Gly Gln Glu Ile Leu Leu Gly Pro Ala Asp Gly Met Val Ser
   1010                1015                1020

Lys Gly Trp Arg Leu Leu Ala Pro Ile Thr Ala Tyr Ala Gln Gln Thr
1025                1030                1035                1040

Arg Gly Leu Leu Gly Cys Ile Ile Thr Ser Leu Thr Gly Arg Asp Lys
                1045                1050                1055

Asn Gln Val Glu Gly Glu Val Gln Ile Val Ser Thr Ala Thr Gln Thr
            1060                1065                1070

Phe Leu Ala Thr Cys Ile Asn Gly Val Cys Trp Thr Val Tyr His Gly
       1075                1080                1085

Ala Gly Thr Arg Thr Ile Ala Ser Pro Lys Gly Pro Val Ile Gln Met
   1090                1095                1100

Tyr Thr Asn Val Asp Gln Asp Leu Val Gly Trp Pro Ala Pro Gln Gly
1105                1110                1115                1120
```

Ser Arg Ser Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu
1125 1130 1135

Val Thr Arg His Ala Asp Val Ile Pro Val Arg Arg Arg Gly Asp Ser
1140 1145 1150

Arg Gly Ser Leu Leu Ser Pro Arg Pro Ile Ser Tyr Leu Lys Gly Ser
1155 1160 1165

Ser Gly Gly Pro Leu Leu Cys Pro Ala Gly His Ala Val Gly Leu Phe
1170 1175 1180

Arg Ala Ala Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Ile
1185 1190 1195 1200

Pro Val Glu Asn Leu Gly Thr Thr Met Arg Ser Pro Val Phe Thr Asp
1205 1210 1215

Asn Ser Ser Pro Pro Ala Val Pro Gln Ser Phe Gln Val Ala His Leu
1220 1225 1230

His Ala Pro Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr
1235 1240 1245

Ala Ala Gln Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala
1250 1255 1260

Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala His Gly Val Asp Pro
1265 1270 1275 1280

Asn Ile Arg Thr Gly Val Arg Thr Ile Thr Thr Gly Ser Pro Ile Thr
1285 1290 1295

Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly
1300 1305 1310

Ala Tyr Asp Ile Ile Ile Cys Asp Glu Cys His Ser Thr Asp Ala Thr
1315 1320 1325

Ser Ile Leu Gly Ile Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Gly
1330 1335 1340

Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr
1345 1350 1355 1360

Val Ser His Pro Asn Ile Glu Glu Val Ala Leu Ser Thr Thr Gly Glu
1365 1370 1375

```
Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu Val Ile Lys Gly Gly
          1380                1385                1390

Arg His Leu Ile Phe Cys His Ser Lys Lys Lys Cys Asp Glu Leu Ala
       1395                1400                1405

Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly
   1410                1415                1420

Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp Val Val Val Val Ser
1425                1430                1435                1440

Thr Asp Ala Leu Met Thr Gly Phe Thr Gly Asp Phe Asp Ser Val Ile
               1445                1450                1455

Asp Cys Asn Thr Cys Val Thr Gln Thr Val Asp Phe Ser Leu Asp Pro
          1460                1465                1470

Thr Phe Thr Ile Glu Thr Thr Thr Leu Pro Gln Asp Ala Val Ser Arg
       1475                1480                1485

Thr Gln Arg Arg Gly Arg Thr Gly Arg Gly Lys Pro Gly Ile Tyr Arg
   1490                1495                1500

Phe Val Ala Pro Gly Glu Arg Pro Ser Gly Met Phe Asp Ser Ser Val
1505                1510                1515                1520

Leu Cys Glu Cys Tyr Asp Ala Gly Cys Ala Trp Tyr Glu Leu Thr Pro
               1525                1530                1535

Ala Glu Thr Thr Val Arg Leu Arg Ala Tyr Met Asn Thr Pro Gly Leu
          1540                1545                1550

Pro Val Cys Gln Asp His Leu Glu Phe Trp Glu Gly Val Phe Thr Gly
       1555                1560                1565

Leu Thr His Ile Asp Ala His Phe Leu Ser Gln Thr Lys Gln Ser Gly
   1570                1575                1580

Glu Asn Phe Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg
1585                1590                1595                1600

Ala Gln Ala Pro Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile
               1605                1610                1615

Arg Leu Lys Pro Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu
          1620                1625                1630
```

Gly Ala Val Gln Asn Glu Val Thr Leu Thr His Pro Ile Thr Lys Tyr
1635 1640 1645

Ile Met Thr Cys Met Ser Ala Asp Leu Glu Val Val Thr Ser Thr Trp
1650 1655 1660

Val Leu Val Gly Gly Val Leu Ala Ala Leu Ala Ala Tyr Cys Leu Ser
1665 1670 1675 1680

Thr Gly Cys Val Val Ile Val Gly Arg Ile Val Leu Ser Gly Lys Pro
1685 1690 1695

Ala Ile Ile Pro Asp Arg Glu Val Leu Tyr Gln Glu Phe Asp Glu Met
1700 1705 1710

Glu Glu Cys Ser Gln His Leu Pro Tyr Ile Glu Gln Gly Met Met Leu
1715 1720 1725

Ala Glu Gln Phe Lys Gln Lys Ala Leu Gly Leu Leu Gln Thr Ala Ser
1730 1735 1740

Arg His Ala Glu Val Ile Thr Pro Ala Val Gln Thr Asn Trp Gln Lys
1745 1750 1755 1760

Leu Glu Val Phe Trp Ala Lys His Met Trp Asn Phe Ile Ser Gly Ile
1765 1770 1775

Gln Tyr Leu Ala Gly Leu Ser Thr Leu Pro Gly Asn Pro Ala Ile Ala
1780 1785 1790

Ser Leu Met Ala Phe Thr Ala Ala Val Thr Ser Pro Leu Thr Thr Gly
1795 1800 1805

Gln Thr Leu Leu Phe Asn Ile Leu Gly Gly Trp Val Ala Ala Gln Leu
1810 1815 1820

Ala Ala Pro Gly Ala Ala Thr Ala Phe Val Gly Ala Gly Leu Ala Gly
1825 1830 1835 1840

Ala Ala Ile Gly Ser Val Gly Leu Gly Lys Val Leu Val Asp Ile Leu
1845 1850 1855

Ala Gly Tyr Gly Ala Gly Val Ala Gly Ala Leu Val Ala Phe Lys Ile
1860 1865 1870

Met Ser Gly Glu Val Pro Ser Thr Glu Asp Leu Val Asn Leu Leu Pro
1875 1880 1885

```
Ala Ile Leu Ser Pro Gly Ala Leu Val Val Gly Val Val Cys Ala Ala
   1890                1895                1900

Ile Leu Arg Arg His Val Gly Pro Gly Glu Gly Ala Val Gln Trp Met
1905                1910                1915                1920

Asn Arg Leu Ile Ala Phe Ala Ser Arg Gly Asn His Val Ser Pro Thr
               1925                1930                1935

His Tyr Val Pro Glu Ser Asp Ala Ala Ala Arg Val Thr Ala Ile Leu
           1940                1945                1950

Ser Ser Leu Thr Val Thr Gln Leu Leu Arg Arg Leu His Gln Trp Ile
       1955                1960                1965

Ser Ser Glu Cys Thr Thr Pro Cys Ser Gly Ser Trp Leu Arg Asp Ile
   1970                1975                1980

Trp Asp Trp Ile Cys Glu Val Leu Ser Asp Phe Lys Thr Trp Leu Lys
1985                1990                1995                2000

Ala Lys Leu Met Pro Gln Leu Pro Gly Ile Pro Phe Val Ser Cys Gln
               2005                2010                2015

Arg Gly Tyr Arg Gly Val Trp Arg Gly Asp Gly Ile Met His Thr Arg
           2020                2025                2030

Cys His Cys Gly Ala Glu Ile Thr Gly His Val Lys Asn Gly Thr Met
       2035                2040                2045

Arg Ile Val Gly Pro Arg Thr Cys Arg Asn Met Trp Ser Gly Thr Phe
   2050                2055                2060

Pro Ile Asn Ala Tyr Thr Thr Gly Pro Cys Thr Pro Leu Pro Ala Pro
2065                2070                2075                2080

Asn Tyr Lys Phe Ala Leu Trp Arg Val Ser Ala Glu Glu Tyr Val Glu
               2085                2090                2095

Ile Arg Arg Val Gly Asp Phe His Tyr Val Ser Gly Met Thr Thr Asp
           2100                2105                2110

Asn Leu Lys Cys Pro Cys Gln Ile Pro Ser Pro Glu Phe Phe Thr Glu
       2115                2120                2125

Leu Asp Gly Val Arg Leu His Arg Phe Ala Pro Pro Cys Lys Pro Leu
   2130                2135                2140
```

Leu Arg Glu Glu Val Ser Phe Arg Val Gly Leu His Glu Tyr Pro Val
2145 2150 2155 2160

Gly Ser Gln Leu Pro Cys Glu Pro Glu Pro Asp Val Ala Val Leu Thr
2165 2170 2175

Ser Met Leu Thr Asp Pro Ser His Ile Thr Ala Glu Ala Ala Gly Arg
2180 2185 2190

Arg Leu Ala Arg Gly Ser Pro Pro Ser Met Ala Ser Ser Ser Ala Ser
2195 2200 2205

Gln Leu Ser Ala Pro Ser Leu Lys Ala Thr Cys Thr Ala Asn His Asp
2210 2215 2220

Ser Pro Asp Ala Glu Leu Ile Glu Ala Asn Leu Leu Trp Arg Gln Glu
2225 2230 2235 2240

Met Gly Gly Asn Ile Thr Arg Val Glu Ser Glu Asn Lys Val Val Ile
2245 2250 2255

Leu Asp Ser Phe Asp Pro Leu Val Ala Glu Glu Asp Glu Arg Glu Val
2260 2265 2270

Ser Val Pro Ala Glu Ile Leu Arg Lys Ser Arg Arg Phe Ala Arg Ala
2275 2280 2285

Leu Pro Val Trp Ala Arg Pro Asp Tyr Asn Pro Pro Leu Val Glu Thr
2290 2295 2300

Trp Lys Lys Pro Asp Tyr Glu Pro Pro Val Val His Gly Cys Pro Leu
2305 2310 2315 2320

Pro Pro Pro Arg Ser Pro Pro Val Pro Pro Pro Arg Lys Lys Arg Thr
2325 2330 2335

Val Val Leu Thr Glu Ser Thr Leu Ser Thr Ala Leu Ala Glu Leu Ala
2340 2345 2350

Thr Lys Ser Phe Gly Ser Ser Ser Thr Ser Gly Ile Thr Gly Asp Asn
2355 2360 2365

Thr Thr Thr Ser Ser Glu Pro Ala Pro Ser Gly Cys Pro Pro Asp Ser
2370 2375 2380

Asp Val Glu Ser Tyr Ser Ser Met Pro Pro Leu Glu Gly Glu Pro Gly
2385 2390 2395 2400

```
Asp Pro Asp Leu Ser Asp Gly Ser Trp Ser Thr Val Ser Ser Gly Ala
                2405                2410                2415

Asp Thr Glu Asp Val Val Cys Cys Ser Met Ser Tyr Ser Trp Thr Gly
            2420                2425                2430

Ala Leu Val Thr Pro Cys Ala Ala Glu Glu Gln Lys Leu Pro Ile Asn
        2435                2440                2445

Ala Leu Ser Asn Ser Leu Leu Arg His His Asn Leu Val Tyr Ser Thr
    2450                2455                2460

Thr Ser Arg Ser Ala Cys Gln Arg Gln Lys Lys Val Thr Phe Asp Arg
2465                2470                2475                2480

Leu Gln Val Leu Asp Ser His Tyr Gln Asp Val Leu Lys Glu Val Lys
                2485                2490                2495

Ala Ala Ala Ser Lys Val Lys Ala Asn Leu Leu Ser Val Glu Glu Ala
            2500                2505                2510

Cys Ser Leu Thr Pro Pro His Ser Ala Lys Ser Lys Phe Gly Tyr Gly
        2515                2520                2525

Ala Lys Asp Val Arg Cys His Ala Arg Lys Ala Val Ala His Ile Asn
    2530                2535                2540

Ser Val Trp Lys Asp Leu Leu Glu Asp Ser Val Thr Pro Ile Asp Thr
2545                2550                2555                2560

Thr Ile Met Ala Lys Asn Glu Val Phe Cys Val Gln Pro Glu Lys Gly
                2565                2570                2575

Gly Arg Lys Pro Ala Arg Leu Ile Val Phe Pro Asp Leu Gly Val Arg
            2580                2585                2590

Val Cys Glu Lys Met Ala Leu Tyr Asp Val Val Ser Lys Leu Pro Leu
        2595                2600                2605

Ala Val Met Gly Ser Ser Tyr Gly Phe Gln Tyr Ser Pro Gly Gln Arg
    2610                2615                2620

Val Glu Phe Leu Val Gln Ala Trp Lys Ser Lys Lys Thr Pro Met Gly
2625                2630                2635                2640

Phe Ser Tyr Asp Thr Arg Cys Phe Asp Ser Thr Val Thr Glu Ser Asp
                2645                2650                2655
```

Ile Arg Thr Glu Glu Ala Ile Tyr Gln Cys Cys Asp Leu Asp Pro Gln
2660 2665 2670

Ala Arg Val Ala Ile Lys Ser Leu Thr Glu Arg Leu Tyr Val Gly Gly
2675 2680 2685

Pro Leu Thr Asn Ser Arg Gly Glu Asn Cys Gly Tyr Arg Arg Cys Arg
2690 2695 2700

Ala Ser Gly Val Leu Thr Thr Ser Cys Gly Asn Thr Leu Thr Cys Tyr
2705 2710 2715 2720

Ile Lys Ala Arg Ala Ala Cys Arg Ala Ala Gly Leu Gln Asp Cys Thr
2725 2730 2735

Met Leu Val Cys Gly Asp Asp Leu Val Val Ile Cys Glu Ser Ala Gly
2740 2745 2750

Val Gln Glu Asp Ala Ala Ser Leu Arg Ala Phe Thr Glu Ala Met Thr
2755 2760 2765

Arg Tyr Ser Ala Pro Pro Gly Asp Pro Pro Gln Pro Glu Tyr Asp Leu
2770 2775 2780

Glu Leu Ile Thr Ser Cys Ser Ser Asn Val Ser Val Ala His Asp Gly
2785 2790 2795 2800

Ala Gly Lys Arg Val Tyr Tyr Leu Thr Arg Asp Pro Thr Thr Pro Leu
2805 2810 2815

Ala Arg Ala Ala Trp Glu Thr Ala Arg His Thr Pro Val Asn Ser Trp
2820 2825 2830

Leu Gly Asn Ile Ile Met Phe Ala Pro Thr Leu Trp Ala Arg Met Ile
2835 2840 2845

Leu Met Thr His Phe Phe Ser Val Leu Ile Ala Arg Asp Gln Leu Glu
2850 2855 2860

Gln Ala Leu Asn Cys Glu Ile Tyr Gly Ala Cys Tyr Ser Ile Glu Pro
2865 2870 2875 2880

Leu Asp Leu Pro Pro Ile Ile Gln Arg Leu His Gly Leu Ser Ala Phe
2885 2890 2895

Ser Leu His Ser Tyr Ser Pro Gly Glu Ile Asn Arg Val Ala Ala Cys
2900 2905 2910

Leu Arg Lys Leu Gly Val Pro Pro Leu Arg Ala Trp Arg His Arg Ala
2915 2920 2925

Arg Ser Val Arg Ala Arg Leu Leu Ser Arg Gly Gly Arg Ala Ala Ile
2930 2935 2940

Cys Gly Lys Tyr Leu Phe Asn Trp Ala Val Arg Thr Lys Leu Lys Leu
2945 2950 2955 2960

Thr Pro Ile Ala Ala Ala Gly Arg Leu Asp Leu Ser Gly Trp Phe Thr
2965 2970 2975

Ala Gly Tyr Ser Gly Gly Asp Ile Tyr His Ser Val Ser His Ala Arg
2980 2985 2990

Pro Arg Trp Phe Trp Phe Cys Leu Leu Leu Leu Ala Ala Gly Val Gly
2995 3000 3005

Ile Tyr Leu Leu Pro Asn Arg
3010 3015

<210> 9
<211> 9611
<212> DNA
<213> Hepatitis C virus

<400> 9
gccagccccc tgatgggggc gacactccac catgaatcac tcccctgtga ggaactactg 60
tcttcacgca gaaagcgtct agccatggcg ttagtatgag tgtcgtgcag cctccaggac 120
ccccccteee gggagagcca tagtggtctg cggaaccggt gagtacaccg gaattgccag 180
gacgaccggg tcctttcttg gataaacccg ctcaatgcct ggagatttgg gcgtgccccc 240
gcaagactgc tagccgagta gtgttgggtc gcgaaaggcc ttgtggtact gcctgatagg 300
gtgcttgcga gtgccccggg aggtctcgta gaccgtgcac catgagcaca aatcctaaac 360
ctcaaagaaa aaccaaaaga aacaccaacc gtcgcccaca agacgttaag tttccgggcg 420
gcggccagat cgttggcgga gtatacttgt tgccgcgcag gggccccagg ttgggtgtgc 480
gcgcgacaag gaagacttcg gagcggtccc agccacgtgg aaggcgccag cccatcccta 540
aagatcggcg ctccactggc aaatcctggg gaaaaccagg ataccccctgg cccctatacg 600
ggaatgaggg actcggctgg gcaggatggc tcctgtcccc ccgaggttcc cgtccctctt 660
ggggccccaa tgaccccegg cataggtcgc gcaacgtggg taaggtcatc gataccctaa 720
cgtgcggctt tgccgacctc atggggtaca tccctgtcgt gggcgccccg ctcggcggcg 780
tcgccagagc tctcgcgcat ggcgtgagag tcctggagga cggggttaat tttgcaacag 840
ggaacttacc cggttgctcc ttttctatct tcttgctggc cctgctgtcc tgcatcacca 900
ccccggtctc cgctgccgaa gtgaagaaca tcagtaccgg ctacatggtg actaacgact 960
gcaccaatga cagcattacc tggcagctcc aggctgctgt cctccacgtc cccgggtgcg 1020
tcccgtgcga gaaagtgggg aatgcatctc agtgctggat accggtctca ccgaatgtgg 1080
ccgtgcagcg gcccggcgcc ctcacgcagg gcttgcggac gcacatcgac atggttgtga 1140
tgtccgccac gctctgctct gccctctacg tgggggacct ctgcggtggg gtgatgctcg 1200

cagcccaaat gttcattgtc tcgccgcagc accactggtt tgtccaagac tgcaattgct 1260
ccatctaccc tggtaccatc actggacacc gcatggcatg ggacatgatg atgaactggt 1320
cgcccacggc taccatgatc ttggcgtacg cgatgcgtgt ccccgaggtc attatagaca 1380
tcattagcgg ggctcattgg ggcgtcatgt tcggcttggc ctacttctct atgcagggag 1440
cgtgggcgaa agtcgttgtc atccttctgt tggccgccgg ggtggacgcg cgcacccata 1500
ctgttggggg ttctgccgcg cagaccaccg ggcgcctcac cagcttattt gacatgggcc 1560
ccaggcagaa aatccagctc gttaacacca atggcagctg gcacatcaac cgcaccgccc 1620
tgaactgcaa tgactccttg cacaccggct ttatcgcgtc tctgttctac acccacagct 1680
tcaactcgtc aggatgtccc gaacgcatgt ccgcctgccg cagtatcgag gccttccggg 1740
tgggatgggg cgccttgcaa tatgaggata atgtcaccaa tccagaggat atgagaccct 1800
attgctggca ctacccacca aggcagtgtg gcgtggtctc cgcgaagact gtgtgtggcc 1860
cagtgtactg tttcaccccc agcccagtgg tagtgggcac gaccgacagg cttggagcgc 1920
ccacttacac gtgggggggag aatgagacag atgtcttcct attgaacagc actcgaccac 1980
cgctggggtc atggttcggc tgcacgtgga tgaactcttc tggctacacc aagacttgcg 2040
gcgcaccacc ctgccgtact agagctgact tcaacgccag cacggacctg ttgtgcccca 2100
cggactgttt taggaagcat cctgatacca cttacctcaa atgcggctct gggccctggc 2160
tcacgccaag gtgcctgatc gactaccct acaggctctg gcattacccc tgcacagtta 2220
actataccat cttcaaaata aggatgtatg tgggaggggt tgagcacagg ctcacggctg 2280
catgcaattt cactcgtggg gatcgttgca acttggagga cagagacaga agtcaactgt 2340
ctcctttgtt gcactccacc acggaatggg ccattttacc ttgctcttac tcggacctgc 2400
ccgccttgtc gactggtctt ctccacctcc accaaaacat cgtggacgta caattcatgt 2460
atggcctatc acctgccctc acaaaataca tcgtccgatg ggagtgggta atactcttat 2520
tcctgctctt agcggacgcc agggtttgcg cctgcttatg gatgctcatc ttgttgggcc 2580
aggccgaagc agctttggag aacctcgtaa tactcaatgc agcatccctg gccgggacgc 2640
acggtcttgt gtccttcctc gtgttcttct gctttgcgtg gtatctgaag ggtaggtggg 2700
tgcccggagc ggtctacgcc ctctacggga tgtggcctct cctcctgctc ctgctggcgt 2760
tgcctcagcg ggcatatgca ctggacacgg aggtggccgc gtcgtgtggc ggcgttgttc 2820
ttgtcgggtt aatggcgctg actctgtcgc catattacaa gcgctatatc agctggtgca 2880
tgtggtggct tcagtatttt ctgaccagag tagaagcgca actgcacgtg tgggttcccc 2940
ccctcaacgt ccgggggggg cgcgatgccg tcatcttact catgtgtgta gtacacccga 3000
ccctggtatt tgacatcacc aaactactcc tggccatctt cggacccctt tggattcttc 3060
aagccagttt gcttaaagtc ccctacttcg tgcgcgttca aggccttctc cggatctgcg 3120
cgctagcgcg gaagatagcc ggaggtcatt acgtgcaaat ggccatcatc aagttagggg 3180
cgcttactgg cacctatgtg tataaccatc tcacccctct tcgagactgg gcgcacaacg 3240
gcctgcgaga tctggccgtg gctgtggaac cagtcgtctt ctcccgaatg gagaccaagc 3300
tcatcacgtg gggggcagat accgccgcgt gcggtgacat catcaacggc ttgcccgtct 3360
ctgcccgtag gggccaggag atactgcttg ggccagccga cggaatggtc tccaaggggt 3420
ggaggttgct ggcgcccatc acggcgtacg cccagcagac gagaggcctc ctagggtgta 3480
taatcaccag cctgactggc cgggacaaaa accaagtgga gggtgaggtc cagatcgtgt 3540
caactgctac ccaaaccttc ctggcaacgt gcatcaatgg ggtatgctgg actgtctacc 3600
acggggccgg aacgaggacc atcgcatcac ccaagggtcc tgtcatccag atgtatacca 3660
atgtggacca agaccttgtg ggctggcccg ctcctcaagg ttcccgctca ttgacaccct 3720
gtacctgcgg ctcctcggac ctttacctgg tcacgaggca cgccgatgtc attcccgtgc 3780
gccggcgagg tgatagcagg ggtagcctgc tttcgccccg gcccatttcc tacttgaaag 3840
gctcctcggg gggtccgctg ttgtgccccg cgggacacgc cgtgggccta ttcagggccg 3900
cggtgtgcac ccgtggagtg gctaaagcgg tggactttat ccctgtggag aacctaggga 3960
caaccatgag atccccggtg ttcacggaca actcctctcc accagcagtg ccccagagct 4020
tccaggtggc ccacctgcat gctcccaccg gcagcggtaa gagcaccaag gtcccggctg 4080

cgtacgcagc ccagggctac aaggtgttgg tgctcaaccc ctctgttgct gcaacgctgg 4140
gctttggtgc ttacatgtcc aaggcccatg gggttgatcc taatatcagg accggggtga 4200
gaacaattac cactggcagc cccatcacgt actccaccta cggcaagttc cttgccgacg 4260
gcgggtgctc aggaggtgct tatgacataa taatttgtga cgagtgccac tccacggatg 4320
ccacatccat cttgggcatc ggcactgtcc ttgaccaagc agagactgcg ggggcgagac 4380
tggttgtgct cgccactgct acccctccgg gctccgtcac tgtgtcccat cctaacatcg 4440
aggaggttgc tctgtccacc accggagaga tccccttta cggcaaggct atccccctcg 4500
aggtgatcaa gggggaaga catctcatct tctgccactc aaagaagaag tgcgacgagc 4560
tcgccgcgaa gctggtcgca ttgggcatca atgccgtggc ctactaccgc ggtcttgacg 4620
tgtctgtcat cccgaccagc ggcgatgttg tcgtcgtgtc gaccgatgct ctcatgactg 4680
gctttaccgg cgacttcgac tctgtgatag actgcaacac gtgtgtcact cagacagtcg 4740
atttcagcct tgaccctacc tttaccattg agacaaccac gctcccccag gatgctgtct 4800
ccaggactca acgccggggc aggactggca gggggaagcc aggcatctat agatttgtgg 4860
caccgggggа gcgcccctcc ggcatgttcg actcgtccgt cctctgtgag tgctatgacg 4920
cgggctgtgc ttggtatgag ctcacgcccg ccgagactac agttaggcta cgagcgtaca 4980
tgaacacccc ggggcttccc gtgtgccagg accatcttga attttgggag ggcgtcttta 5040
cgggcctcac tcatatagat gcccactttt tatcccagac aaagcagagt ggggagaact 5100
ttccttacct ggtagcgtac caagccaccg tgtgcgctag ggctcaagcc cctcccccat 5160
cgtgggacca gatgtggaag tgtttgatcc gccttaaacc caccctccat gggccaacac 5220
ccctgctata cagactgggc gctgttcaga atgaagtcac cctgacgcac ccaatcacca 5280
aatacatcat gacatgcatg tcggccgacc tggaggtcgt cacgagcacc tgggtgctcg 5340
ttggcggcgt cctggctgct ctggccgcgt attgcctgtc aacaggctgc gtggtcatag 5400
tgggcaggat cgtcttgtcc gggaagccgg caattatacc tgacagggag gttctctacc 5460
aggagttcga tgagatggaa gagtgctctc agcacttacc gtacatcgag caagggatga 5520
tgctcgctga gcagttcaag cagaaggccc tcggcctcct gcagaccgcg tcccgccatg 5580
cagaggttat caccctgct gtccagacca actggcagaa actcgaggtc ttttgggcga 5640
agcacatgtg gaatttcatc agtgggatac aatacttggc gggcctgtca acgctgcctg 5700
gtaaccccgc cattgcttca ttgatggctt ttacagctgc cgtcaccagc ccactaacca 5760
ctggccaaac cctcctcttc aacatattgg gggggtgggt ggctgcccag ctcgccgccc 5820
ccggtgccgc tactgccttt gtgggtgctg gcctagctgg cgccgccatc ggcagcgttg 5880
gactggggaa ggtcctcgtg gacattcttg cagggtatgg cgcgggcgtg gcgggagctc 5940
ttgtagcatt caagatcatg agcggtgagg tcccctccac ggaggacctg gtcaatctgc 6000
tgcccgccat cctctcgcct ggagcccttg tagtcggtgt ggtctgcgca gcaatactgc 6060
gccggcacgt tggcccgggc gaggggggcag tgcaatggat gaaccggcta atagccttcg 6120
cctcccgggg gaaccatgtt tcccccacgc actacgtgcc ggagagcgat gcagccgccc 6180
gcgtcactgc catactcagc agcctcactg taacccagct cctgaggcga ctgcatcagt 6240
ggataagctc ggagtgtacc actccatgct ccggttcctg gctaagggac atctgggact 6300
ggatatgcga ggtgctgagc gactttaaga cctggctgaa agccaagctc atgccacaac 6360
tgcctgggat tccctttgtg tcctgccagc gcgggtatag gggggtctgg cgaggagacg 6420
gcattatgca cactcgctgc cactgtggag ctgagatcac tggacatgtc aaaaacggga 6480
cgatgaggat cgtcggtcct aggacctgca ggaacatgtg gagtgggacg ttccccatta 6540
acgcctacac cacgggcccc tgtactcccc ttcctgcgcc gaactataag ttcgcgctgt 6600
ggagggtgtc tgcagaggaa tacgtggaga taaggcgggt gggggacttc cactacgtat 6660
cgggtatgac tactgacaat cttaaatgcc cgtgccagat cccatcgccc gaatttttca 6720
cagaattgga cggggtgcgc ctacacaggt ttgcgccccc ttgcaagccc ttgctgcggg 6780
aggaggtatc attcagagta ggactccacg agtacccggt ggggtcgcaa ttaccttgcg 6840
agcccgaacc ggacgtagcc gtgttgacgt ccatgctcac tgatccctcc catataacag 6900
cagaggcggc cgggagaagg ttggcgagag ggtcaccccc ttctatggcc agctcctcgg 6960

ctagccagct gtccgctcca tctctcaagg caacttgcac cgccaaccat gactcccctg 7020
acgccgagct catagaggct aacctcctgt ggaggcagga gatgggcggc aacatcacca 7080
gggttgagtc agagaacaaa gtggtgattc tggactcctt cgatccgctt gtggcagagg 7140
aggatgagcg ggaggtctcc gtacctgcag aaattctgcg gaagtctcgg agattcgccc 7200
gggccctgcc cgtctgggcg cggccggact acaacccccc gctagtagag acgtggaaaa 7260
agcctgacta cgaaccacct gtggtccatg gctgcccgct accacctcca cggtcccctc 7320
ctgtgcctcc gcctcggaaa aagcgtacgg tggtcctcac cgaatcaacc ctatctactg 7380
ccttggccga gcttgccacc aaaagttttg gcagctcctc aacttccggc attacgggcg 7440
acaatacgac aacatcctct gagcccgccc cttctggctg ccccccccgac tccgacgttg 7500
agtcctattc ttccatgccc cccctggagg gggagcctgg ggatccggat ctcagcgacg 7560
ggtcatggtc gacggtcagt agtggggccg acacggaaga tgtcgtgtgc tgctcaatgt 7620
cttattcctg gacaggcgca ctcgtcaccc cgtgcgctgc ggaagaacaa aaactgccca 7680
tcaacgcact gagcaactcg ttgctacgcc atcacaatct ggtgtattcc accacttcac 7740
gcagtgcttg ccaaaggcag aagaaagtca catttgacag actgcaagtt ctggacagcc 7800
attaccagga cgtgctcaag gaggtcaaag cagcggcgtc aaaagtgaag gctaacttgc 7860
tatccgtaga ggaagcttgc agcctgacgc ccccacattc agccaaatcc aagtttggct 7920
atggggcaaa agacgtccgt tgccatgcca gaaaggccgt agcccacatc aactccgtgt 7980
ggaaagacct tctggaagac agtgtaacac caatagacac taccatcatg gccaagaacg 8040
aggttttctg cgttcagcct gagaaggggg gtcgtaagcc agctcgtctc atcgtgttcc 8100
ccgacctggg cgtgcgcgtg tgcgagaaga tggccctgta cgacgtggtt agcaagctcc 8160
ccctggccgt gatgggaagc tcctacggat tccaatactc accaggacag cgggttgaat 8220
tcctcgtgca agcgtggaag tccaagaaga ccccgatggg gttctcgtat gatacccgct 8280
gttttgactc cacagtcact gagagcgaca tccgtacgga ggaggcaatt taccaatgtt 8340
gtgacctgga cccccaagcc cgcgtggcca tcaagtcccc cactgagagg ctttatgttg 8400
ggggccctct taccaattca agggggggaaa actgcggcta ccgcaggtgc cgcgcgagcg 8460
gcgtactgac aactagctgt ggtaacaccc tcacttgcta catcaaggcc cgggcagcct 8520
gtcgagccgc agggctccag gactgcacca tgctcgtgtg tggcgacgac ttagtcgtta 8580
tctgtgaaag tgcgggggtc caggaggacg cggcgagcct gagagccttc acggaggcta 8640
tgaccaggta ctccgccccc cccggggacc ccccacaacc agaatacgac ttggagctta 8700
taacatcatg ctcctccaac gtgtcagtcg cccacgacgg cgctggaaag agggtctact 8760
accttacccg tgaccctaca acccccctcg cgagagccgc gtgggagaca gcaagacaca 8820
ctccagtcaa ttcctggcta ggcaacataa tcatgtttgc ccccacactg tgggcgagga 8880
tgatactgat gacccatttc tttagcgtcc tcatagccag ggatcagctt gaacaggctc 8940
ttaactgtga gatctacgga gcctgctact ccatagaacc actggatcta cctccaatca 9000
ttcaaagact ccatggcctc agcgcatttt cactccacag ttactctcca ggtgaaatca 9060
atagggtggc cgcatgcctc agaaaacttg gggtcccgcc cttgcgagct tggagacacc 9120
gggcccggag cgtccgcgct aggcttctgt ccagaggagg cagggctgct atatgtggca 9180
agtacctctt caactgggca gtaagaacaa agctcaaact cactccaata gcggccgctg 9240
gccggctgga cttgtccggt tggttcacgg ctggctacag cgggggagac atttatcaca 9300
gcgtgtctca tgcccggccc cgctggttct ggttttgcct actcctgctc gctgcagggg 9360
taggcatcta cctcctcccc aaccgatgaa ggttggggta aacactccgg cctcttaagc 9420
catttcctgt ttttttttt ttttttttt ttttttcttt ttttttttc tttcctttcc 9480
ttctttttt cctttctttt tcccttcttt aatggtggct ccatcttagc cctagtcacg 9540
gctagctgtg aaaggtccgt gagccgcatg actgcagaga gtgctgatac tggcctctct 9600
gcagatcatg t 9611

<210> 10

<211> 3015
<212> PRT
<213> Hepatitis C virus

<400> 10

```
Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn
  1               5                  10                  15

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly
             20                  25                  30

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala
         35                  40                  45

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro
     50                  55                  60

Ile Pro Lys Asp Arg Arg Ser Thr Gly Lys Ser Trp Gly Lys Pro Gly
 65                  70                  75                  80

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Leu Gly Trp Ala Gly Trp
                 85                  90                  95

Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Asn Asp Pro
            100                 105                 110

Arg His Arg Ser Arg Asn Val Gly Lys Val Ile Asp Thr Leu Thr Cys
        115                 120                 125

Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Val Val Gly Ala Pro Leu
    130                 135                 140

Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp
145                 150                 155                 160

Gly Val Asn Phe Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile
                165                 170                 175

Phe Leu Leu Ala Leu Leu Ser Cys Ile Thr Thr Pro Val Ser Ala Ala
            180                 185                 190

Glu Val Lys Asn Ile Ser Thr Gly Tyr Met Val Thr Asn Asp Cys Thr
        195                 200                 205

Asn Asp Ser Ile Thr Trp Gln Leu Gln Ala Ala Val Leu His Val Pro
    210                 215                 220

Gly Cys Val Pro Cys Glu Lys Val Gly Asn Ala Ser Gln Cys Trp Ile
```

225 230 235 240

Pro Val Ser Pro Asn Val Ala Val Gln Arg Pro Gly Ala Leu Thr Gln
245 250 255

Gly Leu Arg Thr His Ile Asp Met Val Val Met Ser Ala Thr Leu Cys
260 265 270

Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Gly Val Met Leu Ala Ala
275 280 285

Gln Met Phe Ile Val Ser Pro Gln His His Trp Phe Val Gln Asp Cys
290 295 300

Asn Cys Ser Ile Tyr Pro Gly Thr Ile Thr Gly His Arg Met Ala Trp
305 310 315 320

Asp Met Met Met Asn Trp Ser Pro Thr Ala Thr Met Ile Leu Ala Tyr
325 330 335

Ala Met Arg Val Pro Glu Val Ile Ile Asp Ile Ile Ser Gly Ala His
340 345 350

Trp Gly Val Met Phe Gly Leu Ala Tyr Phe Ser Met Gln Gly Ala Trp
355 360 365

Ala Lys Val Val Val Ile Leu Leu Leu Ala Ala Gly Val Asp Ala Arg
370 375 380

Thr His Thr Val Gly Gly Ser Ala Ala Gln Thr Thr Gly Arg Leu Thr
385 390 395 400

Ser Leu Phe Asp Met Gly Pro Arg Gln Lys Ile Gln Leu Val Asn Thr
405 410 415

Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser
420 425 430

Leu His Thr Gly Phe Ile Ala Ser Leu Phe Tyr Thr His Ser Phe Asn
435 440 445

Ser Ser Gly Cys Pro Glu Arg Met Ser Ala Cys Arg Ser Ile Glu Ala
450 455 460

Phe Arg Val Gly Trp Gly Ala Leu Gln Tyr Glu Asp Asn Val Thr Asn
465 470 475 480

Pro Glu Asp Met Arg Pro Tyr Cys Trp His Tyr Pro Pro Arg Gln Cys

485 490 495

Gly Val Val Ser Ala Lys Thr Val Cys Gly Pro Val Tyr Cys Phe Thr
500 505 510

Pro Ser Pro Val Val Val Gly Thr Thr Asp Arg Leu Gly Ala Pro Thr
515 520 525

Tyr Thr Trp Gly Glu Asn Glu Thr Asp Val Phe Leu Leu Asn Ser Thr
530 535 540

Arg Pro Pro Leu Gly Ser Trp Phe Gly Cys Thr Trp Met Asn Ser Ser
545 550 555 560

Gly Tyr Thr Lys Thr Cys Gly Ala Pro Pro Cys Arg Thr Arg Ala Asp
565 570 575

Phe Asn Ala Ser Thr Asp Leu Leu Cys Pro Thr Asp Cys Phe Arg Lys
580 585 590

His Pro Asp Thr Thr Tyr Leu Lys Cys Gly Ser Gly Pro Trp Leu Thr
595 600 605

Pro Arg Cys Leu Ile Asp Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys
610 615 620

Thr Val Asn Tyr Thr Ile Phe Lys Ile Arg Met Tyr Val Gly Gly Val
625 630 635 640

Glu His Arg Leu Thr Ala Ala Cys Asn Phe Thr Arg Gly Asp Arg Cys
645 650 655

Asn Leu Glu Asp Arg Asp Arg Ser Gln Leu Ser Pro Leu Leu His Ser
660 665 670

Thr Thr Glu Trp Ala Ile Leu Pro Cys Ser Tyr Ser Asp Leu Pro Ala
675 680 685

Leu Ser Thr Gly Leu Leu His Leu His Gln Asn Ile Val Asp Val Gln
690 695 700

Phe Met Tyr Gly Leu Ser Pro Ala Leu Thr Lys Tyr Ile Val Arg Trp
705 710 715 720

Glu Trp Val Ile Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Val Cys
725 730 735

Ala Cys Leu Trp Met Leu Ile Leu Leu Gly Gln Ala Glu Ala Ala Leu

740 745 750

Glu Asn Leu Val Ile Leu Asn Ala Ala Ser Leu Ala Gly Thr His Gly
755 760 765

Leu Val Ser Phe Leu Val Phe Phe Cys Phe Ala Trp Tyr Leu Lys Gly
770 775 780

Arg Trp Val Pro Gly Ala Val Tyr Ala Leu Tyr Gly Met Trp Pro Leu
785 790 795 800

Leu Leu Leu Leu Leu Ala Leu Pro Gln Arg Ala Tyr Ala Leu Asp Thr
805 810 815

Glu Val Ala Ala Ser Cys Gly Gly Val Val Leu Val Gly Leu Met Ala
820 825 830

Leu Thr Leu Ser Pro Tyr Tyr Lys Arg Tyr Ile Ser Trp Cys Met Trp
835 840 845

Trp Leu Gln Tyr Phe Leu Thr Arg Val Glu Ala Gln Leu His Val Trp
850 855 860

Val Pro Pro Leu Asn Val Arg Gly Gly Arg Asp Ala Val Ile Leu Leu
865 870 875 880

Met Cys Val Val His Pro Thr Leu Val Phe Asp Ile Thr Lys Leu Leu
885 890 895

Leu Ala Ile Phe Gly Pro Leu Trp Ile Leu Gln Ala Ser Leu Leu Lys
900 905 910

Val Pro Tyr Phe Val Arg Val Gln Gly Leu Leu Arg Ile Cys Ala Leu
915 920 925

Ala Arg Lys Ile Ala Gly Gly His Tyr Val Gln Met Ala Ile Ile Lys
930 935 940

Leu Gly Ala Leu Thr Gly Thr Tyr Val Tyr Asn His Leu Thr Pro Leu
945 950 955 960

Arg Asp Trp Ala His Asn Gly Leu Arg Asp Leu Ala Val Ala Val Glu
965 970 975

Pro Val Val Phe Ser Arg Met Glu Thr Lys Leu Ile Thr Trp Gly Ala
980 985 990

Asp Thr Ala Ala Cys Gly Asp Ile Ile Asn Gly Leu Pro Val Ser Ala

995 1000 1005

Arg Arg Gly Gln Glu Ile Leu Leu Gly Pro Ala Asp Gly Met Val Ser
1010 1015 1020

Lys Gly Trp Arg Leu Leu Ala Pro Ile Thr Ala Tyr Ala Gln Gln Thr
1025 1030 1035 1040

Arg Gly Leu Leu Gly Cys Ile Ile Thr Ser Leu Thr Gly Arg Asp Lys
1045 1050 1055

Asn Gln Val Glu Gly Glu Val Gln Ile Val Ser Thr Ala Thr Gln Thr
1060 1065 1070

Phe Leu Ala Thr Cys Ile Asn Gly Val Cys Trp Thr Val Tyr His Gly
1075 1080 1085

Ala Gly Thr Arg Thr Ile Ala Ser Pro Lys Gly Pro Val Ile Gln Met
1090 1095 1100

Tyr Thr Asn Val Asp Gln Asp Leu Val Gly Trp Pro Ala Pro Gln Gly
1105 1110 1115 1120

Ser Arg Ser Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu
1125 1130 1135

Val Thr Arg His Ala Asp Val Ile Pro Val Arg Arg Arg Gly Asp Ser
1140 1145 1150

Arg Gly Ser Leu Leu Ser Pro Arg Pro Ile Ser Tyr Leu Lys Gly Ser
1155 1160 1165

Ser Gly Gly Pro Leu Leu Cys Pro Ala Gly His Ala Val Gly Leu Phe
1170 1175 1180

Arg Ala Ala Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Ile
1185 1190 1195 1200

Pro Val Glu Asn Leu Gly Thr Thr Met Arg Ser Pro Val Phe Thr Asp
1205 1210 1215

Asn Ser Ser Pro Pro Ala Val Pro Gln Ser Phe Gln Val Ala His Leu
1220 1225 1230

His Ala Pro Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr
1235 1240 1245

Ala Ala Gln Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala

1250 1255 1260

Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala His Gly Val Asp Pro
1265 1270 1275 1280

Asn Ile Arg Thr Gly Val Arg Thr Ile Thr Thr Gly Ser Pro Ile Thr
1285 1290 1295

Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly
1300 1305 1310

Ala Tyr Asp Ile Ile Ile Cys Asp Glu Cys His Ser Thr Asp Ala Thr
1315 1320 1325

Ser Ile Leu Gly Ile Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Gly
1330 1335 1340

Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr
1345 1350 1355 1360

Val Ser His Pro Asn Ile Glu Glu Val Ala Leu Ser Thr Thr Gly Glu
1365 1370 1375

Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu Val Ile Lys Gly Gly
1380 1385 1390

Arg His Leu Ile Phe Cys His Ser Lys Lys Lys Cys Asp Glu Leu Ala
1395 1400 1405

Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly
1410 1415 1420

Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp Val Val Val Val Ser
1425 1430 1435 1440

Thr Asp Ala Leu Met Thr Gly Phe Thr Gly Asp Phe Asp Ser Val Ile
1445 1450 1455

Asp Cys Asn Thr Cys Val Thr Gln Thr Val Asp Phe Ser Leu Asp Pro
1460 1465 1470

Thr Phe Thr Ile Glu Thr Thr Thr Leu Pro Gln Asp Ala Val Ser Arg
1475 1480 1485

Thr Gln Arg Arg Gly Arg Thr Gly Arg Gly Lys Pro Gly Ile Tyr Arg
1490 1495 1500

Phe Val Ala Pro Gly Glu Arg Pro Ser Gly Met Phe Asp Ser Ser Val

1505 1510 1515 1520

Leu Cys Glu Cys Tyr Asp Ala Gly Cys Ala Trp Tyr Glu Leu Thr Pro
1525 1530 1535

Ala Glu Thr Thr Val Arg Leu Arg Ala Tyr Met Asn Thr Pro Gly Leu
1540 1545 1550

Pro Val Cys Gln Asp His Leu Glu Phe Trp Glu Gly Val Phe Thr Gly
1555 1560 1565

Leu Thr His Ile Asp Ala His Phe Leu Ser Gln Thr Lys Gln Ser Gly
1570 1575 1580

Glu Asn Phe Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg
1585 1590 1595 1600

Ala Gln Ala Pro Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile
1605 1610 1615

Arg Leu Lys Pro Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu
1620 1625 1630

Gly Ala Val Gln Asn Glu Val Thr Leu Thr His Pro Ile Thr Lys Tyr
1635 1640 1645

Ile Met Thr Cys Met Ser Ala Asp Leu Glu Val Val Thr Ser Thr Trp
1650 1655 1660

Val Leu Val Gly Gly Val Leu Ala Ala Leu Ala Ala Tyr Cys Leu Ser
1665 1670 1675 1680

Thr Gly Cys Val Val Ile Val Gly Arg Ile Val Leu Ser Gly Lys Pro
1685 1690 1695

Ala Ile Ile Pro Asp Arg Glu Val Leu Tyr Gln Glu Phe Asp Glu Met
1700 1705 1710

Glu Glu Cys Ser Gln His Leu Pro Tyr Ile Glu Gln Gly Met Met Leu
1715 1720 1725

Ala Glu Gln Phe Lys Gln Lys Ala Leu Gly Leu Leu Gln Thr Ala Ser
1730 1735 1740

Arg His Ala Glu Val Ile Thr Pro Ala Val Gln Thr Asn Trp Gln Lys
1745 1750 1755 1760

Leu Glu Val Phe Trp Ala Lys His Met Trp Asn Phe Ile Ser Gly Ile

1765 1770 1775

Gln Tyr Leu Ala Gly Leu Ser Thr Leu Pro Gly Asn Pro Ala Ile Ala
1780 1785 1790

Ser Leu Met Ala Phe Thr Ala Ala Val Thr Ser Pro Leu Thr Thr Gly
1795 1800 1805

Gln Thr Leu Leu Phe Asn Ile Leu Gly Gly Trp Val Ala Ala Gln Leu
1810 1815 1820

Ala Ala Pro Gly Ala Ala Thr Ala Phe Val Gly Ala Gly Leu Ala Gly
1825 1830 1835 1840

Ala Ala Ile Gly Ser Val Gly Leu Gly Lys Val Leu Val Asp Ile Leu
1845 1850 1855

Ala Gly Tyr Gly Ala Gly Val Ala Gly Ala Leu Val Ala Phe Lys Ile
1860 1865 1870

Met Ser Gly Glu Val Pro Ser Thr Glu Asp Leu Val Asn Leu Leu Pro
1875 1880 1885

Ala Ile Leu Ser Pro Gly Ala Leu Val Val Gly Val Val Cys Ala Ala
1890 1895 1900

Ile Leu Arg Arg His Val Gly Pro Gly Glu Gly Ala Val Gln Trp Met
1905 1910 1915 1920

Asn Arg Leu Ile Ala Phe Ala Ser Arg Gly Asn His Val Ser Pro Thr
1925 1930 1935

His Tyr Val Pro Glu Ser Asp Ala Ala Ala Arg Val Thr Ala Ile Leu
1940 1945 1950

Ser Ser Leu Thr Val Thr Gln Leu Leu Arg Arg Leu His Gln Trp Ile
1955 1960 1965

Ser Ser Glu Cys Thr Thr Pro Cys Ser Gly Ser Trp Leu Arg Asp Ile
1970 1975 1980

Trp Asp Trp Ile Cys Glu Val Leu Ser Asp Phe Lys Thr Trp Leu Lys
1985 1990 1995 2000

Ala Lys Leu Met Pro Gln Leu Pro Gly Ile Pro Phe Val Ser Cys Gln
2005 2010 2015

Arg Gly Tyr Arg Gly Val Trp Arg Gly Asp Gly Ile Met His Thr Arg

2020 2025 2030

Cys His Cys Gly Ala Glu Ile Thr Gly His Val Lys Asn Gly Thr Met
2035 2040 2045

Arg Ile Val Gly Pro Arg Thr Cys Arg Asn Met Trp Ser Gly Thr Phe
2050 2055 2060

Pro Ile Asn Ala Tyr Thr Thr Gly Pro Cys Thr Pro Leu Pro Ala Pro
2065 2070 2075 2080

Asn Tyr Lys Phe Ala Leu Trp Arg Val Ser Ala Glu Glu Tyr Val Glu
2085 2090 2095

Ile Arg Arg Val Gly Asp Phe His Tyr Val Ser Gly Met Thr Thr Asp
2100 2105 2110

Asn Leu Lys Cys Pro Cys Gln Ile Pro Ser Pro Glu Phe Phe Thr Glu
2115 2120 2125

Leu Asp Gly Val Arg Leu His Arg Phe Ala Pro Pro Cys Lys Pro Leu
2130 2135 2140

Leu Arg Glu Glu Val Ser Phe Arg Val Gly Leu His Glu Tyr Pro Val
2145 2150 2155 2160

Gly Ser Gln Leu Pro Cys Glu Pro Glu Pro Asp Val Ala Val Leu Thr
2165 2170 2175

Ser Met Leu Thr Asp Pro Ser His Ile Thr Ala Glu Ala Ala Gly Arg
2180 2185 2190

Arg Leu Ala Arg Gly Ser Pro Pro Ser Met Ala Ser Ser Ser Ala Ser
2195 2200 2205

Gln Leu Ser Ala Pro Ser Leu Lys Ala Thr Cys Thr Ala Asn His Asp
2210 2215 2220

Ser Pro Asp Ala Glu Leu Ile Glu Ala Asn Leu Leu Trp Arg Gln Glu
2225 2230 2235 2240

Met Gly Gly Asn Ile Thr Arg Val Glu Ser Glu Asn Lys Val Val Ile
2245 2250 2255

Leu Asp Ser Phe Asp Pro Leu Val Ala Glu Glu Asp Glu Arg Glu Val
2260 2265 2270

Ser Val Pro Ala Glu Ile Leu Arg Lys Ser Arg Arg Phe Ala Arg Ala

2275 2280 2285

Leu Pro Val Trp Ala Arg Pro Asp Tyr Asn Pro Pro Leu Val Glu Thr
2290 2295 2300

Trp Lys Lys Pro Asp Tyr Glu Pro Pro Val Val His Gly Cys Pro Leu
2305 2310 2315 2320

Pro Pro Pro Arg Ser Pro Pro Val Pro Pro Pro Arg Lys Lys Arg Thr
2325 2330 2335

Val Val Leu Thr Glu Ser Thr Leu Ser Thr Ala Leu Ala Glu Leu Ala
2340 2345 2350

Thr Lys Ser Phe Gly Ser Ser Ser Thr Ser Gly Ile Thr Gly Asp Asn
2355 2360 2365

Thr Thr Thr Ser Ser Glu Pro Ala Pro Ser Gly Cys Pro Pro Asp Ser
2370 2375 2380

Asp Val Glu Ser Tyr Ser Ser Met Pro Pro Leu Glu Gly Glu Pro Gly
2385 2390 2395 2400

Asp Pro Asp Leu Ser Asp Gly Ser Trp Ser Thr Val Ser Ser Gly Ala
2405 2410 2415

Asp Thr Glu Asp Val Val Cys Cys Ser Met Ser Tyr Ser Trp Thr Gly
2420 2425 2430

Ala Leu Val Thr Pro Cys Ala Ala Glu Glu Gln Lys Leu Pro Ile Asn
2435 2440 2445

Ala Leu Ser Asn Ser Leu Leu Arg His His Asn Leu Val Tyr Ser Thr
2450 2455 2460

Thr Ser Arg Ser Ala Cys Gln Arg Gln Lys Lys Val Thr Phe Asp Arg
2465 2470 2475 2480

Leu Gln Val Leu Asp Ser His Tyr Gln Asp Val Leu Lys Glu Val Lys
2485 2490 2495

Ala Ala Ala Ser Lys Val Lys Ala Asn Leu Leu Ser Val Glu Glu Ala
2500 2505 2510

Cys Ser Leu Thr Pro Pro His Ser Ala Lys Ser Lys Phe Gly Tyr Gly
2515 2520 2525

Ala Lys Asp Val Arg Cys His Ala Arg Lys Ala Val Ala His Ile Asn

2530 2535 2540

Ser Val Trp Lys Asp Leu Leu Glu Asp Ser Val Thr Pro Ile Asp Thr
2545 2550 2555 2560

Thr Ile Met Ala Lys Asn Glu Val Phe Cys Val Gln Pro Glu Lys Gly
2565 2570 2575

Gly Arg Lys Pro Ala Arg Leu Ile Val Phe Pro Asp Leu Gly Val Arg
2580 2585 2590

Val Cys Glu Lys Met Ala Leu Tyr Asp Val Val Ser Lys Leu Pro Leu
2595 2600 2605

Ala Val Met Gly Ser Ser Tyr Gly Phe Gln Tyr Ser Pro Gly Gln Arg
2610 2615 2620

Val Glu Phe Leu Val Gln Ala Trp Lys Ser Lys Lys Thr Pro Met Gly
2625 2630 2635 2640

Phe Ser Tyr Asp Thr Arg Cys Phe Asp Ser Thr Val Thr Glu Ser Asp
2645 2650 2655

Ile Arg Thr Glu Glu Ala Ile Tyr Gln Cys Cys Asp Leu Asp Pro Gln
2660 2665 2670

Ala Arg Val Ala Ile Lys Ser Leu Thr Glu Arg Leu Tyr Val Gly Gly
2675 2680 2685

Pro Leu Thr Asn Ser Arg Gly Glu Asn Cys Gly Tyr Arg Arg Cys Arg
2690 2695 2700

Ala Ser Gly Val Leu Thr Thr Ser Cys Gly Asn Thr Leu Thr Cys Tyr
2705 2710 2715 2720

Ile Lys Ala Arg Ala Ala Cys Arg Ala Ala Gly Leu Gln Asp Cys Thr
2725 2730 2735

Met Leu Val Cys Gly Asp Asp Leu Val Val Ile Cys Glu Ser Ala Gly
2740 2745 2750

Val Gln Glu Asp Ala Ala Ser Leu Arg Ala Phe Thr Glu Ala Met Thr
2755 2760 2765

Arg Tyr Ser Ala Pro Pro Gly Asp Pro Pro Gln Pro Glu Tyr Asp Leu
2770 2775 2780

Glu Leu Ile Thr Ser Cys Ser Ser Asn Val Ser Val Ala His Asp Gly

2785 2790 2795 2800

Ala Gly Lys Arg Val Tyr Tyr Leu Thr Arg Asp Pro Thr Thr Pro Leu
2805 2810 2815

Ala Arg Ala Ala Trp Glu Thr Ala Arg His Thr Pro Val Asn Ser Trp
2820 2825 2830

Leu Gly Asn Ile Ile Met Phe Ala Pro Thr Leu Trp Ala Arg Met Ile
2835 2840 2845

Leu Met Thr His Phe Phe Ser Val Leu Ile Ala Arg Asp Gln Leu Glu
2850 2855 2860

Gln Ala Leu Asn Cys Glu Ile Tyr Gly Ala Cys Tyr Ser Ile Glu Pro
2865 2870 2875 2880

Leu Asp Leu Pro Pro Ile Ile Gln Arg Leu His Gly Leu Ser Ala Phe
2885 2890 2895

Ser Leu His Ser Tyr Ser Pro Gly Glu Ile Asn Arg Val Ala Ala Cys
2900 2905 2910

Leu Arg Lys Leu Gly Val Pro Pro Leu Arg Ala Trp Arg His Arg Ala
2915 2920 2925

Arg Ser Val Arg Ala Arg Leu Leu Ser Arg Gly Gly Arg Ala Ala Ile
2930 2935 2940

Cys Gly Lys Tyr Leu Phe Asn Trp Ala Val Arg Thr Lys Leu Lys Leu
2945 2950 2955 2960

Thr Pro Ile Ala Ala Ala Gly Arg Leu Asp Leu Ser Gly Trp Phe Thr
2965 2970 2975

Ala Gly Tyr Ser Gly Gly Asp Ile Tyr His Ser Val Ser His Ala Arg
2980 2985 2990

Pro Arg Trp Phe Trp Phe Cys Leu Leu Leu Leu Ala Ala Gly Val Gly
2995 3000 3005

Ile Tyr Leu Leu Pro Asn Arg
3010 3015

<210> 11
<211> 24
<212> DNA

<213> Hepatitis C virus

<400> 11
actggacacg gaggtggccg cgtc 24

<210> 12
<211> 24
<212> DNA
<213> Hepatitis C virus

<400> 12
ttgttcttgt cgggttaatg gcgc 24

<210> 13
<211> 24
<212> DNA
<213> Hepatitis C virus

<400> 13
gggtgtacta cacacatgag taag 24

<210> 14
<211> 22
<212> DNA
<213> Hepatitis C virus

<400> 14
aagcgcccct aacttgatga tg 22

<210> 15
<211> 40
<212> DNA
<213> Hepatitis C virus

<400> 15
cgtcatcgat acctcagcgg gcatatgcac tggacacgga 40

<210> 16
<211> 24
<212> DNA
<213> Hepatitis C virus

<400> 16

gtccagtgca tatgcccgct gagg 24

<210> 17
<211> 32
<212> DNA
<213> Hepatitis C virus

<400> 17
catgcaccag ctgatatagc gcttgtaata tg 32

<210> 18
<211> 30
<212> DNA
<213> Hepatitis C virus

<400> 18
tccgtagagg aagcttgcag cctgacgccc 30

<210> 19
<211> 34
<212> DNA
<213> Hepatitis C virus

<400> 19
cagaggaggc agggctgcta tatgtggcaa gtac 34

<210> 20
<211> 34
<212> DNA
<213> Hepatitis C virus

<400> 20
gtacttgcca catatagcag ccctgcctcc tctg 34

<210> 21
<211> 43
<212> DNA
<213> Hepatitis C virus

<400> 21
cgtctctaga caggaaatgg cttaagaggc cggagtgttt acc 43

<210> 22
<211> 65
<212> DNA
<213> Hepatitis C virus

<400> 22
ttatggatgc tcatcttgtt gggccaggcc gaagcagctt tggagaacct cgtaatactc 60
aatgc 65

<210> 23
<211> 32
<212> DNA
<213> Hepatitis C virus

<400> 23
aggatttgtg ctcatggtgc acggtctacg ag 32

<210> 24
<211> 50
<212> DNA
<213> Hepatitis C virus

<400> 24
tttttttgc ggccgctaat acgactcact atagacccgc ccctaatagg 50

<210> 25
<211> 31
<212> DNA
<213> Hepatitis C virus

<400> 25
ccgtgcacca tgagcacaaa tcctaaacct c 31

<210> 26
<211> 26
<212> DNA
<213> Hepatitis C virus

<400> 26
ggatgtaccc catgaggtcg gcaaag 26

<210> 27
<211> 30

<212> DNA
<213> Hepatitis C virus

<400> 27
gtttgcgcct gcttatggat gctcatcttg 30

<210> 28
<211> 26
<212> DNA
<213> Hepatitis C virus

<400> 28
gcgtcataag catatgcctg ttgggg 26

<210> 29
<211> 23
<212> DNA
<213> Hepatitis C virus

<400> 29
ccctcagcac tggagtacat ctg 23

<210> 30
<211> 39
<212> DNA
<213> Hepatitis C virus

<400> 30
cgtcatgcat acccctaggg cggctctcat tgaagaggg 39

<210> 31
<211> 30
<212> DNA
<213> Hepatitis C virus

<400> 31
cgtcccctct tcaatgagag ccgctctaga 30

<210> 32
<211> 28
<212> DNA
<213> Hepatitis C virus

<400> 32
gcggtgaaga ccaagctcaa actcactc 28

<210> 33
<211> 41
<212> DNA
<213> Hepatitis C virus

<400> 33
aatctagaag gcgcgcttcc ggcaatggag tgagtttgag c 41

<210> 34
<211> 38
<212> DNA
<213> Hepatitis C virus

<400> 34
cgtctctaga ggataaatcc aggaggcgcg cttccggc 38

<210> 35
<211> 27
<212> DNA
<213> Hepatitis C virus

<400> 35
tacttttttgt aggggtaggc cttttcc 27

<210> 36
<211> 34
<212> DNA
<213> Hepatitis C virus

<400> 36
cgtctctaga gtgtagctaa tgtgtgccgc tcta 34

<210> 37
<211> 24
<212> DNA
<213> Hepatitis C virus

<400> 37
ctatggagtg tagctaatgt gtgc 24

<210> 38
<211> 66
<212> DNA
<213> Hepatitis C virus

<400> 38
cgtctctaga catgatctgc agagagacca gttacggcac tctctgcagt catgcggctc 60
acggac 66

<210> 39
<211> 41
<212> DNA
<213> Hepatitis C virus

<400> 39
ctttcacagc tagccgtgac tagggctaag atggagccac c 41

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 December 2000 (14.12.2000)

PCT

(10) International Publication Number
WO 00/75338 A3

(51) International Patent Classification[7]: C12N 15/51, C07K 14/18, 16/18, A61K 38/00, 39/00

(21) International Application Number: PCT/US00/15446

(22) International Filing Date: 2 June 2000 (02.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/137,693 4 June 1999 (04.06.1999) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 60/137,693 (CON)
Filed on 4 June 1999 (04.06.1999)

(71) Applicant *(for all designated States except US)*: **THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES** [US/US]; Office of Technology Transfer, National Institutes of Health, Suite 325, 6011 Executive Boulevard, Rockville, MD 20852 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **YANAGI, Masayuki** [JP/US]; 257 Congressional Lane, #402, Rockville, MD 20852 (US). **BUKH, Jens** [DK/US]; 2018 Baltimore Road #J42, Rockville, MD 20851 (US). **EMERSON, Suzanne, U.** [US/US]; 4517 Everett Street, Kensington, MD 20895 (US). **PURCELL, Robert, H.** [US/US]; 17517 White Ground Road, Boyds, MD 20841 (US).

(74) Agents: **FEILER, William, S.** et al.; Morgan & Finnegan, L.L.P., 345 Park Avenue, New York, NY 10154 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(88) Date of publication of the international search report:
1 November 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CLONED GENONE OF INFECTIOUS HEPATITIS C VIRUS OF GENOTYPE 2a AND USES THEREOF



(57) Abstract: The present invention discloses nucleic acid sequence which encodes infectious hepatitis C virus of strain HC-J6$_{CH}$, genotype 2a, and the use of the sequence, and polypeptides encoded by all or part of the sequence, in the development of vaccines and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV.

WO 00/75338 A3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/15446

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/51 C07K14/18 C07K16/18 A61K38/00 A61K39/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07K C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, EMBASE, MEDLINE, STRAND, CAB Data, WPI Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	EP 0 532 167 A (JAPAN IMMUNO INC) 17 March 1993 (1993-03-17) the whole document	1-37
X	H. OKAMOTO ET AL.: "Nucleotide sequence of the genomic RNA of hepatitis C virus isolated from a human carrier: comparison with reported isolates for conserved and divergent regions." JOURNAL OF GENERAL VIROLOGY, vol. 72, 1991, pages 2697-2704, XP000911895 the whole document	1-37

-/—

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
6 February 2001	23. 02. 2001

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016	Hix, R

3

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/15446

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	HAN J H ET AL: "GROUP SPECIFIC SEQUENCES AND CONSERVED SECONDARY STRUCTURE AT THE 3' END OF HCV GENOME AND ITS IMPLICATION FOR VIRAL REPLICATION" NUCLEIC ACIDS RESEARCH,OXFORD UNIVERSITY PRESS, SURREY,GB, vol. 20, no. 13, April 1992 (1992-04), page 3520 XP000938816 ISSN: 0305-1048 the whole document	1-3
Y	M. YANAGI ET AL.: "Transcripts of a chimeric cDNA clone of Hepatitis C virus genotype 1b are infectious in vivo." VIROLOGY, vol. 244, 1998, pages 161-172, XP002149625 cited in the application the whole document	1-20,23, 24,29-37
Y	OHNO T. ET AL: "New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a." JOURNAL OF CLINICAL MICROBIOLOGY, (1997) 35/1 (201-207)., XP000911892 the whole document	1-20,23, 24,29-37
Y	HASHIMOTO M. ET AL: "Typing six major hepatitis C virus genotypes by polymerase chain reaction using primers derived from nucleotide sequences of the NS5 region." INTERNATIONAL HEPATOLOGY COMMUNICATIONS, (1996) 4/5 (263-267)., XP000911896 the whole document	1-20,23, 24,29-37
Y	YONG YUAN ZHANG ET AL: "Greater diversity of hepatitis C virus genotypes found in Hong Kong than in Mainland China." JOURNAL OF CLINICAL MICROBIOLOGY, (1995) 33/11 (2931-2934)., XP000911893 the whole document	1-20,23, 24,29-37
Y	FOX S A ET AL: "Rapid genotyping of hepatitis C virus isolates by dideoxy fingerprinting." JOURNAL OF VIROLOGICAL METHODS, (1995 MAY) 53 (1) 1-9., XP000911899 the whole document	1-20,23, 24,29-37

-/--

3

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/15446

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	M. YANAGI ET AL.: "Hepatitis C Virus: An infectious molecular clone of a second major genotype (2a) and lack of viability of intertypic 1a and 2a chimeras." VIROLOGY, vol. 262, 1999, pages 250-263, XP000911930 the whole document	1-37
Y	DE FRANCESCO R. ET AL: "A zinc binding site in viral serine proteinases." BIOCHEMISTRY, (1996) 35/41 (13282-13287), XP000981213 the whole document	12-26, 29-32, 35-37
Y	STEMPNIAK M. ET AL: "The NS3 proteinase domain of hepatitis C virus is a zinc-containing enzyme." JOURNAL OF VIROLOGY, (1997) 71/4 (2881-2886), XP000981212 the whole document	12-26, 29-32, 35-37
Y	Y.M. PARK ET AL.: "Monitoring antibody titers to recombinant core-NS3 fusion polypeptide is useful for evaluating hepatitis C virus infection and responses to interferon-alpha therapy" J. KOREAN MED. SCI., vol. 14, April 1999 (1999-04), pages 165-170, XP000980030 the whole document	12-32, 35-37
Y	L.M. MISON ET AL.: "Prevalence of hepatitis C virus and genotype distribution in an Australian volunteer blood donor population." TRANSFUSION, vol. 37, January 1997 (1997-01), pages 73-78, XP000981247 the whole document	12-26, 29-32, 35-37
P,X	WRIGHT-MINOGUE J. ET AL: "Cross-genotypic interaction between hepatitis C virus NS3 protease domains and NS4A cofactors." JOURNAL OF HEPATOLOGY, (2000) 32/3 (497-504)., XP000981249 the whole document	12-26, 29-32, 35-37
A	WO 91 15575 A (CHIRON CORP) 17 October 1991 (1991-10-17) the whole document	12-26, 29-32, 35-37

-/-

3

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/15446

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No
Y	MARTIN J. ET AL: "In vitro effect of amantadine and interferon.alpha.- 2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus-infected patients." ANTIVIRAL RESEARCH, (1999) 42/1 (59-70). , XP000980547 the whole document	23-28
Y	URUSHIHARA A. ET AL: "Changes in antibody titers to hepatitis C virus following interferon therapy for chronic infection." JOURNAL OF MEDICAL VIROLOGY, (1994) 42/4 (348-356). , XP000980020 the whole document	23-28
Y	D.L. SALI ET AL.: "Serine protease of Hepatitis C virus expressed in insect cells as the NS3/4A complex" BIOCHEMISTRY, vol. 37, no. 10, 1998, pages 3392-3401, XP002159433 the whole document	25,26
P,X	WO 00 26418 A (UNIV LELAND STANFORD JUNIOR) 11 May 2000 (2000-05-11) the whole document	12-24, 27-32, 35-37
X	P.L. CALVO ET AL.: "Hepatitis C virus heteroduplex tracking assay for genotype determination reveals diverging Genotype 2 isolates in Italian hemodialysis patients." JOURNAL OF CLINICAL MICROBIOLOGY, vol. 36, no. 1, January 1998 (1998-01), pages 227-233, XP000981214 the whole document	12-24, 29-32, 35-37
X	BUKH J ET AL: "At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 90, September 1994 (1994-09), pages 8234-8238, XP002159434 ISSN: 0027-8424 cited in the application the whole document	12-24, 29-32, 35-37

-/—

3

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/15446

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
X	P. SIMMONDS ET AL.: "Identification of genotypes of hepatitis C virus by sequence comparisons in the core, E1 and NS-5 regions." JOURNAL OF GENERAL VIROLOGY, vol. 75, 1994, pages 1053-1061, XP000979107 the whole document	12-24, 29-32, 35-37
A	L.J. VAN DOORN ET AL.: "Sequence analysis of hepatitis C virus genotypes 1 to 5 reveals multiple novel subtypes in the Benelux countries." JOURNAL OF GENERAL VIROLOGY., vol. 76, 1995, pages 1871-1876, XP000979102 the whole document	12-24, 29-32, 35-37
X	WU CHAODONG ET AL.: "Antibody response to E2 glycoprotein induced in mice by immunization with plasmid DNA containing sequence derived from a Chinese genotype III/2a isolate of hepatitis C virus." CHINESE MEDICAL JOURNAL, vol. 112, no. 2, February 1999 (1999-02), pages 166-168, XP000980092 the whole document	12-24, 29-32, 35-37
X	N. YUKI ET AL.: "Quantitative analysis of antibody to Hepatitis C virus Envelope 2 Glycoprotein in patients with chronic Hepatitis C virus infection." HEPTOLOGY, vol. 23, no. 5, May 1996 (1996-05), pages 947-952, XP000981263 the whole document	29-32
X	G. LONGOMBARDO ET AL.: "Immune response to an epitope of the NS4 protein of Hepatitis C virus in HCV-related disorders." CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. 87, May 1998 (1998-05), pages 124-129, XP000981260 the whole document	12-22, 29-32
X	F. FABRIZI ET AL.: "Hepatitis C virus genotpyes in chronic dialysis patients." NEPHROL. DIAL. TRANSPLANT., vol. 11, 1996, pages 679-683, XP000981328 the whole document	29-32

-/--

3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/15446

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	H-H. LIN ET AL.: "Serotypes, genotypes and levels of Hepatitis C Viremia in pregnant women in Taiwan." J. FORMOS MEDL ASSOC. , vol. 95, no. 6, 1996, pages 429-434, XP000981246 the whole document	29-32
X	M. DEVESA ET AL.: "Reduced antibody reactivity to Hepatitis C virus antigen in Hemodialysis patients coinfected with hepatitis B virus." CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, vol. 4, no. 6, November 1997 (1997-11), pages 639-642, XP000981261 the whole document	29-32
X	N. YUKI ET AL.: "Hepatitis C virus replicative levels and efficiency of genotyping by specific PCR and antibody assay." JOURNAL OF CLINICAL MICROBIOLOGY, vol. 35, no. 5, May 1997 (1997-05), pages 1184-1189, XP000981255 the whole document	29-32
X	Z-X.ZHANG ET AL.: "Evaluation of the multiple peptide assay for typing of antibodies to the Hepatitis C Virus: Relation to genomic typing by the Polymerase Chain Reaction." JOURNAL OF MEDICAL VIROLOGY, vol. 45, 1995, pages 50-55, XP000569306 the whole document	29-32
X	H. NOMURA ET AL.: "Interferon therapy and Hepatitis C virus." JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol. 14, no. 1, January 1999 (1999-01), pages 85-89, XP000980021 the whole document	27,28
X	N. FURUSYO ET AL.: "Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection." DIGESTIVE DISEASES AND SCIENCES., vol. 44, no. 3, March 1999 (1999-03), pages 608-617, XP000981254 the whole document	27,28

-/—

3

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/15446

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	G.B. YAO ET AL.: "Long-term efficacy of recombinant interferon alpha 2a in the treatment of chronic Hepatitis C: A randomized prospective study comparing two dose schedules in Chinese patients." HEPATO-GASTROENTEROLOGY, vol. 46, March 1999 (1999-03) - April 1999 (1999-04), pages 1059-1064, XP000981266 the whole document	27,28
X	M. MARTINOT-PEIGNOUX ET AL.: "Predictors of sustained response to alpha interferon therapy in chronic hepatitis C." JOURNAL OF HEPATOLOGY, vol. 29, no. 2, August 1998 (1998-08), pages 214-223, XP000980024 the whole document	27,28
X	W.M. LEE: "Therapy of Hepatitis C: Interferon Alfa-2a trials." HEPATOLOGY, vol. 26, 1997, pages 89S-95S, XP000981288 the whole document	27,28
X	K.L. LINDSAY : "Therapy of Hepatitis C: Overview" HEPATOLOGY, vol. 26, 1997, pages 71S-77S, XP000981298 the whole document	27,28
X,P	T. MARAKAMI ET AL.: "Mutations in Nonstructural protein 5A gene and response to interferon in Hepatitis C virus genotype 2 infection." HEPATOLOGY, vol. 30, October 1999 (1999-10), pages 1045-1053, XP000981333 the whole document	27,28

3

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 00/15446

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-11, 33, 34,
37 completely and partially claims 12-20, 23, 24, 29-32, 35, 36 and 37

A purified and isolated nucleic acid molecule which encodes human hepatitis C virus of genotype 2a, DNA constructs comprising said nucleic acid, RNA transcript of said construct, cell transfected with said transcript, hepatitis C virus polypeptide produced by said cell and whose genome comprises said nucleic acid, method for assaying candidate antiviral agents against for activity against HCV using said cell containing HCV, antibody to said polypetide or to said HCV, method for determining the susceptibility of cells in vitro to support HCV infection using the cells transfected with the nucleic acid of claim 1 and compositions comprising said polypeptide suspended in a pharmaceutically acceptable diluent or excipient.

2. Claims: 25 and 26 completely and 12-23, 24, 29-32, 35, 36 and 37 partially

A hepatitis C virus polypeptide produced by a cell transfected with a DNA construct comprising a nucleic acid molecule which encodes human hepatitis C virus of genotype 2a which is an NS3 protease and method for assaying candidate antiviral agents against for activity against HCV comprising exposing said HCV protease to candidate antiviral agents, antibody to said polypeptide or HCV and compositions comprising said polypeptide suspended in a pharmaceutically acceptable diluent or excipient.

3. Claims: 12-23, 24, 29-32, 35, 36 and 37 partially

A hepatitis C virus polypeptide produced by a cell transfected with a DNA construct comprising a nucleic acid molecule which encodes human hepatitis C virus of genotype 2a which is an E1 protein, antibody to said polypeptide or HCV and compositions comprising said polypeptide suspended in a pharmaceutically acceptable diluent or excipient..

4. Claims: 12-23, 24, 29-32, 35, 36 and 37 partially

A hepatitis C virus polypeptide produced by a cell transfected with a DNA construct comprising a nucleic acid molecule which encodes human hepatitis C virus of genotype 2a which is an E2 protein, antibody to said polypeptide or HCV and compositions comprising said polypeptide suspended

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

in a pharmaceutically acceptable diluent or excipient.

5. Claims: 12-23, 24, 29-32, 35, 36 and 37 partially

A hepatitis C virus polypeptide produced by a cell transfected with a DNA construct comprising a nucleic acid molecule which encodes human hepatitis C virus of genotype 2a which is an NS4 protein, antibody to said polypeptide or HCV and compositions comprising said polypeptide suspended in a pharmaceutically acceptable diluent or excipient..

6. Claim : 27 and 28 completely

Antiviral agent identified as having antiviral activity for HCV by the method of claims 23 and/or 25.

INTERNATIONAL SEARCH REPORT

In .ational Application No
PCT/US 00/15446

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0532167 A	17-03-1993	JP 6121689 A	06-05-1994
		JP 6133778 A	17-05-1994
		CA 2075611 A	10-02-1993
		US 5428145 A	27-06-1995
WO 9115575 A	17-10-1991	AU 7675491 A	30-10-1991
		CA 2079105 A	05-10-1991
		EP 0527788 A	24-02-1993
		IE 911129 A	09-10-1991
		PL 169273 B	28-06-1996
		US 5585258 A	17-12-1996
		US 5597691 A	28-01-1997
		US 5371017 A	06-12-1994
		US 5712145 A	27-01-1998
		US 5885799 A	23-03-1999
WO 0026418 A	11-05-2000	AU 1462300 A	22-05-2000

Form PCT/ISA/210 (patent family annex) (July 1992)